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Abstract 
This research involves the NMR studies of two analogues of Insulin-Like Growth Factor-I 
(IGF-I) proteins, 15N-labelled Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I. Both of these 
analogues have a thirteen amino acid extension appended to the N-terminus. In addition, 
Long-[Arg3]-IGF-I has been 1nodified by a Glu3 Arg mutation while Long-[Leu60]-IGF-I 
has been modified by a Tyr60Leu mutation. For both analogues, the resonance 
assignments, secondary structure, amide proton exchange rates, 3 JNHa coupling constants, 
and backbone dyna1nics have been determined using high resolution NMR spectroscopy. 
For Long-[Arg3]-IGF-I, the three dimensional solution structure has been determined 
using restrained molecular dynamics. Chemical shift 1napping studies of Long-[Leu60]-
IGF-I have been performed by forming a complex between Long-[Leu60]-IGF-I and 
insulin-like growth factor binding protein 2 (IGFBP-2). 
In both analogues, the secondary structural elements of IGF-I, three a-helices forming a 
hydrophobic core, have been retained. In Long-[Arg3]-IGF-I, some variations in the 
structure are noted in the N-terminus and a slight reorientation of helices 2 and 3 relative 
to helix 1. These results are interpreted in terms of lower binding affinity for the IGFBPs. 
The N-terminal extension of Long-[Arg3]-IGF-I has very few NOE contacts either to the 
IGF-I domain or within the extension. However, many amide protons of the N-terminal 
extension are slowly exchanging, leading to the postulate of a molten helical stn1cture for 
this extension. The backbone dynamics analysis indicate that there is a considerable 
degree of flexibility in both Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I, leading to an 
anomalously high estimate for the overall correlation time. The highest order parameters 
are observed in the helical regions and the lowest order parameters in the C-domain loop 
separating helices 1 and 2 and in the N-terminal extension. There are some subtle 
differences in the order parameters between the two analogues, particularly for the residues 
following a-helix 1, a region implicated in binding to the type 1 IGF receptor. 
There are differences in the chemical shifts of the 15N, HN and Ha nuclei for the two 
analogues, in the proximity of residue 60 and the N-terminal extension as well as the C-
domain and a-helix 1 which are well separated in primary sequence from residue 60 but 
close in three dimensional space. There are quite substantial changes in the solvent 
accessibility between the two proteins, with approximately half the number of slowly 
exchanging amide protons in Long-[Leu60]-IGF-I. Whilst many of the amide protons in 
Vl 
the N-terminal extension are slowly exchanging, Leu60 is the only helical residue with an 
amide proton observed in the 2D 15N-HSQC spectra after 24 hours. 
Many Long-[Leu60]-IGF-I residues were implicated by chemical shift mappmg 
experiinents at the binding interface with IGFBP-2. These residues were located primarily 
in the N-tenninus of the IGF-I domain of the protein and the C-terminal end of a-helix 2. 
Some resonances from residues in the less well defined N- and C-termini were also 
perturbed upon binding of IGFBP-2, likely a result of indirect conformational changes. 
Overall, these investigations contribute to the understanding of the stn1cture and mobility 
of the IGF family and their interactions with IGF receptors and IGFBPs. 
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Insulin-like growth factors (IGFs) are small proteins that participate in the control of cell 
growth and replication. In vivo, IGFs are bound to insulin-like growth factor binding 
proteins (IGFBPs) which 1nodulate the half life of IGFs in blood and assist in the 
transport and delivery of IGFs to their cellular receptors (reviewed by Walton et al. , 1990). 
1.1 Historical Perspective 
The IGFs were discovered as a result of the contributions fro1n three separate lines of 
research. In 1957, Salmon and Daughaday observed that growth hormone (GH), m 
isolation, does not stimulate growth processes, but rather, induces the biosynthesis of 
factors that mediate the 1nessages of GH. These factors were initially referred to as 
"sulphation factors" and later as "somatomedins". 
Following the development of a radioitn1nunoassay for insulin, it becaine apparent that 
serum contained far more insulin-like activity than could be accounted for simply by its 
content of itnmunoreactive insulin. In addition, the insulin effects of serum were not 
suppressed by the addition of anti-insulin senun, contrary to the effects of insulin. 
Froesch et al. (1963) termed this insulin-like activity "non suppressible insulin-like 
activity" (NSILA). 
In 1972, Pierson and Temin extracted factors from serum which stimulated cells to 
replicate when added to culture mediu1n. These factors were named "multiplication-
stimulating activity" (MSA). Later, it was found that cultured liver cells secrete MSA into 
the culture medium, demonstrating that MSA is produced in the liver and that MSA may 
lead to autocrine stitnulation of the same cells from which it is secreted. 
Rinderknecht and Humbel, in 1976, purified and sequenced NSILA from a Cohn fraction 
of human plasma (Rinderknecht and Humbel, 1978). The pritnary sequence was found to 
be 48% homologous with human proinsulin. The sequence of a second insulin-like 
molecule was found to be similar. These biologically active peptides were termed IGF-I 
and IGF-IL Subsequent sequencing of purified somatomedin C from human plasma 
showed its sequence to be identical to that of IOF-1 (Svoboda, et al. , 1980). 
The biosynthesis of IOF-II is under less stringent control by OH than the biosynthesis of 
IOF-I (Humbel, 1990). Since the name so1natomedin had been introduced to imply OH 
3 
regulation, it was an inadequate term to describe both of these homologous peptides. Thus 
in 1987, it was reco1nmended that the term IGF be e1nployed to refer to this family of 
peptides (Sara and Hall, 1990). The IGFs are members of the insulin superfamily, which 
includes insulin, IGF-1, IGF-II, relax.in, bo1nbyxin, and the molluscan insect peptides 
(Murray-Rust et al., 1992). 
1.2 IGF-1 and IGF-11 Sequences and Homology 
IGF-I and IGF-II were characterized by Rinderknecht and Humbel (1976 and 1978). 
IGF-I and IGF-II are single chain polypeptides of 70 (mol. wt. 7649) and 67 (mol. wt. 
7471) amino acids respectively, each with three disulfide bonds. The two proteins are 65% 
homologous with each other, while IGF-I and IG~-II are 43% and 41 % homologous with 
insulin respectively. 
The polypeptides consist of four domains; B, C, A, and D in sequential order from the N-
terminus. The A and B domains are structurally homologous with the insulin A and B 
chains. Table 1.1 shows the sequences of human IGF-1, IGF-II and insulin. In IGF-1, 
residues 3-29 correspond to the B chain of insulin while residues 42-62 correspond to the 
insulin A chain. In IGF-II, residues 6-32 correspond to the insulin B chain while residues 
41-61 correspond to the insulin A chain. 111e C domain is analogous to the connecting 
peptide in proinsulin, though it is quite different in sequence. The IGFs are the only 
members of the insulin superfamily in which the C region is not removed proteolytically 
after translation. Unlike proinsulin, the IGFs also have a carboxyl tenninal extension of 
eight amino acids fro1n residues 63 to 70 in IGF-I and residues 60 to 67 in IGF-II, which 
is known as the D domain. There are three disulfide bonds linking residue 6 with 48, 18 
with 61, and 47 with 52 in IGF-1, while the corresponding linkages in IGF-II are 9 with 
47, 21 with 60, and 46 with 51. 
Table 1.1: Sequences of Human Insulin, IGF-I and IGF-II with the B, C, 
A and D Domains shown. 
B -2 -1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Insulin p V N Q H L C G s H L V E A L y L V C 
IGF-I G p E T L C G A E L V D A L Q F V C 
IGF-II A y R p s E T L C G G E L V D T L Q F V C 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
20 21 22 23 24 25 26 27 28 29 30 
Insulin G E R G F F y T p K A 
IGF-I G D R G F y F N K p T 
IGF-II G D R G F y F s R p A 
19 20 21 22 23 24 25 26 27 28 29 
C 30 31 32 33 34 35 36 37 38 39 40 41 
IGF-I G T G s s s R R A p Q T 
IGF-II s - - R V s R R s R - -
A 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
Insulin G I V E Q C C T s I C s L y Q L E N y C N 
IGF-I G I V D E C C p R s C D L R R L E M y C A 
IGF-II G I V E E C C F R s C D L A L L E T y C A 
42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 
D 63 63 65 66 67 68 69 70 
IGF-I p L K p A K s A 
IGF-II T - - p A K s A 
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The sequence homology of IGFs is well conserved across species as is dernonstrated by 
the following cornparisons. Bovine, porcine and human IGF-I are identical, whereas rat 
and 1nouse IGF-I differ from human IGF-I by three and four amino acids respectively. 
Human and bovine IGF-II differ by three amino acids, while rat and 1nouse IGF-II differ 
from human IGF-II by four and six amino acids respectively. These species differences in 
IGF-II occur toward the end of the B domain and within the C domain (Sara and Hall, 
1990). The arginine residues of IGF-I, which are involved in binding interactions with 
other proteins (Jansson et al., 1998; Zhang et al., 1994), are highly conserved in 
vertebrates. The only common variant is the arginine to glutamine substitution at position 
50 in chicken, frog, and salrnon IGF-I. 
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1.3 Solution Structures of IGFs 
Refined structures of proteins from the IGF family include two reports of the IGF-I 
structure (Cooke et al., 1991; Sato et al., 1992,1993), two structures of IGF-II (Torres et 
al., 1995; Terasawa et al., 1994) and the structure of a 1nini-IGF-I, in which the C-domain 
is deleted (DeWolf et al., 1996). The biological ilnplications of the deletion of the C-
domain of mini-IGF-I are discussed in section 1.8. No crystals suitable for X-ray analysis 
have been obtained for either IGF-I or IGF-II. The tertiary structures of IGFs have been 
modeled on that of porcine insulin (Blundell et al., 1978, 1983). Structures detennined by 
NMR spectroscopy in solution are consistent with the modeled structure. 
1.3.1 IGF-1 
The secondary structure and three-dimensional structure of IGF-I were determined by 1 H 
NMR spectroscopy by Cooke et al. (1991) followed by Sato et al. (1992, 1993). In IGF-I 
there are three helical segments corresponding to the regions Ala8-Cys18 (helix 1), Gly42_ 
Cys48 (helix 2) and Leu54_Cys61(helix 3). A ~-tum, enco1npassing residues Glyl9_Gly22, 
immediately follows helix 1. Residues Phe23 through to Thr41 exist in an extended 
structure with the possibility of some fixed conformation in the region Thf29_Ser35. The D 
domain is considered to be unstructured. 
The spatial arrangement of the three helices of insulin is conserved in the human IGF-I 
structure, despite the C domain being inserted between the A and B domains. The three 
helical rods form a rigid stn1ctural core which may be stabilized through hydrophobic 
interactions. The C-domain is flexible and unstructured and forms an exposed loop. 
Figure 1.1 shows the average solution structure of native IGF-I with the spatial orientation 
of the three helices (Cooke et al., 1991). The axes of helices 2 and 3 are parallel to each 
other and roughly perpendicular to helix 1 (Sato et al., 1993). 
1.3.2 IGF-11 
The structure of IGF-II (Terasawa et al., 1994; Torres et al., 1995) in the well defined 
regions is very similar to those of the corresponding regions of insulin and IGF-I. The 
main secondary stn1cture elements of IGF-II are a-helices encompassing residues 11-21 
in the B domain, and residues 42-48 and 53-59 in the A do1nain. The two helices in the A 
domain are anti-parallel to each other and perpendicular to helix 1. Residues 6-9 and 25-
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30 are in extended conformations. A reverse tum occurs at residues 22-25 leading into the 
extended region. The amide protons of residues 25-28, which are in an extended 
conformation, are all slowly exchanging and have downfield Hex chemical shifts relative to 
random coil values suggesting a ~-sheet confonnation. Thus, in IGF-II it appears that 
there is a s1nall region of anti-parallel sheet fonned by residues 25-27 and 59-61 
iffilnediately after helix 3 (Torres et al., 1995). 
H2 
Figure 1.1: NMR solution structure of IGF-I (Cooke et al. , 1991). The three a -helices are 
labeled Hl, H2 and H3 respectively. The N- and C-termini are also labeled. 
1.3.3 Mini-IGF-1 
The secondary stn1cture elements of IGF-I are retained in mini-IGF-I (De Wolf et al., 
1996). The two structures, IGF-I and mini-IGF-I are similar globally, although the 
deletion of the C-domain results in differences in the spatial arrangement of the helices. 
The axes of helix 2 and helix 3 in mini-IGF-I are no longer parallel. The confonnation of 
the seg1nent encompassing residues Phe23, Tyr24 and Phe25 differs from that of wild-type 
IGF-I. If the conformation of this segment were the same as that of wild-type IGF-I, the 
restrictions imposed by the deletion of the C-domain would result in exposure of residues 
of the hydrophobic core to the solvent, in particular Phe23 and Phe25. However, a 
displacement of this segment, facilitated by the flexibility of the preceding ~-turn (Glyl9_ 
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Gly22) allows the core to remain shielded and the important interactions of Phe23 and 
Phe25 with residues in the neighbouring helices to be maintained. It is postulated that this 
change in conformation of the seg1nent Phe23, Tyr24 and Phe25 1nay be the driving force 
for the movement of the helix 2-tum-helix 3 motif relative to helix 1. 
1.3.4 Partially Reduced IGF-1 and an Alanine Model 
Hua et al. (1996) trapped a folding intermediate containing two of the three native disulfide 
bonds of IGF-I. This intermediate contained the [ 18-61; 6-48] disulfide bonds, while the 
reduced cysteines were identified as Cys47 and Cys52. In the native state, the disulfide 
bond between residues 47 and 52 anchors a-helix 2 to the hydrophobic core. This 
intermediate is only partially folded and contains elements of native secondary and tertiary 
structure. NMR spectra necessary for the elucidation of secondary and tertiary structure 
could not be obtained because of resonance broadening due to the intermediate 
conformational exchange of this variant. An equilibriu1n model with Cys47 Ala and 
Cys52Ala mutations was shown to have a very sin1ilar 1D 1H NMR spectrun1 to the [18-
61 ;6-48] intermediate. The structure of this model was detennined from 2D 1 H NMR 
data. Removal of the Cys47 _Cys52 disulfide bond is associated with local unfolding of the 
adjoining a-helix 2. The native secondary structure (including a-helices 1 and 3) was 
otherwise retained and defines a folded sub do1nain. The hydrophobic core enclosed by 
helix 1, the receptor binding strand (Phe23 to Phe25) and helix 3 was retained. Hua et al. 
( 1996) proposed that the folding of the insulin motif is directed by a subset of native 
structural elements and that these elements form at an early step in the folding pathway of 
IGF-I. Formation of helix 2, despite its prominence in the native state, is likely to represent 
a late step in the folding process. Hydrophobic collapse of this segment 1nay precede helix 
formation. 
1.4 Gene Expression, Synthesis and Regulation 
Single genes code for IGF-I and IGF-II (Rutanen and Pekonen, 1990). The IGF-I gene is 
located on the long ann of chro1nosome 12, containing five exons over a region of 85 
kilobase pairs (kb) of genomic DNA (Walton et al., 1990). The human IGF-I gene is 
transcribed and processed into at least two types of 1nessenger RNA (mRNA) (Rutanen 
and Pekonen, 1990). The IGF-II gene is located on the short arm of chromoso1ne 11, 4.4 
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kb downstream from the insulin gene (Walton, et al. , 1990). This gene contains eight 
exons, five non-coding and three protein encoding exons, and is transcribed into three 
mRNAs (Rutanen and Pekonen, 1990). IGF-II is synthesized as a 22 kDa prepropeptide 
and then post-translationally processed to a 20 kDa propeptide, prior to final processing to 
the mature IGF-II peptide (Walton et al., 1990). 
IGF-I and IGF-II are synthesized in multiple organs and tissues. Most tissues express 
both IGFs at some stage of pre- or postnatal development (Rutanen and Pekonen, 1990). 
Han et al. (1987) demonstrated that expression of both IGF-I and IGF-II are localized to 
connective tissue or cells of mesenchymal origin. IGF-II dominates during the prenatal 
period (Rutanen and Pekonen, 1990). The liver represents the major site of expression and 
of synthesis during postnatal growth (Steele and Elsasser, 1989). 
The major factor regulating IGF-I production is growth hormone (GH) (Mathews et al., 
1986). GH stimulates the induction of IGF-I 1nRNA in various organs, tissues, primary 
cell cultures and in established cell lines. A rapid rise in sen1m IGF-I levels is seen after 
GH treatment of patients with GH deficiency (Rutanen and Pekonen, 1990). Oestrogen 
also stimulates IGF-I expression (Murphy et al., 1987; Ernst et al., 1989; and Johnson et 
al., 1989), while parathyroid hormone has been shown to stimulate IGF-I production in 
bone cells (Canalis et al., 1989). During fasting, protein malnutrition, and diabetes, IGF-I 
production and IGF-I mRNA expression in the liver is decreased. Serum IGF-I 
production is low in the hu1nan neonatal period, rises to peak values during puberty, and 
then slowly declines during aging (Hall and Sara, 1983). 
The factors regulating IGF-II production are poorly characterized (Rutanen and Pekonen, 
1990). IGF-II mRNA expression is not GH dependent. The highest levels of mRNA 
expression of IGF-II are detected in the brain and expression is barely detected in the liver 
(Murphy et al., 1987; and Hynes et al., 1987). Placental lactogen has a stimulatory effect 
on foetal fibroblast IGF-II production (Adams et al. , 1983). IGF-II 1nRNA in hu1nans is 
highest during foetal development and declines in the postnatal period (Rutanen and 
Pekonen, 1990). Follicle Stimulating Hormone (FSH) regulates IGF-II mRNA in human 
granulosa cells and ACTH in foetal adrenal cells (Voutilainen et al., 1987). In adult, high 
levels of IGF-II are found in bone, where it 1nay be a mediator of remodelling, and in the 
central nervous system. High levels of IGF-II mRNA are also found in a nu1nber of 
tumours, including mesenchy1nal tumours and Wilms' tumours (Rechler et al., 1991). 
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IGF-II also has insulin-like metabolic effects, and overproduction of IGF-II in certain 
non-islet cell tumours results in refractory clinical hypoglycaemia (Daughaday and 
Rotwein, 1989). The insulin-dependent delivery of the IGF-II/Man-6-P receptor to the cell 
surface from the intracellular storage pool is mediated by the tissue-specific glucose 
transporter isoform vesicles (GLUT4) (Kandror and Pilch, 1996). 
1.5 IGF Receptors 
1.5.1 Introduction 
The biological actions of IGFs are mediated by specific cell membrane receptors, mainly 
through the type 1 IGF receptor which is found on the surface of most cell types (Leroith 
et al., 1997; Ballard et al., 1994). The receptors that recognise the IGFs can be 
distinguished by their primary structure, relative affinities for their respective ligands, as 
well as by im1nunological methods (Rutanen and Pekonen, 1990). IGF-I and IGF-II bind 
to three types of membrane-bound receptors on target cells: the type 1 IGF receptor, the 
type 2 IGF receptor and the insulin receptor. Insulin cross reacts weakly with the type 1 
IGF receptor but has no measurable affinity for the type 2 IGF receptor (Massague & 
Czech, 1982). The type 1 IGF receptor has a high degree of sequence homology with the 
insulin receptor, while the type 2 IGF receptor is homologous with the cation-independent 
mannose-6-phosphate receptor, which functions in the trafficking of lysosomal enzy1nes 
but has no known IGF signalling function. The insulin receptor binds the IGFs with low 
affinity. Hybrid IGF/insulin receptors have been isolated that bind the IGFs and 
potentially transmit a cytoplas1nic signal in vitro (Jones and Clemmons, 1995). Soos et al. 
(1990) demonstrated the existence of hybrid receptors in nonnal tissues of rat fibroblasts 
and showed that both insulin and IGF-I are bound with high affinity. 
A chimeric type 1 IGF receptor in which the C-terminal domain was replaced with that of 
the insulin receptor was constructed by Tartare et al. (1994). This receptor possessed fully 
functional kinase activity and biological properties. The C-terminal do1nain of the insulin 
receptor is more tightly coupled to the stimulation of glycogen synthesis than is that of the 
type 1 IGF receptor. It was proposed that this domain plays a crucial role in the 
transmission of biological effects and could account, in part, for receptor specificity. 
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1.5.2 IGF Receptor and Insulin Receptor Structures 
Specific growth factor receptors with high affinity for IGF-I and IGF-II were identified 
and characterized by Massague and Czech (1982). 
The type 1 receptor, like the insulin receptor, is a glycosylated heterotetramer composed of 
two a subunits and two ~ subunits linked by disulfide bonds. The a subunits consist of 
706 amino acids ( 135 kDa in mass) and exist extracellularly while the ~ subunits are 90 
kDa in mass (626 amino acids), and contain a trans1ne1nbrane domain and the intracellular 
tyrosine autophosphory lation site. The a subunits contain the cysteine-rich, extracellular 
ligand binding site (Humbel, 1990). The subunits of the insulin receptor are very similar to 
the type 1 IGF receptor in size and have regions with a high degree of sequence homology 
(50-60% overall sequence identity and 84% in the tyrosine kinase domains) (Walton et al., 
1990). The type 1 IGF receptor is synthesized on the ribosome as a single polypeptide 
chain of 1367 amino acid residues which is post-translationally modified by the removal 
of a 30 amino acid signal peptide and cleavage of the proreceptor into a and ~ subunits 
linked by disulfide bonds, which is referred to as an a~-half receptor. The a~-half 
receptor is subsequently linked to another a~-half receptor to form the mature a2~2-
holoreceptor (Jones and Clemmons, 1995). 
The type 2 IGF receptor is structurally unrelated to the type 1 IGF and insulin receptors, 
although, as mentioned above, it is homologous with the rnannose-6-phosphate receptor 
Which is believed to be involved in the transport of lysosomal enzymes (Walton et al., 
1990). It is a single chain, 250 kDa polypeptide chain and has no intrinsic kinase activity 
(Rutanen and Pekonen, 1990). There is a large extracellular domain (approximately 93% 
of the protein) which contains 15 repeat sequences of cysteine residues and hydrophobic 
regions (Humbel, 1990), and a small cytoplasmic domain. Although the type 2 IGF 
receptor and the mannose-6-phosphate receptor are hornologous, their functions are 
unrelated. The mannose-6-phosphate receptor is located on both the cell surface and the 
Golgi apparatus where it binds lysosomal proteins and mediates their transport to the 
lysosomes. The type 2 IGF receptor and the mannose-6-phosphate receptor also have 
distinct binding sites on the receptor for their different ligands. However, the two ligands 
appear to act synergistically since mannose-6-phosphate increases the affinity of the 
receptor for IGF-II (Jones and Clemmons, 1995). Murayama et al. (1990) also showed 
that the mannose-6-phosphate receptor has two distinct signalling functions that positively 
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or negatively regulate the activity of Gi-2 (subunit of a guanidine nucleotide protein) in 
response to the binding of IGF-II or mannose-6-phosphate. 
1.5.3 Ligand Binding 
Type 1 and type 2 IGF receptors and insulin receptors are present on 1nost cells in the 
body (Htnnbel, 1990). This arrangement has complicated the assignment of a particular 
response to a particular receptor. The nomenclature of the IGF receptors is based on their 
specificity for binding to each peptide. In most tissues, the type 1 IGF receptor binds IGF-
I most strongly, followed by, with decreasing affinity, IGF-II and then insulin. The insulin 
receptor binds insulin more strongly than IGF-I and IGF-II with the latter two having 
similar binding affinities. The binding of IGF-I and insulin to the type 2 IGF-I receptor is 
very low and the association constant is biologically insignificant (Kiess et al., 1994). The 
IGFs themselves appear to undergo a conformational change on binding to their receptors 
(Gill et al., 1996; Jansson et al., 1998). Upon binding of IGFs to the type 1 IGF receptor, 
the intracellular part of the receptor undergoes autophosphory lation, which is a 
prerequisite for all known IGF-mediated biological actions. The growth promoting effects 
of insulin and the metabolic activity of IGF-I are thought to arise from the cross binding to 
each other's receptors. 
Differences in affinities of IGF-I and IGF-II for the various receptors arise predominantly 
from differences in key sidechains rather than from structural differences between the two 
proteins. Cascieri et al. (1988) showed that the structural determinants of IGF-I required 
to maintain binding to the type 1 IGF receptor and to the type 2 IGF receptor and serum 
binding proteins are different. Cascieri et al. (1988) identified Tyr24 of IGF-I as an 
important residue for binding of the protein to the type 1 IGF receptor. Mutation of Tyr24 
to the non-aromatic residues, Leu or Ser, resulted in a large decrease in type 1 IGF 
receptor affinity. Combination of this mutation with deletion of the D domain led to a 
further loss in receptor affinity. TI1e mutation of IGF-I at Tyr24 also resulted in a loss of 
affinity for the insulin receptor, though it was not as marked as the loss in type 1 IGF 
receptor affinity. However, the alteration of IGF-I from the wild type Phe23, Tyr24, Phe25 
to give the mutant [Phe23, Phe24, Tyr25]IGF-I does not result in major changes in affinity 
for either the type 1 or type 2 IGF receptors, indicating that the tyrosine hydroxyl group at 
residue 24 does not have a direct effect on binding affinity. While the loss of aromaticity 
at residue 24 of IGF-I results in a loss of affinity for the type 1 IGF and insulin receptors, 
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there is little difference in affinity for the type 2 IGF receptor (Cascieri et al., 1988). 
Mutation of the aro1natic residue at position 23 results in a loss in affinity for all receptors 
(Cascieri et al., 1988). Maly and Luthi (1988) performed iodination experiments to 
elucidate the IGF-I binding site, involving three tyrosine residues, Tyr24, Tyr31 and Tyr60, 
and proposed that the minimal receptor binding region of IGF-I would include amino acid 
residues Tyr24 to Tyr31 and, possibly, the C-terminal part of the A-domain with Tyr60. 
Bayne et al. (1988) mutated three tyrosine residues of IGF-I, Tyr24, Tyr31 and Tyr60 to 
either an alanine or a leucine to generate either single, double or triple point 1nutations. 
These molecules showed reduced binding to the type 1 IGF receptor compared with the 
parent molecule. 
The C domain of IGF-I has been shown to be important for the binding interaction with 
IGF receptors. Mini-IGF-I (deletion of the C domain residues 28-41) was found to have 
much lower affinity for the type 1 receptor (De Wolf et al. , 1996). Gill et al. (1996) 
reported that mini-IGF-I has 100 times lower affinity than IGF-I for the type 1 IGF 
receptor. Bayne et al. (1988) prepared a mutant of IGF-I in which the C do1nain (residues 
28-37) was replaced with a four glycine bridge. This mutant had a 3O-fold loss of affinity 
for the type 1 IGF receptor, however deletion of the D do1nain (residues 63-70) had little 
effect on binding to the type 1 IGF receptor. Neither the C- or D-domains of IGF-I were 
required for high affinity binding to the type 2 IGF receptor. However, Zhang et al. (1994) 
have subsequently shown the positively charged residues of Arg36 and Arg37 in the C 
domain and Lys65 and Lys68 in the D do1nain contribute to receptor-binding specificity 
and high-affinity binding to the type 1 IGF receptor. 
Blundell et al. (1978) have proposed that a number of invariant residues shared between 
IGF-I and insulin participate in IGF-I binding to the type 1 IGF receptor and its cross 
reactivity with the insulin receptor. Structural determinants in the C- and D-domains are 
involved in maintaining receptor binding specificity between the two receptors (Bayne et 
al. , 1988; Zhang et al., 1994). The distinct physiological roles of IGF-I and insulin have 
been enhanced during evolution by variation in receptor signalling, receptor tissue 
distribution and ligand binding specificity. It is still unclear how the receptors differentiate 
between the physiological roles of IGF-I and insulin. A number of A- and B-domain 
positions in IGF-I that are important for maintaining high-affinity receptor binding and 
specificity have been identified (for example, Ala8, Met59, Ala62) (Shooter et al., 1996). 
The receptor specificity of IGF-I evolved with a number of sequence changes within the 
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B- and A-domains that collectively contribute to the observed receptor binding prope11ies 
of IGF-I (Shooter et al., 1996). 
Cascieri et al. (1989) prepared IGF-I mutants with specific residues in the A-domain 
replaced with the corresponding residues in the A chain of insulin in order to investigate 
determinants for type 2 IGF receptor binding. Residues Phe49, Arg50 and Ser51 were 
found to be important for maintaining binding to the type 2 IGF receptor, while binding to 
the type 1 IGF receptor was unaffected. Bayne et al. (1987) prepared an IGF-I 1nutant in 
which the 16 a1nino-terminal residues were replaced with the 17 amino-tenninal residues 
of the insulin B chain, and found that this change causes a dra1natic loss of binding 
affinity for the type 2 IGF receptor. While the binding detenninants in IGF-I, important 
for type 2 IGF receptor binding, are different from those required for maintaining high 
affinity for the type 1 IGF receptor, this region in the A-domain overlaps with the 
determinants in IGF-I for high affinity binding to insulin-like growth factor binding 
proteins (IGFBPs) (discussed in section 1.6). 
Sakano et al. (1991) identified the amino acids Phe48, Arg49, Ser50, Ala54 and Leu55 as the 
residues in IGF-II which are critical for binding of IGF-II to the type 2 IGF/lnannose-6-
phosphate receptor. These residues form a patch when mapped on a three-dimensional 
structure of IGF-II (Terasawa et al., 1994). In contrast, the residues in IGF-II which are 
responsible for the binding of IGF-II to the type 1 IGF receptor or the insulin receptor are 
Phe26, Tyr27 and Val43 (Sakano et al. , 1991). Roth et al. (1991 ) also found Tyr27 to be an 
important detenninant for type 1 IGF receptor binding, and proposed that the D-domain of 
IGF-I forms part of the binding region for the type 1 IGF receptor since it is close in 
space to Tyr27. 
1.5.4 Biologi,cal Responses Mediated by IGFs 
In general, the insulin receptor has been implicated in rapid anabolic responses, while the 
mitogenic functions of the IGFs are almost always mediated by the type 1 IGF receptor 
(Humbel, 1990). However, insulin stimulates a proliferative response in certain cells 
through its own receptor, and the type 1 IGF receptor can, in some cells, mediate rapid 
anabolic responses. Most of the responses stimulated by IGF-II are thought to be 
mediated by the insulin and type 1 IGF receptors (Humbel, 1990), although IGF-II 1nay 
stimulate some responses through its own receptor. For example, stimulation of glycogen 
14 
synthesis by IGF-II is not mediated by the type 2 IGF receptor, but through the type 1 or 
insulin receptors (Clemmons et al., 1992). In foetal growth and development, the actions of 
IGF-II may be mediated via the type 2 receptor. This is suggested by the observation of 
high levels of expression of the receptor in foetal tissues and a decline in postnatal 
receptor expression and circulating IGF-II levels (Sklar et al. , 1989). Little is known about 
the responses mediated through the type 2 IGF receptor. 
The hybrid type I/insulin receptors can form in cells that express both receptor genes. 
They are composed of one insulin receptor a and ~ subunit and one type 1 receptor a and 
~ subunit (Cohick and Cleffilnons, 1993). These hybrid receptors have ligand specificity 
profiles more comparable to the type 1 IGF receptor than the insulin receptor (Jones and 
Clemmons, 1995). 
1.6 IGF Binding Proteins 
1.6.1 Introduction 
The insulin-like growth factor binding proteins (IGFBPs) are a family of six proteins that 
bind the IGFs with high affinity. These proteins were first identified by Hintz ( 1977) who 
reported the presence of specific somatomedin carrier proteins in sen1m. The IGFBPs 
exist extracellularly and, like IGFs, are synthesized in many tissues. Circulating and tissue 
IGFs are found tightly co1nplexed to IGFBPs. There are at least six different IGFBPs 
which bind IGF-I and IGF-II with high specificity and affinity and no other peptide 
hormone is able to compete for binding. The IGFBP fainily possibly consists also of an 
additional four proteins that can associate with IGFs with lower affinity (Oh et al., 1997; 
Rechler, 1997). It has been reported that insulin is unable to bind to IGFBPs (De Vroede 
et al., 1985; Szabo et al., 1988), however, Reding et al. (1996), using a BIAcore instrument 
found human insulin to have a measurable, though extremely low, affinity for IGFBP-3. 
The BIAcore assay used in the study was found to be more sensitive for the detection of 
low affinity interactions than the competition assays used previously. The circulating IGF-
IGFBP complex is biologically inactive (Rutanen and Pekonen, 1990). 
The major functions of IGFBPs that are essential to coordinate and regulate the biological 
activities of the IGFs include; to act as transport proteins in plasma and to control the 
efflux of IGFs fro1n the vascular space; to prolong the half-lives of the IGFs and regulate 
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their metabolic clearance; to provide a means of tissue and cell type specific localisation; 
and to modulate direct interaction of the IGFs with their receptors and thereby indirectly 
control biological actions (Jones and Clemmons, 1995). The IGFBPs are also believed to 
participate in the in vivo folding of IGFs (Hober et al., 1994), and inhibit IGF binding to 
the insulin receptor. The IGFBPs have also been shown to either inhibit or stimulate the 
growth-promoting effects the IGFs have on cell cultures, most likely by altering the 
interaction of IGFs with their cell surface receptors (Mohan et al., 1995). IGFBPs either 
inhibit or potentiate IGF activity depending on whether they are soluble or cell membrane 
associated (Bach and Rechler, 1995). Although some IGFBPs can limit access of IGF to 
receptors (Ritvos et al., 1988; Gopinath et al., 1989), IGFBP-3 and IGFBP-5 can associate 
with cell surfaces themselves (Mccusker et al. , 1991) and thereby, increase the amount of 
IGF bound to cell surfaces (Mccusker et al. , 1990), as well as inhibit the rate of receptor 
internalisation (Conover and Powell, 1991). 
The IGFBPs, in turn, are regulated by the IGFBP proteases, a group of proteolytic 
enzymes that are capable of cleaving IGFBPs into srnaller fragments with lower affinity 
for IGFs, thus enhancing IGF action. Various endocrine factors also play a role in IGFBP 
regulation (Levitt Katz et al., 1995). The affinity of IGFBPs for IGFs is also controlled by 
phosphorylation (Conover, 1995). 
The growing number of IGFBP 1nutagenic studies described to date has focused on 
aspects of IGFBP biology such as extracellular matrix or heparin binding (Arai et al., 
1996), integrin receptor binding (Jones et al., 1993), specific proteolysis (Conover, 1995; 
Chernausek et al. , 1995) or phosphorylation (Jones et al. , 1993) rather than systematic 
identification and characterisation of a coffilnon IGF binding motif. 
Among the six binding proteins there is a high degree of sequence homology due to the 
conservation of the prirnary sequence of cysteine residues which are involved in disulfide 
bond formation. Human IGFBP-1, -2, -3, and -5 each contain 18 cysteine residues in 
conserved positions; IGFBP-4 contains two additional cysteines; and IGFBP-6 has only 
16. The highest conservation is found in the N- (residues 1 to~ 100) and C- (from residue 
170 to the C-terminus) terminal cysteine-rich regions. Twelve conserved cysteines are 
found in the N-terminal domain and six in the C-terminal domain. The IGFBPs have a 
characteristic N-terminal cysteine pattern; GC(G/S)CCXXCAXXXXXXC, which can also 
be found _ in the human proteins MAC25 (Swisshelrn et al. , 1995) and connective tissue 
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growth factor. While all of the cysteine residues of IGFBPs are believed to participate in 
disulfide bonds (Sommer et al. , 1993), it is still unknown whether all IGFBPs share the 
same disulfide-bridging pattern. The central, weakly conserved region (L-domain) contains 
most of the cleavage sites for specific proteases (Chernausek et al., 1995), phosphorylation 
and glycosy lation sites and sites of association with other biomolecules such as heparin or 
the integrin receptor (Rechler, 1993; Jones and Clemmons, 1995). 
,-., 
LJ 
~-sheet 2 
~-J 
Figure 1.2: Ribbon drawing of inini-IGFBP-5 showing the three ~-sheets (Kalus et al., 
1998). The N- and C-termini of the frag1nent are labeled. 
Disulfide mapping experiments and three-dimensional structures of IGFBPs are important 
for an understanding of the actions of these proteins. No high resolution structure is 
available for any intact member of the IGFBP family. The NMR structures of two N-
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terminal fragments from IGFBP-5 which retain IGF-binding activity have recently been 
reported (Kalus et al., 1998), including a mini-IGFBP-5 which encompasses residues 
Ala40 to Ile92 of IGFBP-5 (Figure 1.2). The solution structure of mini-IGFBP-5 discloses 
a rigid and globular structure that consists of a centrally located three-stranded anti-parallel 
P-sheet, further stabilized by two inside packed disulfide bridges. Interestingly, no silnilar 
fold was found by the authors in database searches. A 1nodel for the IGF binding to 
IGFBP-3 has also been proposed (Spencer and Chan, 1995). 
IGF binding to the IGFBPs is dependent on the three-dimensional protein structure, 
although determinants of IGF binding to IGFBPs are poorly characterized in terms of 
residues in the IGFBPs essential for the binding process. It has been predicted that there 
are at least two independent domains in the IGFBP tertiary structure and that both N- and 
C-terminal dornains act in a cooperative fashion to bind IGFs (Lee et al. , 1993; Bayne et 
al., 1988; Zapf et al., 1990; Andress et al., 1993; Chemausek et al. , 1995; Fowlkes et al., 
1995; Durham et al. , 1997; Hashimoto et al., 1997; Kalus et al., 1998). Kalus et al. (1998) 
showed that IGFBP-5 contains only one high-affinity binding site for IGFs, located in the 
segment Ala40 to Ile92. A hydrophobic patch on the surface of IGFBP-5 containing Leu 
and Val residues is conserved across the family of IGFBPs and was found to interact with 
IGFs. In particular, Val49, Leu70 and Leu74 are proposed to interact with Phe48 of IGF-II. 
The full length IGFBP-5 was found to have higher affinity for IGF-I and IGF-II than 
rnini-IGFBP-5 (Kalus et al., 1998). The authors propose that residues located in the C-
terminal domain of intact IGFBP-5 1nust be involved with additional stabilisation of the 
IGF complex. Lys68 in IGFBP-5, part of a hydrophilic and variable loop, is proposed to 
interact with Glu6 of IGF-II. These residues were identified using NMR spectroscopy by 
changes in the 15N chemical shifts of IGFBP-5 induced by IGF-II complexation. A recent 
study of IGF binding to IGFBP-4 (Qin et al., 1998) showed that the N-terminal sequence, 
Leu72-Ser91, was essential for IGF binding, although residues Cys205_ Val214 facilitated 
IGF binding. The regions of IGF-I involved in IGFBP binding and the conformation of 
the IGFBP may influence the distribution of IGF-I between receptors and IGFBPs at 
equilibrium (Clemmons et al., 1992). 
The primary structure of IGFBP-2 contains six tyrosine residues: Tyr60 and Tyr71 are 
located in the cysteine dch N-terminal region, Tyr98 is located in the middle region, while 
Tyr213, Tyr226 and Tyr269 lie in the cysteine-rich C-terminal region of the molecule 
(Upton et al., 1990). Hobba et al. (1996) used tyrosine iodination as a structural and 
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functional probe to establish that Tyr60 of IGF-I as essential for binding to bovine 
IGFBP-2. This method was used to minimise the structural disruption introduced by the 
random substitution of amino acids. Previously, this approach has been successfully used 
to identify tyrosine residues of IGF-I which are important for association with the type 1 
IGF receptor (Maly et al., 1988; Schaffer et al., 1993) and tyrosine residues of both IGF-I 
and IGF-II which are important for association with IGFBP-2 (Moss et al., 1991). 
Tyrosine residues are found at the position equivalent to Tyr60 of IGFBP-2 in all IGFBP 
family me1nbers with the sole exception being IGFBP-1, where an alanine exists at this 
position (Lee et al., 1993). Adjacent residues, VaI59, Thr61, Pro62 and Arg63 are well 
conserved in IGFBP family members, however, substitution of these residues did not 
reduce the IGF binding affinity of bovine IGFBP-2 (Hobba et al., 1998). Both the 
aromatic nature and the hydrogen bonding potential of the tyrosyl sidechain of Tyr60 were 
identified as important structural detenninants of the IGF binding site of IGFBP-2 
(Hobba et al., 1998). These researchers proposed that the hydroxyl group of Tyr60 
participates in a hydrogen bond that is important for the initial complex formation with 
IGF-I and the stabilisation of this complex. 
The high degree of structural similarity between IGF-I and IGF-II (Torres et al., 1995) 
suggests that both IGF molecules interact with IGFBPs through similar sidechain 
contacts. The N-terminal region of IGF-I has been implicated as an important region for 
binding to the IGFBPs. In particular, deletion of the first three residues of IGF-I leads to 
greatly reduced affinity for the binding protein (Ross et al., 1989; Bagley et al., 1989, King 
et al., 1992; and Francis et al., 1992). Long-[Arg3]-IGF-I, which has the addition of a 13 
amino acid N-terminal extension and the replacement of Glu3 with Arg3, has a seven-fold 
reduced affinity for IGFBP-3 (Heding et al., 1996). Clemmons et al. (1992) have found 
that mutation of the IGF-I residues 3 and 4 as well as 49-51 leads to reduced affinity for 
IGFBP-1. Terasawa et al. (1994) identified Phe26 of IGF-II as playing a role in changing 
the local structure of IGF-II to facilitate binding but it does not itself bind directly to 
IGFBPs. 
Using NMR spectroscopy, Jansson et al. ( 1998) defined a structural binding epitope for 
IGF-I by comparing 15N and 13c chemical shifts in the presence and absence of IGFBP-
1. A number of residues in IGF-I were affected by IGFBP-1 binding: Pro2, Glu3, Cys6 
and Gly 7, further confinning the importance of the N-tenninus for IGFBP binding. Other 
residues affected were Pro28_Gly30, Gly32, Arg36, Arg37, Gm40_Giy42, Pro63, Lys65, 
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Pro66 and Lys68-Ala70. This area spans most of one face of the molecular surface of IGF-
I. Three arginine sidechains: Arg36, Arg37 and Arg50 were shown to be involved in 
IGFBP-1 binding. Arg36 and Arg37, together with Arg21 and Arg56 also participate in 
binding to the type 1 IGF receptor. Jansson et al. (1998) found that the IGF-I/IGFBP-1 
complex does not associate with the type 1 IGF receptor. This confinns that only free 
IGF-I is capable of binding to the type 1 IGF receptor, since the binding determinants on 
IGF-I for IGFBP-1 and the type 1 IGF-I receptor overlap. The binding of IGFBPs and 
the type 1 IGF receptor to IGF-I is competitive, since the presence of either will partially 
block the other's binding surface on IGF-I. This competitive binding of IGFBPs and IGF 
receptors for IGFs is supported by Kalus et al (1998) who found that IGFBP-5 inhibits 
IGF-stimulated autophosphory lation of the receptor and complete inhibition is achieved 
when IGFBP-5 is in excess of the IGFs. 
The structures of each of the IGFBPs are discussed briefly below along with their roles in 
circulation. Some IGFBPs inhibit IGF actions while others enhance the mitogenic effects 
of IGFs. Levitt Katz et al. (1995) have provided an extensive review of the individual 
IGFBPs including their physiological characteristics and regulation and this review 
provides the basis for the information presented below. 
1.6.2 IGFBP-1 
IGFBP-1 is a 25 kDa protein that is able to inhibit or enhance IGF action in vitro. Its 
secretion by the liver into serum is regulated by insulin while glucocorticoids, glucagon, 
cAMP and somatostatin have a stimulatory effect on IGFBP-1 production. IGFBP-1 
serum levels are also dependent on age and food intake. Its main biological activity 
appears to be in carbohydrate regulation. IGFBP-1 carries IGF-I in the circulation as a 
binary complex (Twigg and Baxter, 1998). The method of cellular binding is via an Arg-
Gly-Asp (RGD) sequence near the carboxyl terminal. Glu3 and Phe49 of IGF-I were 
identified by Dubaquie and Lowman (1999) as 1najor specificity determinants for IGFBP-
1. The corresponding alanine mutations, Glu3 Ala and Phe49 Ala, selectively decreased 
IGFBP-1 binding by 34- and 1OO-fold respectively. Clemmons et al. (1992) also showed 
that optimal binding of IGF-I and IGF-II to IGFBP-1 requires contacts between residues 
Glu3 and Tlu4 at the N-terminus and Phe49_Ser51 in the A-domain. The A-domain 
residues 48-50 and Phe26 of IGF-II are important for binding to IGFBP-1 (Bach et al. 
1993). 
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1.6.3 IGFBP-2 
IGFBP-2 is a 31 kDa protein which is found in seminal plasma in high concentrations and 
in cerebrospinal fluid and serum in lower concentrations. It is secreted by many cell types 
and is expressed in many foetal and adult tissues. It has an inhibitory effect on IGF 
actions. IGFBP-2 carries IGF-I in the circulation as a binary complex (Twigg et al., 1998). 
IGFBP-2 has a preference for IGF-II over IGF-I (Jones and Clem1nons, 1995). The 
method of cellular binding is through the RGD sequence described above. 
Hobba et al. (1998) proposed that Tyr60 is located in the IGF binding interface of IGFBP-
2 and that modification or mutagenic replacement of Tyr60 directly disrupts contacts 
between IGF and IGFBP-2. However, the alternative possibility that Tyr60 modification 
and mutagenic replacement indirectly affect IGF binding for example, by preventing a 
change in conformation that is necessary for high affinity IGF binding, was not eliminated 
by the authors. The presence of an aromatic residue at position 60 of IGFBP-2 reduces 
the rate of formation of the IGFBP-2/IGF complex, but also enhances the stabilisation of 
the complex. Hobba et al. (1996) concluded that both the aromatic nature and the 
hydrogen bonding potential of the tyrosyl sidechain of Tyr60 are important structural 
determinants of the IGF-binding site of IGFBP-2. Hobba et al. (1998) found that Tyr60 
mutants had disproportionate sensitivity toward IGF-I binding, suggesting that the 
IGFBP-2/IGF-II complex contains additional points of molecular interaction that are 
absent in the IGFBP-2/IGF-I complex. Forbes et al. (1998) found that the C-terminal 
cysteine rich domain of IGFBP-2 contains determinants of IGF-II binding specificity. 
Clemmons et al. (1992) showed that substitutions of residues Phe49-Ser51 of IGF-I result 
in the greatest loss of binding activity for IGFBP-2, while substitutions of Glu3 and Thr4 
of the B-domain result in marked attenuation but not total loss of binding affinity for 
IGFBP-2. The A-domain residues 48-50 of IGF-II are important for binding to IGFBP-2 
(Bach et al., 1993). 
1.6.4 IGFBP-3 
The majority of IGF-I present in serum circulates as a co1nplex with IGFBP-3, and 
another protein, acid-labile subunit (ALS) (Baxter et al., 1989). IGFBP-3 is synthesized in 
many cells and is the major IGFBP in postnatal serum. Levels of IGFBP-3 rise 
throughot1t childhood and further increase during puberty, remaining stable throughout 
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most of adult life and slowly falling during aging. In plasma, IGFBP-3 circulates as a 
glycosylated protein of 40-44 kDa and when IGF binds is found as part of a 150 kDa 
complex that includes ALS. Proteolytic cleavage of the IGFBP-3 150 kDa complex 
reduces its affinity for IGF and the functional properties of IGFBP-3 are altered such that 
IGF is released and becomes available to target cells. The primary regulators of IGFBP-3 
are GH and proteases. In vitro, the action of IGFBP-3 has been described to be IGF 
inhibitory, IGF stimulatory or IGF independent, depending on the experimental system 
used (reviewed in Levitt Katz et al., 1995). Reding et al. (1996) found non-glycosylated 
IGFBP-3 to have a comparable affinity for IGF-1 and IGF-II with a slight preference for 
IGF-II. 
No IGF-1 sidechain specificity determinant was found for IGFBP-3 by alanine screening 
(Dubaquie and Lowman, 1999). Instead, their results suggest that the N-terminal backbone 
region of IGF-1 is important for binding to IGFBP-3. The A-domain residues Phe48, 
Arg49, and Ser50 of IGF-II are important for binding to IGFBP-3 (Bach et al. , 1993). 
1.6.5 IGFBP-4 
IGFBP-4 carries IGF-1 in the circulation as a binary complex (Twigg et al., 1998). 
IGFBP-4 is a 24 kDa protein which also appears in a glycosylated 28 kDa fonn. It is 
found in serum and seminal plasma as well as in numerous cell types including prostate 
and bone. Cellular binding is through membrane association. IGFBP-4 is inhibitory to 
IGF action. Fowlkes and Freemark (1992) demonstrated that IGF-I and IGF-II can 
directly promote the proteolytic degradation of IGFBP-4 into fragments that do not bind 
IGFs, providing a novel mechanism by which the IGFs may increase their own availability 
and/or activity in biological fluids. 
Clem1nons et al. ( 1992) found any alteration of the B-domain amino terminus or helix 1 of 
IGF-I results in a loss of affinity for IGFBP-4. Substitution of Phe49_Ser51 of IGF-I also 
results in reduced affinity for IGFBP-4. Helices 1, 2 and 3 of IGF-I are all necessary for 
optimum binding to IGFBP-4, while IGFBP-4 has additional determinants in the D-
domain of IGF-I and the carboxyl terminus of the B-domain. Clemmons et al. (1992) 
concluded that the binding pocket of IGFBP-4 is larger than the binding pockets of 
IGFBP-1, 2, and 3 and suggests that it may assu1ne a different conformation to IGFBP-1, 
2, and 3. The A-domain residues Phe48, Arg49, and Arg50 of IGF-II are important for 
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binding to IGFBP-4 (Bach et al. , 1993). 
1.6.6 IGFBP-5 
IGFBP-5 is a glycosylated 29 kDa protein which has been observed in cerebrospinal fluid, 
serum and rapidly growing foetal tissues. IGFBP-5 potentiates the action of IGF-I on 
smooth muscle cells, fibroblasts or osteoblasts (Bautista et al., 1991). IGF-I is carried by 
IGFBP-5 in a ternary complex with ALS (Twigg et al. , 1998). IGFBP-5 binds to the 
extracellular matrix of heparins and this binding leads to a 8- to 17-fold decrease of the 
IGFBP-5 affinity for IGF-I and enhances the biological action of IGF-I on the cells 
(Jones et al., 1993; Arai et al., 1996; Campbell and Andress, 1997). IGFBP-5 has been 
shown to have an inhibitory effect on the growth of carcinoma C33A cells (Higo et al., 
1997) and on the induction of alkaline phosphatase in foetal rat calvarial cells by OP-1 
(Yeh et al., 1997), demonstrating the ability of IGFBP-5 to act as an inhibitor of cell 
proliferation or differentiation. IGF-I receptor binding assays of IGFBP-5 showed that 
IGFBP-5 inhibits the binding of IGFs to the type 1 IGF receptor, resulting in reduction of 
receptor stimulation and autophosphorylation and the inhibition of IGF biological activity 
(Kalus et al., 1998). 
IGFBP-5 has been shown to contain one high affinity binding site for IGFs, located in the 
N-terminal segment Ala40 to Ile92 (Kalus et al. , 1998). The NMR solution structure 
(Figure 1.2) of this seg1nent demonstrated a globular structure consisting of a centrally 
located three-stranded anti-parallel ~-sheet (Kalus et al. , 1998). Kalus et al. (1998) found 
that the binding of IGF-II to its receptor is sterically hindered by the C-tenninal domain of 
IGFBP-5. Clemmons et al. (1992) found IGFBP-5 to be the binding protein with the 1nost 
stringent require1nents for IGF binding. Mutations in the A, B and D-domains of IGF-I 
result in reduced affinity for IGFBP-5 suggesting a larger binding pocket than IGFBP-1, 
2 or 3. In contrast to IGFBP-4, alteration of the N-tenninal region of IGF-I greatly 
reduces the affinity for IGFBP-5 which indicates that IGFBP-5 has a 1nore stringent 
requirement for contact at Glu3 and Thr4 of IGF-I relative to IGFBP-4. As for other 
IGFBPs, the A-domain residues Phe48, Arg49 and Ser50 of IGF-II are important for 
IGFBP-5 binding (Bach et al., 1993). 
1.6.7 IGFBP-6 
IGFBP-6 carries IGF-I in the circulation as binary complex (Twigg et al. 1998). IGFBP-6 
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is a glycosylated 34 kDa protein found in cerebrospinal fluid and serum. It is the only 
IGFBP that is specific for one of the IGFs, whereby it has higher specificity for IGF-II 
over IGF-I (Twigg et al., 1998). Substitution of the A-domain residues Phe48, Arg49, and 
Ser50 of IGF-II resulted in more than 5O-fold reduced binding to IGFBP-6. Phe26 of 
IGF-II is also important for binding to IGFBP-6 (Bach et al. , 1993). 
1. 7 Biological Activity 
The growth in research involving the IGF system is to a large extent due to findings 
indicating a pivotal role for these proteins in cancer and several metabolic disorders such 
as neurodegenerative diseases and osteoporosis (Walsh, 1995; Rosen et al., 1997; Werner 
and De Roth, 1998). The original somatomedin hypothesis of Daughaday et al. (1972) 
stated that GH acts on peripheral tissues, not directly, but by stimulating the liver synthesis 
of IGF, which then mediates the somatogenic actions of GH in the target tissues in an 
endocrine manner. However, the findings that IGFs are produced by many tissues in 
addition to the liver, and that this production is also GH stimulated, have changed the 
concept of IGF action from prirnarily hormonal to local, i.e. paracrine or autocrine 
(Humbel, 1990). 
1. 7.1 In Vitro Effects 
The in vitro effects of IGFs are classified into short-term insulin-like metabolic effects and 
long-term mitogenic effects. The rapid effects are readily observed with classical insulin 
target cells and, in terms of the cell response, are quantitatively indistinguishable from 
those of insulin. Metabolic effects include stimulation of glucose uptake and glycogen and 
lipid synthesis in adipose tissue. In certain cell types, short-term effects may be mediated 
via the insulin receptor, in other cell types, via the type 1 IGF receptor (Walton et al., 
1990). 
The long-term effects are mostly mediated by the type 1 IGF receptor and include 
stimulation of mitosis and cell differentiation, enhanced synthesis of DNA, RNA, protein, 
glycogen, lipid, and steroid hormones and the inhibition of protein breakdown (Humbel, 
1990). 
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A negative feedback loop also exists in which high IGF-I and IGF-II levels inhibit G H 
synthesis and secretion in pituitary cells. IGFs also stimulate transport, including calcium 
uptake and transf errin receptor up regulation. It is believed that the type 2 receptor does 
not usually mediate any of the above-mentioned effects (Walton et al., 1990). 
In vitro, IGF-II is an autocrine growth factor in neuroblastoma and rhabdomyosarcoma 
cell lines and an autocrine differential factor for skeletal muscle (Bach et al., 1993). IGF-II 
can stimulate a response through its own receptor, including the stimulation of DNA 
synthesis in a human erythroleuke1nia cell line and a rat cell line, proliferation of K-562 
cells (Tally et al., 1987), glycogen synthesis in hepato1na cells (Hari et al., 1987), 
alkalinisation of cells of the proximal tubular segment of canine kidney by stimulating 
Na+/H+ exchange across the brush border 1ne1nbrane (Mellas et al., 1986) and stimulation 
of Ca2+ influx and DNA synthesis in competent Balb/c 3T3 cells primed with epidermal 
growth factor (Lobel et al., 1988). Minniti et al. (1992) found that in rhabdomyosarcoma 
cells, IGF-II stimulates two different responses 1nediated by distinct receptors: 1) a 
mitogenic response through the type 1 IGF receptor and 2) a 1notility response through 
the type 2 IGF receptor. 
1.7.2 In Vivo Effects 
In vivo studies with IGFs have confirmed that these peptides have both an acute insulin-
like action as well as a chronic growth promoting effect and the effects of IGFs depend on 
their mode of ad1ninistration, with intravenous bolus injections causing acute insulin-like 
effects, while long-term subcutaneous administration induces growth (reviewed in Zapf, 
1995). The acute metabolic actions of IGF-I and IGF-II were observed by Zapf et al. 
(1979) (reviewed in Zapf, 1995) when a bolus 40 µg of recombinant human IGF-I was 
injected into rats intravenously, and a resultant transient hypoglycae1nia with a maximum at 
15 min after injection was observed (reviewed in Zapf, 1995). Even more pronounced was 
the fall in blood sugar when a bolus of 100 µg/kg body 1nass was injected into healthy 
human volunteers. Acute injections temporarily result in such high concentrations of IGF-
I that they exceed the binding capacity of the IGFBPs (reviewed in Zapf, 1995). Bolus 
injection of IGF-II also induced hypoglycaemic effects with decreased potency (reviewed 
in Zapf, 1995). 
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Subcutaneous infusion of IGF-I was administered over six days to hypophysectomised 
rats (in which the pituitary gland has been removed) (Guler et al., 1989). This resulted in 
increased body weight, long bone growth and accumulation of lean body mass. Similar 
results were obtained for normal rats and Snell dwarf mice. Body weight gain, tibial 
epiphyseal width and epiphyseal growth rate were stimulated to the same extent by either 
GH or IGF-I. The accumulated longitudinal bone length was slightly 1nore following 
administration of OH than of IGF-I. GH increased the weights of two examined muscles 
in comparison to IGF-I, although IGF-I and not OH increased the weights of the kidney, 
spleen and thymus, and decreased the weight of the fat pads. Due to the slow, continuous 
infusion, no hypoglycae1nia occurred. IGF-II was found to be less potent than IGF-I in 
promoting growth (Guler et al., 1989). Normal growth of diabetic rats was restored by 
infusion of recombinant human IGF-I without normalisation of the blood sugar level and 
insulin acts via an increase in IGF-I synthesis on growth of diabetic rats (Scheiwiller et al., 
1986). 
Chronic infusion of exogenous IGF-I has a nu1nber of other effects in addition to 
stimulating growth. Recombinant IGF-I infused into healthy human subjects resulted in 
inhibition of insulin secretion, increases in renal plas1na flow and glo1nentlar filtration rate 
(Guler et al. , 1989). In comparable studies with rodents, the kidney weight was increased 
substantially (Kurtz et al., 1988). The same research group found that infusion of 
exogenous IGF-I stimulated erythrocyte synthesis and proposed that this effect 1nay have 
been due to erythropoeiten synthesis. In both starved mice and diabetic rats, IGF-I reduces 
body weight losses. Spencer et al. (1988) found that IGF-I directly applied to wounds 
caused an increased growth of fibrous tissue in rats and rabbits . Further study is required 
to assess the efficacy of IGF-I as a therapy for impaired renal function, reduced 
erythrocyte synthesis, or wound healing. 
DeChiara et al. (1990) examined the developmental role of IGF-II by introducing 
mutations at the IGF-II gene locus in the mouse germ line. The authors demonstrated the 
first direct evidence for a physiological role of IGF-II in embryonic growth, since growth 
deficient animals which were otherwise nonnal and fertile resulted from the inactivated 
IGF-II gene. The growth-deficiency phenotype becomes apparent at least as early as 
embryonic day 16 and persists after birth. The possibility exists that the growth-deficiency 
phenotype is the indirect consequence of impaired placental trophic functions. IGF-II 
stimulates a nmnber of responses through its own receptor including stimulation of 
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calcium ion influx in 3T3 fibroblasts (Nishimoto et al., 1987) and amino acid uptake in 
human myoblasts (Shimizu et al., 1986). 
A summary of the biological actions and interactions of IGFs with their receptors and 
binding proteins is presented in Table 1.2. 
Table 1.2. Biological actions of IGFs in vivo and in vitro 
In Vivo 
Glucose Metabolism 
Increased glucose uptake 
Decreased hepatic glucose production 
Increased apparent insulin sensitivity 
Hypoglycaemia 
Fat Metabolism 
Decreased serum ketones 
Decreased serum free fatty acids 
Decreased triglycerides 
Protein Anabolism 
Increased protein synthesis 
Decreased nitrogen secretion 
Increased total body protein accretion 
Increased body organ weight 
Improved wound healing 
Reduces weight loss in starvation 
Renal Function 
Increased glomerular filtration rate 
Increased renal plasma flow 
Stimulates kidney growth 
Increased speed of recovery from ischaemic 
acute renal failure 
Hormones 
Decreased growth hormone 
Decreased glucagon 
Increased catecholamines 
Growth 
Increase in hypopituitary and 
GR-insensitive subiects 
In Vitro 
Stimulate transport 
Nutrient uptake (glucose, amino acids) 
Calcium influx 
Transferrin receptor upregulation 
Stimulate Biosynthesis 
DNA synthesis 
RN A synthesis 
Protein synthesis 
Glycogen synthesis 
Lipid synthesis 
Steroid synthesis 
Inhibit Catabolism 
Protein breakdown 
Stimulate Cell Division 
of cartilage, muscle and bone cells 
Stimulate Cell Differentiation 
Feedback Loop 
Inhibits GH release from pituitary cells 
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1.8 Insulin-Like Growth Factor Analogues 
A number of analogues of both IGF-I and IGF-II have been produced. These include 
IGFs with various site mutations (e.g. Sakano et al., 1991), deletions (e.g. King et al., 
1992; De Wolf et al. , 1996) and fusion proteins (e.g. Francis et al. , 1992). The majority of 
these analogues were produced using recombinant gene technology in order to investigate 
the binding sites of IGF-I and IGF-II to either the IGFBPs or the type 1, type 2 or insulin 
receptors. 
1.8.1 N-terminal Modifications 
Some of these analogues have been found to be more potent than the respective parent 
IGF-I or IGF-II. For example, a naturally occurring analogue, Des-(1-3)-IGF-I, which has 
a sequence identical to IGF-I but with the N-terminal tripeptide Gly 1-Pro2-Glu3 omitted, 
was found to be more potent at stimulating protein or DNA synthesis and inhibiting 
protein breakdown (Francis et al., 1986; Francis et al., 1988; and Ballard et al., 1987). 
Ross et al. (1989) concluded that this enhanced potency of Des-(1-3)-IGF-I is a 
consequence of its poor binding to IGFBPs. In order to further investigate the role of the 
N-terminus of IGF-I with respect to its biological properties, analogues of IGF-I truncated 
by 1-5 amino acid residues from the N-terminus were chemically synthesized. (Bagley et 
al. , 1989). Increased biological potency was observed for Des-(1 -3)-IGF-I and Des-(1-4)-
IGF-I presumably due to a lower affinity for binding to the IGFBPs. However, Des-(1-4)-
IGF-I has a lower potency than Des-(1-3)-IGF-I as a consequence of a lower affinity for 
the type 1 IGF receptor. 
The same research group found [Gly3]-IGF-I and [Arg3]-IGF-I to be more potent than 
IGF-I in biological assays measuring stimulation of protein synthesis and DNA synthesis 
or inhibition of protein breakdown (King et al. , 1992). Again, both analogues bound 
poorly to IGFBP-2 and slightly less well to the type 1 IGF receptor. It would seem from 
these results that the binding of IGF-I to IGFBP-2 is mediated, at least in part, by 
electrostatic interactions involving Glu3 of IGF-I. It was concluded that reduced binding to 
IGFBPs rather than increased receptor binding is responsible for the greater biological 
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potency of the analogues compared with IGF-I. Following this, Francis et al. (1992) found 
several fusion peptide analogues to be more potent than the native IGFs in stimulating 
protein and DNA synthesis and inhibiting protein breakdown. The analogues comprise the 
first 11 amino acids of methionyl porcine growth hormone (pGH) and the dipeptide Val-
Asn, followed by the native IGF-I sequence and were named Long-IGF-I. Two of the 
fusion peptides also contain substitutions at position 3 with Gly and Arg replacing Glu. 
The order of biological potency was found to be Long-[Arg3]-IGF-I > Des-(1-3)-IGF-I > 
Long-[Gly3]-IGF-I > Long-IGF-I > IGF-I. Investigations of receptor and IGFBP 
association by these IGF-I analogues with N-terminal modifications show increased 
biological potency, which was attributed to a decreased affinity for the IGFBPs (e.g. 
Francis et al., 1992). The Long-[Arg3]-IGF-I species is the most potent of these analogues 
because it has the weakest IGFBP affinity. The N-terminal IGF-I mutants Des(l-3)-IGF-I 
and Long-[Arg3]-IGF-I both had reduced affinity for IGFBP-3. Long-[Arg3]-IGF-I has 
much lower affinity than Des(l-3)-IGF-I for IGFBP-3, indicating that the 13 amino acid 
N-terminal extension and the sidechain charge reversal at residue 3 of Long-[Arg3]-IGF-I 
impedes IGFBP-3 binding. 
1.8.2 A- and B-Domain Mutants 
Mutations of IGF-I in the B- (residues 1-29) and A- (residues 42-62) domains were 
produced with the aim of identifying IGF-I residues that contribute to the specificity of 
binding to the type 1 IGF receptor as opposed to the insulin receptor (Shooter et al., 
1996). The B- and A- domains of IGF-I share a high degree of sequence and structural 
similarity to the B- and A-chains of insulin (Blundell et al., 1978). Amino acid residues 
not conserved between insulin and IGF-I were target sites for altering receptor binding 
specificity. Ala8, GlnlS and Ala62 of IGF-I were substituted because of their close 
proxilnity to the proposed receptor binding region (Cooke et al., 1991). Substitutions were 
intended to decrease binding to the insulin receptor by maximising differences in amino 
acid sidechain character between IGF-I and insulin at each position. In addition, a Thr4His 
analogue was chosen to evaluate the role of the N-terminal region in receptor binding, and 
a Met59Phe mutation was made because Met59 is close in space to Tyr24 and because its 
sidechain resides in the cleft between the C- and D-domains. 
The altered specificity of Phe59_IGF-I favoured the type 1 IGF receptor over the insulin 
receptor, which may be due to steric effects produced by reduced flexibility in the C- and 
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D-domains although the direct involvement of this residue in defining receptor binding 
affinity could not be ruled out. Relative to IGF-I, [Leu8]-IGF-I had significantly lower 
affinity for the insulin receptor than it has for the type 1 IGF receptor. Substitution at 
position 62 had minimal impact on insulin receptor binding but reduced affinity for the 
type 1 IGF receptor. The substitution at position 4 resulted in an increase in insulin 
receptor binding with no significant change in relative affinity for the type 1 IGF receptor. 
Substituting Ser for Gln at position 15 had no substantial effect on receptor binding or 
other biological properties. It was concluded that the co-evolution of the IGF and insulin 
receptor/ligand systems has resulted in subtle differences in the A- and B- regions of each 
ligand, and that these two regions are important for defining receptor binding specificity 
(Shooter et al., 1996). 
1.8.3 C-Domain Mutants 
Recently the solution structure of a mini-IGF-I has been determined by NMR 
spectroscopy (Wolf et al., 1996). This inactive 1nutant lacks the C- domain, which is in 
extended conformation in IGF-I. Deletion of the C- domain of IGF-I results in an altered 
relative orientation of the three helical segments (within the A and B domains) with a 
reorganisation of the hydrophobic core and displacement of the Phe23_Tyr24_Phe25_Asn26 
segment which is known to be important for receptor binding. It has been shown by Gill et 
al. (1996) that this mutant has much lower receptor binding affinity and loss of biological 
activity. While mini-IGF-I is still recognised by IGFBP-3, it binds with an association 
constant one sixth of that for wild-type IGF-I. 
Heding et al. ( 1996) investigated the binding kinetics of IGF-I analogues toward IGFBP-
3. 4-Gly IGF-I, which has the C-domain replaced by a 4-Gly bridge, has a 3-fold lower 
affinity for IGF-I. The two-fold lower affinity of mini-IGF-I for IGFBP-3 compared with 
that of 4-Gly IGF-I is attributed to the complete absence of the C-domain in mini-IGF-I, 
since this presumably causes a greater conformational change in the molecule than the 
replacement of the C-domain residues with a 4-Gly bridge. The relatively high affinity of 
these analogues for IGFBP-3 is in contrast to their very low affinity for the type 1 IGF 
receptor (Gill et al. , 1996; Bayne et al., 1989; Cascieri et al. , 1989). Three IGF-I analogues 
in which the disulfide bonds have been swapped, IGF-I swap, 4-Gly IGF-I swap and mini-
IGF-I swap all have low affinities for IGFBP-3, indicating that swapping the disulfide 
bridges in IGF-I greatly impairs the hormone's ability to bind to IGFBP-3 (Heding et al., 
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1996). The disulfide swapped IGF-I analogues also have extremely low receptor affinity 
(Gill et al., 1996), which indicates that swapping of the disulfide bonds causes a major 
conformational change of the entire protein as found by Miller et al. (1993). 
Cara et al. (1990) prepared a two-chain insulin/IGF-I hybrid that contains a synthetic 
peptide related to residues 22-41 of IGF-I linked via peptide bond to ArgB22 of des-
octapeptide-(B23-B3O)-insulin and applied the analogue to the analysis of ligand 
interactions with the type 1 IGF and insulin receptors of placental plasma membranes. The 
major aspects of structure relevant to the conferral of receptor binding affinity lie in the C-
terminal region of the insulin B chain and in the C-terminal region of the IGF-I B-domain 
and in its C-do1nain. 
1.8.4 Indirect Agonists 
Recently, a class of IGF-I analogues have been prepared which have normal binding 
affinities for IGFBPs but reduced binding to the type 1 IGF receptor and the insulin 
receptor (Milner et al., submitted for publication). These analogues which involve mutation 
of the tyrosine residues at positions 24, 31 and 60 to either alanine or leucine, increase the 
levels of endogenous IGF-I by selective displacement of IGF-I from its association with 
IGFBPs, thus pro1noting biological activity through action at the IGF receptor. This class 
of compounds are referred to as 'indirect agonists' (Milner et al., submitted for 
publication). These mutations were based on the observation by Bayne et al. (1990) that 
the three tyrosine residues at positions 24, 31 and 60 in the IGF-I molecule are involved in 
high affinity binding of IGF-I to the type 1 receptor. 
The IGF-I analogues prepared by Milner et al. (submitted for publication) included 
[Leu24]-IGF-I, [Ala31]-IGF-I, [Leu60]-IGF-I, [Leu24Ala31]-IGF-I and [Ala31Leu60]-IGF-
I. [Leu60J-IGF-I was chosen for further study as it exhibits poor binding to the type 1 
IGF receptor and normal binding to acid stripped IGFBPs, weak stilnulation of protein 
synthesis and good binding to ternary and binary complexes in hu1nan seru1n. To 
demonstrate the in vitro effect of displace1nent of IGF-I from binding proteins by an 
'indirect agonist', [Leu60]-IGF-I was added to a mixture of IGF-I and bovine IGFBP-2 
(bIGFBP-2) in the presence of rat myoblast monolayers. When [Leu60]-IGF-I was added 
to the cells with bIGFBP-2, there was very little stimulation of protein synthesis, even in 
the absence of inhibitory IGFBPs. When [Leu60]-IGF-I was added to the cells in the 
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presence of a stoichiometric concentration of IGF-I, endogenous IGF-I was displaced 
from IGFBP-2, and more IGF-I was available to stilnulate the receptor. 
1.8.5 Disulfide Intermediates 
Analogues have also been designed to investigate the oxidative refolding pathway of IGF-I 
(Narhi et al., 1993). The oxidative folding of human IGF-I yields two products of similar 
thermodynainic stability (Raschdorf et al., 1988; Meng et al., 1989; Hober et al., 1992; 
Miller et al., 1993). Analogous isomers of human proinsulin or IGF-II were not seen upon 
oxidative refolding. Miller et al. (1993) monitored the kinetics of the IGF-I folding 
pathway by high performance liquid chromatography (HPLC). Two disulfide isomers 
were obtained as products, which differ by interchange of a strained disulfide bond: one 
with native insulin-like pairing [6-48; 18-61; 47-52] (designated native IGF-I; 60% yield) 
and the other with alternative pairing [6-47; 18-61; 48-52] (designated IGF-swap; 40% 
yield). The predominant early folding intermediate contained the single disulfide 18-61, 
which is coffilnon to both products. Other folding intermediates include [6-48; 18-61] 
which is an iffilnediate precursor of native IGF-I and [18-61; 6-47], an immediate 
precursor to IGF-swap with non native disulfide 6-47. 
Spectroscopic studies employing circular dichroism (CD), infrared spectroscopy (FfIR), 
two dimensional 1H-NMR, and photochemical dynamic nuclear polarisation (photo-
CIDNP) indicated that IGF-I and IGF-swap adopt silnilar secondary stn1ctures but 
distinct tertiary folds (Miller et al., 1993). It is clear that a more general model of protein 
folding must include contributions from accessory and regulatory proteins, including 
chaperones and enzymes such as the disulfide and proline isomerases (Krebs et al., 1983; 
Jaenicke, 1991; Martin et al., 1991; Gething & Sambrook, 1992). Protein folding may also 
be influenced by specific contributions from proline sequences (Zhu et al., 1989; Winter 
& Sorensen, 1991; Weissman & Kiln, 1992) and by differences in the kinetics of 
alternative pathways (Baker et al., 1992). 
The role of the three native disulfide pairings in the folding and function of IGF-I was also 
reported (Narhi et al., 1993). Analogues containing pairwise Cys to Ser or Cys to Ala 
substitutions were expressed in E. coli, purified and analysed with respect to receptor 
binding, solution structure and thermodynamic stability. The analogue lacking all three 
disulfide bonds (designated des-Cys-IGF-I) was found to be inactive and unfolded. 
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Introduction of the [ 18-61] disulfide bond, previously shown to occur in an early 
intermediate in oxidative refolding (Miller et al., 1993), resulted in a compact folded state 
with low but significant biological activity. Additional, but incomplete structural 
organisation and biological activity were observed following the introduction of either the 
[6-48] or the [ 47-52] disulfide bonds. Successive formation of native disulfide bonds 
leads to stepwise stabilisation of native structural ele1nents. The one- and two- disulfide 
analogues may be viewed as molten globules, i.e. compact partially folded states 
containing defined elements of secondary structure with fluctuating tertiary orientation 
(Baum et al., 1989; Kuwajima et al., 1991). 
The folding pathway of Long-[Arg3]-IGF-I has been compared with that of IGF-I by 
Milner et al. (1999). Unlike IGF-I, which yields 45% of the native structure and 24% of 
the alternative structure ( [18-61], [6-47] and [48-52] disulfide bonds), Long-[Arg3]-IGF-I 
yields 85% and 10% of these respective forms. Three native-like intennediates were 
identified, that appear to have a major role in the in vitro refolding pathway of Long-
[Arg3]-IGF-I; a single [18-61] disulfide intermediate, an intermediate with [18-61] and [6-
48] disulfide bonds, and another with [18-61] and [47-52] disulfide bonds. Milner et al. 
(1999) proposed that the [18-61], [6-48] intermediate forms the native structure, not by 
direct formation of the [47-52] disulfide bond, but by rearrangement via the [18-61] 
intermediate and a productive [18-61], [47-52] intermediate. In this pathway, the last 
disulfide bond to form involves Cys6 and Cys48. This pathway was applied to IGF-I and it 
was suggested that the divergence in the in vitro folding pathway of IGF-I is caused by 
non-native interactions involving Glu3 that stabilize the alternative structure. The 
interactions that stabilize the "off-pathway" intermediates are reduced for Long-[Arg3]-
IGF-I due to the N-terminal extension and the charge reversal at position 3. 
1.9 NMR Approach to Protein Structure Determination 
1.9.1 Introduction 
Nuclear magnetic resonance (NMR) spectroscopy can give detailed information about 
protein structure, dynamics and interactions. NMR in bulk matter was demonstrated 
independently by Bloch et al. (1946) and Purcell et al. (1946). Shortly after, it was 
discovered that although the signals were coming from the nucleus, the nuclear resonant 
frequency was sensitive to the chemical environment (Proctor and Yu, 1950). This 
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phenomenon is known as chemical shift. With ilnprovements in the homogeneity of 
magnets, the phenomenon of spin-spin coupling arising from interactions between nuclei 
sharing bonding electrons was discovered (Gutowsky et al. , 1951). In 1955, Overhauser 
suggested that the intensity of an NMR signal would be enhanced by irradiation of 
unpaired electron spins in a sample. This lead to the nuclear Overhauser experiment where 
the mutual dipolar interaction of two protons close in space can be determined, thus giving 
distance information. This experiment is exploited in protein structure determination. Two 
ilnportant technical advances were the introduction in the late 1960s of pulse 1nethods with 
Fourier transformation (Ernst et al. , 1966) and, a decade later, two-dimensional techniques 
(Aue et al., 1976). 
In the late 70s and early 80s, the role of NMR in structural biology became established. 
The first two dilnensional spectrum of a protein was obtained by Nagayama et al. (1977). 
Kurt Wtithrich and colleagues eg., Wtithrich et al., 1982 demonstrated that protein 
conformation can be calculated in a systematic way provided that the 1 H resonances can be 
assigned to particular chemical groups in the protein. The 1nethod by which this is done is 
termed the sequential assigmnent procedure and is described in section 1.9.2. The first 
polypeptide structure determined fro1n NMR data was derived by Williamson et al. 
(1985) . 
The information content available from the sequential assignment method depends on the 
molecular mass of the protein since, with increasing 1nass, the linewidths become broader 
and the overlap of resonances becomes 1nore severe, meaning resolution and assignment 
become increasingly difficult (Ca1npbell et al. , 1991). This problem of overlap is alleviated 
by the use of isotopic labels together with 1nultidimensional pulse techniques. 
Tremendous growth has taken place in the field of NMR spectroscopy and its application 
to the study of macromolecules. NMR can not only be considered an alternative to x-ray 
crystallography when protein crystals are not available, but also a complementary 
technique that provides an alternative perspective to the protein structure and dynamics. 
Higher field magnets have been constructed, with spectrometers operating at 1 H 
frequencies as high as 800 MHz now available, resulting in improved sensitivity and 
resolution. The development of multinuclear, multidimensional NMR experiments based 
on sophisticated pulse schemes, coupled with either specific or uniform isotopic labelling 
of the molecule, has greatly enhanced the utility of NMR for the study of molecular 
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structure and dynamics (Kay and Gardner, 1997). 
The development of pro bes with actively shielded gradient coils has made pulsed field 
gradient technology feasible in high resolution spectroscopy, resulting in substantial 
enhancements in spectral quality, via an improve1nent in artefact and solvent suppression 
(Kay, 1995). Before the development of gradient technology, artefacts in NMR 
experiments were eliminated by phase cycling, i.e. by repeating the experiment several 
times with different phases for the RF pulses and/or the receiver. The phase cycling is 
devised to ensure that the desired coherence transfer pathway is retained and unwanted 
coherence transfer pathways cancel at the end of the phase cycle. This process requires 
excellent spectrometer stability, often for a period of days. In practice, data acquisition 
times often limit the utility of phase cycling. The use of pulsed field gradients permits the 
suppression of artefacts on a per scan basis, thereby reducing the need for long term 
spectrometer stability and permitting acquisitions to be set according to the desired 
resolution and signal-to-noise (Hurd and John, 1991; Vuister et al., 1992). Pulsed field 
gradients are introduced into the pulse sequence to refocus the coherences in the desired 
pathway and dephase coherences that follow unwanted coherence pathways. 
The solution of a protein structure by NMR can best be summarized as a method of 
translating distance and dihedral angle information into atomic coordinates. This process 
follows several well established steps. The initial step is the sequence-specific assignment 
of NMR resonances (Wtithrich et al., 1986). The next step is the translation of scalar (J) 
coupling data into dihedral angle restraints and nuclear Overhauser enhancement data 
(NOEs) into interproton distance restraints. The final step is the calculation of a three-
dimensional structure from these dihedral angle and interproton distance restraints by 
either distance geometry or restrained molecular dynamics. The strategy and the NMR 
experiments required to sequentially assign resonances differ depending on whether an 
unlabelled protein, a 15N-labeled protein, a 13C-labeled or a 15N/13C-labeled protein is 
available. Since the two IGF-I analogues in this study were 15N-labeled proteins, the 
subsequent sections on the sequential assign1nent procedure and the structural restraints 
evaluation used for the three-dimensional structure calculations are specific for a 15N-
labeled protein. 
The combination of two-dilnensional ho1nonuclear, two-dimensional heteronuclear and 
three-di1nensional heteronuclear NMR experiments is utilised for obtaining sequence 
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specific assignments of a 15N-labeled protein. This approach partially resolves the 
chemical shift degeneracy in two-dimensional hornonuclear spectra by dispersing the 
resonances along an additional and better resolved heteronuclear frequency axis. These 
experiments that contain INEPT modules (Morris and Freeman, 1979) transfer 
magnetisation efficiently between the amide protons and a single 15N nucleus via nearly 
conformationally independent one bond coupling constants. The relationship between 2D 
and 3D spectra is outlined in Figure 1.3. Each 3D plane at the 15N shift of the amide 
nitrogen contains a subset of the 2D proton crosspeaks that are related to that particular 
amide group either by a dipolar or scalar interaction depending on the pulse sequence of 
the 3D experiment. 111e 15N labels are incorporated into the protein by modern 
biotechnology methods and replace the naturally abundant 14N nucleus which has less 
desirable NMR properties. The power of these experiments is manifested in the ability not 
only to increase resolution but to reveal connectivity paths between the protons and the 
nitrogen which can be 1nanipulated by the various forms of the heteronuclear NMR 
experiments. For smaller proteins it is relatively rare to find that both the 1 H and 15N 
chemical shifts of two HN groups are degenerate and hence these heteronuclear 
experiments can be used in cornbination with the conventional homonuclear ones to 
resolve ambiguities. The 3D spectn1m is viewed as a series of lH-HN slices edited by the 
chernical shift of the directly bonded 15N atom. Each I H-1 H plane represents the identical 
region covered by the 2D experiment, only containing fewer cross peaks. Connections 
between one residue and the next must be made not only between different sets of peaks 
but also between different planes of the spectrum (Marion et al., 1989). 
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Figure 1.3: Sche1natic representation of the relationship between 3D heteronuclear NMR 
sp·ectra and homonuclear 2D spectra. The 3D spectrum is viewed as a series of Fl (1 H) -
F3 (HN) slices edited by the che1nical shift of the directly bonded 15N ato1n along F2. 
1.9.2 Sequential Assignments 
The sequential assignment method (Wiithrich et al., 1982) consists of three stages. The 
first stage establishes the identity of the systems of spin-spin coupled resonances which 
belong to a particular amino acid residue type. The spin syste1ns can be divided between 
short sidechain (Gly, Ala, and Thr), long sidechain (Val, Ile and Leu), Type J (Ser, Asp, 
Asn, Cys, Trp, Phe, Tyr and His) and Type U (Lys, Arg, Met, Gln, Glu and Pro). The spin 
systems are assigned an amino acid type based on coupling patterns and resonance 
chemical shifts. Assignment of an amino acid type is achieved by inspection of scalar 
coupling connectivities within individual residues using 2D 15N-HSQC-TOCSY and 3D 
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15N-TOCSY-HSQC experiments. The 2D 15N-HSQC spectrum serves as the starting 
point for spin system identification. For each non-proly 1 residue, an HN cross peak is 
observed. The backbone HN cross peak previously located in the HSQC spectrum is 
correlated with Ha and sidechain protons by inspection of 1 H-1 H planes of the 3D 15N-
TOCSY-HSQC spectrum. Experiments that use scalar coupling of protons only, e.g., 
TOCSY, work because no coupling is observed across the peptide bond. Hence the 
connectivities to the amide proton are confined to intraresidue contacts. 
Amide, alpha and methy I-containing protons are recognised by their characteristic shift 
values. The aliphatic random coil 1 H chemical shifts, obtained from the database of 13 
proteins described by Kraulis (1994) are shown in table 1.3. The range given in the table 
extends one standard deviation either side of the mean value. The spin systems for some 
residue types, in particular, glycine, alanine and threonine can be assigned with relative 
ease based on their characteristic chemical shifts (Table 1.3) and spin coupling patterns. 
The remaining methyl-containing residues, valine, isoleucine and leucine can be difficult to 
distinguish. V alines are often recognised by the characteristic high field che1nical shift of 
the a-proton. Type J residues (Ser, Asp, Asn, Cys, Trp, Phe, Tyr and His) have H~ 
resonances which usually resonate downfield of 2.5 ppm and have identical HN-Ha-H~ 
spin subsystems. The aromatic protons of Tyr, Phe, Trp and His residues, and sidechain 
amide protons of Glu and Asp are not scalar coupled to the remainder of the sidechain. 
Association of the sidechain and backbone resonances of these spin systems has to be 
made on the basis of intraresidue NOE correlations. Type U amino acid residues (Lys, 
Arg, Met, Gln, Glu and Pro) all have two protons at the yposition which are coupled to the 
H~ protons. There may be some uncertainties among ~' y, and 8 protons within one spin 
system of some of the Leu, Arg, Lys, Glu and Gln residues. These ambiguities can largely 
be resolved by obtaining 3D 15N-TOCSY-HSQC spectra at two different mixing times. 
Overall, as a result of this first stage of the assignment procedure, the spin systems have 
either been assigned to a unique amino acid or spin system type. The subsequent steps 
assign the 1H spin system residues to a unique amino acid in the sequence. The 
assignment of proline residues must be obtained from the 2D TOCSY and 2D NOESY, 
since the spin systems are not observed in the 15N correlated spectra, as proline residues 
do not possess a free amide proton. 
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Table 1.3. Random coil 1 H chemical shift ranges (ppm) for the 20 common 
amino acids 
Residue I aH I ~H I Other 
Gly 3.5-4.4 
Ala 3.8-4.8 1.1-1.6 
Val 3.6-4.8 1.6-2.2 I y 0.6-1.1 
Ile I 3.7-4.8 I 1.5-2.1 I yl 1.0-1.7 
y2 0.6-1.1 
81 0.5-1.0 
Leu I 3.9-4.9 I 1.4-2.0 I y 1.3-1.9 
8 0.5-1.0 
Pro I 4.0-4.9 I 1.4-2.5 I y 1.S:2.2 
8 3.2-4.1 
I 
Ser 4.2-5.1 3.6-4.2 
Thr 3.9-5.0 3.8-4.5 y 0.9-1.4 
Asp I 4.1-5.0 I 2.4-3.0 
Glu 3.9-4.9 1.8-2.3 y 2.1-2.5 
Lys 3.8-4.7 1.4-2.0 y 1.1-1.6 
8 1.4-1.9 
c 2.8-3.1 
Arg I 3.7-4.7 I 1.5-2.1 I y 1.3-1.8 
8 2.9-3.3 
I 
Asn 4.2-5.0 2.4-3.2 
Gln 3.8-4.8 1.6-2.3 I y 2.0-2.6 
Met I 4.0-5.0 I 1.8-2.2 I y 2.3-2.7 
c 1.6-2.7 
I 
Cys 3.8-5.3 2.6-3.3 
Trp 4.2-5.1 2.2-3.6 
Phe 4.1-5.2 2.6-3.4 
Tyr 4.2-5.2 2.5-3.3 
His 4.3-5 .1 2.6-3.5 
The second stage of the assignment process is to cross the peptide bond and linearly 
connect as many spin systems as possible. In a l5N-labeled protein there is no resolvable 
spin-spin coupling between protons of adjacent residues and therefore, through-bond 
correlation spectra cannot be used to determine the sequential connectivities. Sequential 
assignment is achieved by using through-space 1nediated (NOE) interactions to 
sequentially connect the spin systems identified from scalar correlations using 2D 
NOESY, 2D 15N-HSQC-NOESY and 3D 15N-NOESY-HSQC experiments. The primary 
assumption of the sequential assignment is that the probability is low that the amide proton 
of one residue is simultaneously close to the amide, a and ~ protons of any residue other 
than the preceding one. Individual long range NOEs to one of these protons may be 
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observed, but rarely to all three. In practice, sequential and intraresidue NOEs are usually 
more intense than long-range NOEs, which tend to be mostly weak. Identification of 
intense NOEs from the HN of one spin system (i) to the HN, Ha or H~ of a second 
preceding spin system (i-1) suggests that the two spin systems are adjacent in the primary 
sequence with the first spin system nearer to the C-tenninus of the protein. Identification 
of a series of sequential NOE interactions places several spin systems in the order i, i + 1, i 
+2, i +3, .... .i + n. 
The third stage is alignment in the sequence. As more spin systems are connected, the 
sequence of spin systems will eventually match a unique section of the primary ainino acid 
sequence of the protein (which must be known prior to commencement of the assignment 
procedure). If the spin system types are well characterized (i.e. the majority of sidechain 
resonance positions have been identified), then alignment of four to five spin systems is 
usually sufficient to achieve sequence-specific assignment for those residues. A sche1natic 
diagram (Figure 1.4) of a dipeptide shows the possible short range NOEs used in the 
sequential assignment procedure. 
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Figure 1.4: Dipeptide unit showing the sequential NOE connectivities, dNN, daN and d~N 
used for sequential proton assignments. 
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1.9.3 Structure Determination from NMR Data 
Secondary Structure 
The secondary structure of a protein refers to the local conf onnation of its backbone. 
Regular polypeptide backbone folding patterns include helices, ~-sheets and turns. 
Secondary structures in proteins have characteristic NOE patterns and scalar coupling 
constants (described in detail in section 4.1). Knowledge of the secondary structure 
elements in a protein assists with the stn1ctural determination process. 
Hydrogen bonding has a major influence on the structure of proteins. The internal 
hydrogen bonds of a protein provide a structural basis for its native folding pattern. 
Weakly acidic protons, such as those of amide and hydroxyl groups (X-H) exchange with 
those of water. Protein interiors are largely excluded fro1n contact with their surrounding 
aqueous solvent, and protons cannot exchange with solvent while they are engaged in 
hydrogen bonding. However, internal protons do exchange with solvent, indicating 
transient local unfolding that physically and chemically exposes these exchangeable 
protons to the surface, must occur. Hence, the rate at which a particular proton undergoes 
hydrogen exchange is a reflection of the conformational mobility of its surroundings. 
Hydrogen bond restraints 1nay be added in regions assigned to a regular secondary 
structure if slowly exchanging amide protons are observed in these regions. Hydrogen 
bond restraints have a large impact on the nature and precision of the resulting structures 
and are usually incorporated as restraints in the later stages of structure refinement, only in 
well-defined regions of regular secondary structure, where only one possible hydrogen-
bond acceptor is consistent with the NOE data. 
The deviation of the chemical shifts of the Ha protons from their random coil values can 
be used to support secondary structure information obtained from NOE connectivities 
since Ha chemical shifts are dependent on the nature of secondary structure (discussed in 
detail in section 4.1). Thus, the Ha proton experiences an upfield shift with respect to the 
random coil value when in an a-helical conformation and a downfield shift when in a~-
sheet conformation. 
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NMR Derived Structural Restraints 
Chemical shifts, scalar coupling interactions and dipolar relaxation are sensitive to 
molecular conformation. Quantitative estimates of each of these parameters are used for 
structural analysis. The principal structural data from NMR used in determining protein 
structure are NOE cross peak intensities. The standard experiment for detecting through-
space dipolar interactions is the 2D NOESY experiment, a 2D version of the NOE 
experi1nent (Overhauser, 1955), in which cross-peaks identify resonances fro1n atoms near 
in space. The dipolar cross-relaxation rate is proportional to the inverse sixth power of the 
distance between two interacting protons and hence is sensitive only over short distances. 
In practice, the maxiinUin interproton distance that can give rise to an observable first order 
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NOE is 5A. The sixth order dependence also permits the discrimination of proton pairs on 
the basis of internuclear distance. NOE cross peaks intensities are converted to interproton 
distances by direct calibration of the intensity of peaks observed in 3D 15N-NOESY-
HSQC spectra acquired at relatively short mixing times. The cross peak volume limits and 
upper bound distances for the categories are estilnated fro1n the NOE intensities observed 
for protons of known covalent geometry (e.g. geminal methylene protons) or between 
protons in regions of regular secondary structure. Conservative upper-bound distances 
compensate for cross-peak intensities that may be affected by spin diffusion or partial 
overlap, both of which can lead to unjustifiably tight distance restraints. Intensities can also 
be calculated and converted to upper bounds in an auto1nated fashion. 
The magnitude of 3JHNHcx scalar coupling constants contain valuable information about 
the backbone dihedral angles in a protein. The magnitude of the 3JHNHcx values is related 
to the backbone dihedral angle of a protein, 8 (shown in Figure 1.5) by the Karplus 
equation (Karplus, 1959; Bystrov, 1976) (discussed in section 5.3.2) which has been 
paraineterised for this purpose by correlating the J values measured in small globular 
proteins with dihedral angles obtained from crystallographic studies (Pardi et al., 1984; 
Ludvigsen et al., 1991). Dihedral angle restraints are used in calculating the protein 
structure. 3 J HNHcx values can be used to directly determine secondary structure whereas 
JN~ and Jex~ values are used to identify prochiral groups, i.e. sidechain dihedral angles. 
The latter are particularly ilnportant for buried sidechains that take up fixed positions. 
Surface sidechains frequently are 1nobile and averaged IN~ and la~ values are indicative of 
sidechain conformational averaging. 
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Calculating Protein Structures from NMR Data 
A variety of methods are available for calculating protein structures using NMR-derived 
restraints. These methods determine coordinates for the atoms in the protein that will 
satisfy the input distance and dihedral angle restraints while exploring all regions of 
conformational space compatible with the NMR parameters. Since the restraints are 
included as ranges of allowed values, the data contain experimental uncertainties and 
because not all possible distance, dihedral and hydrogen bonding restraints are observable, 
the structure calculation is repeated to determine an ensemble of low-energy structures 
consistent with the input data. The low-energy ensemble of structures should 1ninimise 
violations of the input restraints and minimise the root-mean-square deviation (RMSD) 
between members of the ensemble. 
The two most common approaches for generating structures are distance geometry (DG) 
and restrained molecular dynamics (rMD), or a 1nethod employing both. Distance 
geometry detennines ensembles of 3D structures consistent with an incomplete set of 
distance constraints. Not all distances between all the possible proton pairs can be used 
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because the NOE effect is limited to distances less than 5A and even these distance 
restraints are not known precisely. In the rMD technique, molecular dynamics force fields 
are supplemented by pseudo-energy terms based on the NMR-derived restraints. The 
potentials drive the structure toward a conformation that will reduce the violation of the 
restraints during a forced heating followed by a cooling annealing cycle. The most 
efficient implementations of the rMD method use a simplified force field in which the 
bond length, the bond angle and the repulsive van der Waals terms are retained. These 
implementations are referred to as dynamic simulated annealing. For this thesis, structures 
were generated using the computer program, DYANA 1.5 which employs simulated 
annealing co1nbined with molecular dynamics in torsion angle space. An iterative process 
of calculation is employed in which successive rounds of structure calculations are used to 
make further NOE assignments. 
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Figure 1.5: Protein backbone with the backbone dihedral angles q> and \V indicated. The 
amino acid sidechain is represented by R. 
The precision to which a structure can be calculated is directly proportional to the number 
of experimental restraints used to generate it. The use of 1SN-labelling allows many more 
1H- 1H NOEs to be unambiguously identified. In addition, extra data are available to 
stereospecifically assign prochiral groups, for example, C~H2 methylene protons, y-CH3 
and 8-CH3 groups of valine and leucine residues, respectively, which helps in obtaining 
structures of high precision. 
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NMR Structures 
Because NMR structures are obtained in the solution state, there is not only a direct 
correlation with structure, but also with backbone and sidechain dynamics. NMR 
structures are commonly presented as a family of structures that are consistent with the 
input restraints. Variations in the dynamics of the backbone are indirectly related to 
variations in the spread of the backbone structures in different regions of the protein. A 
quantitative estimate of mobility can be obtained by calculating an RMSD of the family of 
structures of different regions. A high RMSD is frequently correlated with regions of high 
flexibility, but where possible, direct 1nethods based on relaxation measurements should be 
used to confirm this interpretation. A detailed description of the direct relaxation 
techniques is presented in chapter 6. It is becoming increasingly clear that knowledge of a 
protein's structure is not sufficient to understand the interactions of a protein with other 
proteins and receptors. Protein dynamics provides an alternative and complementary 
insight into these interactions. 
1.10 Research Aims 
The primary aim of this PhD thesis is to use structural infonnation obtained by NMR 
spectroscopy to account for the altered biological activity of the IGF-I analogues, Long-
[Arg3]-IGF-I and Long-[Leu60]-IGF-I. 
As discussed in section 1.8, Long-[Arg3]-IGF-I is one of the most potent of the 
recombinant fusion protein analogues of IGF-I in which the N-terminal region has been 
modified (Francis et al., 1992). It has been postulated that the increased potency of Long-
[Arg3]-IGF-I is due to reduced binding to IGFBPs rather than increased affinity for the 
cell receptors. It is unclear whether the increased potency of Long-[Arg3]-IGF-I is a direct 
result of the N-terminal extension hindering binding to IGFBPs or because the N-terminal 
extension disrupts the secondary and tertiary structure of regions of the IGF-I domain 
involved in IGFBP binding. 
The three-dimensional structure elucidation of Long-[Arg3]-IGF-I will determine whether 
the secondary structural elements of IGF-1, nainely the three helices and their relative 
orientation, have been retained in Long-[Arg3]-IGF-I. Chemical shift index analysis of H <X 
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will provide information as to whether any residues of Long-[Arg3]-IGF-I exist in 
different chemical environments when compared with IGF-I. Chemical shift index, 3JNHa 
values and NOE patterns will be used to identify regions of well defined secondary 
structure in Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I. Amide proton exchange rates 
will indicate which residues are at the surface of the protein and which are protected from 
exchange. This information will be compared with HN exchange data for IGF-I and will 
provide insight into whether the sites of IGF-I involved in IGFBP or receptor binding 
remain solvent accessible in Long-[Arg3]-IGF-I. The three dimensional structure of Long-
[Arg3]-IGF-I will be determined with a particular focus on the N-terminal extension and 
how it interacts with the IGF-I domain of Long-[Arg3]-IGF-I. Backbone dynamics studies 
of Long-[Arg3]-IGF-I will also be performed to gain insight into the degree of mobility of 
regions of Long-[Arg3]-IGF-I critical for IGFBP or receptor binding. This information 
will be used to rationalise the increased biological potency of Long-[Arg3]-IGF-I. 
A similar approach will be taken in examining Long-[Leu60]-IGF-I. However, the global 
fold of Long-[Leu60]-IGF-I will not be calculated unless a significantly different 
secondary structure is detected compared to Long-[Arg3]-IGF-I. Structural para1neters of 
Long-[Leu60]-IGF-I will be compared with IGF-I and Long-[Arg3]-IGF-I and interpreted 
in terms of binding affinities for IGFBPs and receptors and biological potency. In order to 
accurately elucidate the residues involved in IGFBP binding, chemical shift mapping 
studies of Long-[Leu60]-IGF-I with IGFBP-2 will be performed. This involves acquiring 
a series of 2D 15N-HSQC spectra without IGFBP-2 and subsequently with increasing 
concentrations of IGFBP-2, enabling observations of perturbed resonances which are 
implicated in the binding interaction. 
When combined together, regions of secondary structure, amide proton exchange rates, 
3D structural data, backbone dynamics and chemical shift 1napping will provide insight 
into the regions of IGF-I and the IGF-I analogues ilnportant for IGFBP and receptor 
binding. These results will be interpreted in terms of enhanced biological activity of the 
analogues and will, in the longer term, assist in the design of additional potent IGF-I 
analogues. 
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CHAPTER2 
Protein Expression and Purification 
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2.1 Introduction 
The two IGF-I analogues to be characterized by NMR are approximately 9 kDa in mass, 
which is at the liJn_it of structure determination by homonuclear NMR methods alone 
(Oschkinat et al., 1994). This limitation is particularly acute for proteins with a high helical 
content, in which the majority of the alpha protons are expected to resonate within a range 
of just one part per million upfield of the water resonance in a crowded region of the 1 H 
NMR spectrum. The three-dimensional structure of IGF-I was determined by two 
independent groups using purely homonuclear techniques (Cooke et al., 1991; Sato et al., 
1993). The analogues studied in this thesis, Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I 
are larger than IGF-I itself, each with an additional 13 amino acids, resulting in further 
overlap in the 1 H NMR spectrum in comparison with IGF-I. 
Some of the 1H resonance overlap can be alleviated in l5N-labeled proteins by 15N-
separated NMR spectroscopy. Acquisition of 15N-separated multi-dimensional spectra is 
only feasible at normal protein concentrations with a 15N-labeled protein. 15N-separated 
spectra segregate 1 H resonances into a series of planes in a third dimension according to 
the 15N resonance frequency of the directly bonded amide nitrogen. The efficacy of using 
the 15N-labeled protein has been improved by the reduction in price of 15N source 
(15NH4Cl). Both proteins were expressed recombinantly in E. coli on minimal media with 
15NH4Cl as the sole nitrogen source employing the methods developed by King et al. 
(1992). 
Uniformly 15N-labeled Long-[Arg3]-IGF-I had been expressed and purified by Gary 
Shooter (Department of Biochemistry, University of Adelaide) prior to the commencement 
of my PhD project, following the methods outlined by King et al. (1992) and as such, 
these methods and results will not be discussed in this chapter. The expression and 
purification of Long-[Leu60]-IGF-I, described in the subsequent sections of this chapter, 
also followed the general methods of King et al. ( 1992) and was performed initially under 
the guidance of Dr Steve Milner at the CRC for Tissue Growth and Repair in Adelaide 
and continued unsupervised at the Research School of Chemistry, ANU. 
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2.2 Materials 
2.2.1 Expression Vector Construct 
E.coli strain JM1O1 was transformed with the p[Met1]-pGH(l 1)-Val-Asn-[Leu60]-IGF-I 
expression vector and maintained on minimal medium as described by King et al. (1992). 
2.2.2 Chemicals 
( 15NH4)Cl (99% enrichment) was obtained from Cambridge Isotope Laboratories 
(Cambridge, MA). The media components included 15NH4Cl, K2S04, KH2P04, Na2P04, 
glucose and MgS04, thiamine and ampicillin. Isopropyl ~-D-thiogalactopyranoside 
(IPTG) was used for induction. Trace elements included FeS04, MnS04, ZnS04, CuS04, 
sodium citrate, and concentrated HCI. For purification of Long-[Leu60]-IGF-I, urea was 
obtained from Merck, Tris, 2-hydroxyethyldisulphide and LiOH from Aldrich, EDTA and 
acetic acid from Ajax, ZnC12 from Sigma, DTT from Boehringer Mannheim and glycine, 
ammonium acetate, NaCl, TFA, acetonitrile, NaOH, and HCl from BDH. 
2.2.3 Separation and Analytical Columns 
Initial purification of the IGF analogues was by ion exchange chromatography using a 
Pharmacia column of dimensions 400 mm x 30 mm packed with SP Sepharose Fast Flow 
(FFS) (Pharmacia-Biotech) media, a strong cation exchange gel. The pump was a Delta 
Prep 4000 (Waters) with a Millipore Lamda Max absorbance detector (Waters) measuring 
absorbance at 280 nm connected to a Linear Instruments model 555 chart recorder. 
Subsequent purification was by reverse phase HPLC. A Waters C4 column was used with 
0 
a pore size of 300 A and dimensions of 40 mm x 100 mm. The pump and system 
controller used were a Waters Delta Prep 4000 and Waters 4000 System controller with a 
Waters PrepPack RCM Base. Detection was with a Waters Millipore Lamda Max 
absorbance detector monitored with Maxima 820 software. The purity of the column 
fractions was monitored by analytical HPLC using a SGE C4 column of dimensions 4 
0 
mm x 250 mm, pore size 300 A, 15 µm particle size and nucleosil packing. A Waters 510 
HPLC pump with a Rheodyne Injection port was used with a Waters Millipore Lamda 
Max absorbance detector and the system controller was Maxima 820 software. 
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2.2.4 Spectroscopy and Sequencing 
The concentration of the NMR sample was determined by UV-visible spectrophotometry 
using a Cary lE UV-Visible Spectrophotometer with Cary E Software on an IBM PC 
central controller. Mass spectrometric analysis was performed on a Fisons Instruments 
QUATTRO II Triple Quadrupole Mass Spectrometer. The protein was submitted to the 
Biomolecular Resource Facility at the John Curtin School of Medical Research where N-
terminal sequencing of the protein was performed on a Model 494 PROCISE-HT protein 
sequencer in pulsed-liquid mode (Perkin Elmer Applied Biosystems, Foster City, CA). 
2.3 Methods 
2.3.1 Overexpression of Long-[Leu60J.JGF-I 
Preparation of Inoculum 
The E. coli culture containing the Long-[Leu60]-IGF-I construct was plated out on 
minimal media two days prior to the planned commencement of fermentation. A shaker 
culture was prepared the same morning that fermentation commencement was planned. 
Ampicillin (200 µg/ml) was added to 200 ml of Luria Broth (Ausubel et al., 1998) in the 
shaker flask. To this, a single colony of organisms was added to the culture which was 
shaken at room temperature. The optical density of the culture was monitored throughout 
t~e day. 
Fermentation 
The base media for the fermentations was prepared with the following salts: 7 mM 
K2SO4, 12 mM KH2PO4, and 18 mM Na2HPO4. The salts were dissolved in 1.6 L of 
water filtered through a 1 µm filter and the pH adjusted to 7 .0. D-glucose ( 139 mM) and 
MgSO4 (2.3 mM) were dissolved in 0.4 L of water and filtered through a 1 µm filter. 
Both solutions were autoclaved along with the fermentation assembly (Applikon 5 L 
fermenter). 4 ml of trace element stock solution was sterile filtered through a 0.22 µm 
filter and added to the fermenter. The trace element stock solution contained 5 g/L 
Fe2SO4, 1.28 g/L MnSO4, 2.16 g/L ZnSO4, 0.2 g/L CuSO4, 22 g/L sodium citrate and 10 
g/L concentrated HCl. A stock solution of thiamine (0.3 g in 7 .5 ml) was made and sterile-
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filtered through a 0.22 µm filter and 2 ml was added to the fermenter. 1 ml of a 100 mg/ml 
ampicillin solution was also sterile filtered and added to the fermenter. 3.21 g 15NH4Cl 
(30 mM) was dissolved in 10 ml water and sterile-filtered. This solution was added to the 
fermenter through the septum immediately prior to inoculation. 
The shaker culture was left during the day at room temperature and inoculated when the 
organism populations had reached the doubling phase. The inoculum volume was 900 µI. 
The optical density of the fermentation was measured throughout the day, the temperature 
was maintained at 37 °C, dissolved oxygen (initially set to 60%) was monitored and pH 
was maintained at 7.0. The stirrer motors were set at 600 rpm. Once the dissolved 02 
dropped below 60%, the air flow was increased. The fermenter control software, FC4, was 
manufactured by Real Time Engineering, NSW. The fermentation was induced with IPTG 
(0.67 ml of a 1 M solution) when the optical density was 1.5. The fermentation was 
terminated when the optical density reached a reading that remained stable, indicating that 
exponential growth was no longer occurring. 
Homogenisation 
Following the termination of the fermentation, the broth was transferred to a pre-cooled 
stainless steel holding tank using a masterflex peristaltic pump. The broth was 
homogenised by four passes at 10000 psi using a Rannie bench top homogeniser model 
8.30H. 
Centrifugation 
Following homogenisation, the cells were harvested by centrifugation using a Beckman 
J2-21 centrifuge. The homogenate was distributed into 6 x 500 ml Beckman centrifuge 
bottles which were balanced so that the pairs were within 1 g of each other. Initially, the 
homogenate was centrifuged at 10000 rpm at 4 °C for 25 min. This spin was performed to 
reduce the effective volume, retain all the inclusion bodies, but this also included cell debri. 
The supernatant was decanted off into a plastic bottle and retained until the purification 
was complete. 
The inclusion body pellets in each of the centrifuge bottles were resuspended in 200 ml of 
inclusion bodies' washing buffer (30 mM NaCl, 10 mM KH2PO4, 0.5 mM ZnCl2) and 
51 
centrifuged at 6500 rpm at 4 °C for 25 min. This spin was designed to retain the largest 
inclusion bodies but leave most of the cell debri in suspension. The supernatant was 
decanted off and again retained. 
The inclusion body pellets were again resuspended in 200 ml of inclusion bodies' washing 
buffer and centrifuged at 10000 rpm at 4 °c for 25 min. This spin was designed to obtain 
a solid inclusion bodies pellet. The supernatant was decanted off and retained. 
The inclusion body paste was scraped from each of the centrifuge bottles and the yield of 
wet inclusion bodies recorded. Different temperature compensation settings were required 
for different rotor speeds. The supernatant retained from the centrifugation was tested by 
HPLC to ensure that there was no protein present before discarding. 
2.3.2 Purification of Long-[Leu60J-IGF-I 
Dissolution of Inclusion Bodies 
Inclusion bodies were resuspended at 10% (w/v) in a solution of 8 M deionized urea, 50 
mM glycine, 0.5 mM ZnCl2, 16 mM DTT ( dithiothreitol) and 0.1 % (w/v) Tris. The 
dissolution solution was adjusted to pH 9 .0 with concentrated HCl. The resuspended 
inclusion bodies were left to stand at room temperature for one hour. 
~efolding of Reduced Long-[Leu60]-IGF-I 
Refolding of Long-[Leu60]-IGF-I was started immediately following dissolution. The 
refolding mixture contained 4 M urea, 0.1 M Tris, 20 mM glycine, 0.5 mM ZnCl2, 0.4 
mM DTT and 1 mM 2-Hydroxyethyldisulphide at pH 9.0. The dissolved protein was 
0.025% v/v of the total refolding volume. 2-hydroxyethyldisulphide was added quickly 
once the dissolved protein had been added to the remaining refold mixture at pH 9.0, with 
rapid stirring to avoid aggregation of the protein. The refolding reaction was left to 
proceed at room temperature for 2-3 hours with continual stirring and was monitored at 
least three times during the refold by analytical HPLC. The refolding reaction was 
terminated by adding 1.2 ml of concentrated HCl for each 100 ml of the refolding mixture. 
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Ion Exchange 
The column used for Ion Exchange was sanitised and equilibrated by performing the 
following washes at 25 ml/min; 500 ml ethanol, 500 ml milli-Q water, 250 ml 0.5 M 
NaOH, 500 ml sterile water, 500 ml acetic acid, 500 ml Buffer A (8 M urea, 50 mM 
ammonium acetate, pH 4.8) and 500 ml Buffer B (8 M urea, 50 mM ammonium acetate, 
pH 4.8, 2M NaCl). The protein was loaded onto the column and washed free of UV 
absorbing material with several column volumes of Buffer A. Long-[Leu60]-IGF-I was 
eluted using a single step gradient, 100% Buffer A to 100% Buffer B. The gradient was 
repeated to ensure all protein had been eluted from the column. The protein, which was 
detected by an increase in absorbance at 280 nm, was collected as a single fraction. The 
fraction containing the protein was analysed by analytical reverse-phase HPLC. All 
effluent was retained and analysed by analytical reverse-phase HPLC to verify that it 
contained no protein before further purification was performed on the collected fraction. 
Reverse-Phase HPLC Purification of Long-[Leu60]-IGF-I 
The refolded, Long-[Leu60]-IGF-I was purified by reverse phase HPLC chromatography 
0 
on a C4 Prep-Pak column ( 40 mm diameter x 100 mm; 300 A pore size, 15 µm particle 
size; Millipore-Waters) in a Waters PrepPak RCM Base at 7500 psi, using a Waters Delta 
Prep 4000 Preparative Chromatography System with a Waters 4000 System Controller. 
The column was sanitised with 600 ml 100% methanol, 500 ml 0.1 % TFA/40% 
acetonitrile, 500 ml 0.08% TFA/80% acetonitrile, and 500 ml 0.1 % TFA at a flow rate of 
25 ml/min. A gradient (0-80% acetonitrile in 20 min) was run to remove any UV 
absorbing material, followed by 0.1 % TF A for 10 min. The protein was then loaded onto 
the column at a flow rate of 25 ml/min. The protein was eluted with the following gradient; 
0-20% acetonitrile in 10 min, then to 40% acetonitrile in 210 min and to 64 % acetonitrile 
in 211 min) as monitored by absorbance at 280 nm. The fractions were pooled for 
analysis by HPLC. 
In order to separate the desired protein from the smaller components, the protein was 
purified by reverse-phase HPLC on a C4 column employing an n-propanol gradient with 
heptaflourobutyric acid (HFBA) as the counter ion. The pooled fractions were loaded onto 
the column and eluted with a gradient, 20-35% n-propanol in 154 min at a flow rate of 10 
ml/min. 
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2.3.3 HPLC Analysis 
Analysis of the protein concentration and the purity of the sample were performed by 
analytical HPLC at each step of the purification process. Generally 4-8 µg of protein in 
100 µl of liquid was injected onto the column. For the analysis of dissolved inclusion 
bodies, 20 µl was diluted to 1 ml with 0.1 % TFA and 100 µl was injected onto the column. 
Analysis of the protein content in the refolding buffer was performed by diluting 150 µl of 
refolding mixture to 500 µl of 1.5% TFA and 250 µl was injected. Three samples were 
taken, at the commencement of refolding, after 90 minutes of refolding and at the 
termination of refolding after approximately two hours. Following ion exchange 
chromatography, the fractions containing protein were analysed by HPLC by diluting 20 
µl to 1 ml with 0.1 % TFA and injecting 250 µl onto the column. The effluent was checked 
prior to discarding by diluting 150 µl to 500 µl 1.5 % TFA and injecting 250 µl onto the 
column. Following reverse phase HPLC of Long-[Leu60]-IGF-I, 20 µl was taken from 
each fraction containing protein to give a total volume of 100 µl. This was diluted to 400 
µl with 0.1 % TFA, and 250 µl was injected onto the column. 
For analytical HPLC analysis, Buffer A was 0.1 % TFA and Buffer B was 80% CH3CN 
and 0.08% TFA. The gradient run was 20% to 80% CH3CN in 20 min for all runs which 
is 25% Buffer B to 100% Buffer Bin 20 min; the eluent was held at 100% Buffer B until 
30 min and then decreased to 25% Buffer B in 1 min. 
2 . .J.4 Preparation of NMR Sample 
The target sample concentration was 1 mM, which was achieved by weighing 4.6 mg of 
Long-[Leu60]-IGF-I and dissolving in 500 µl 90% H2O / 10% D2O. The pH was 
measured to be 3.3. The protein concentration was verified by UV absorption as discussed 
in section 2.3.5. 
2.3.5 Calculation of Protein Concentration 
The amount and purity of the protein Long-[Leu60]-IGF-I were determined by comparing 
the spectrophotometric absorbance at 214 nm with that of reference IGF-I by reverse-
phase HPLC chromatography on a C4 microbore column as described in section 2.3.3. 
The following relationship was used to estimate the amount of protein, where Ext. Coeff. 
refers to the extinction coefficient. 
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(Area of Peak/ Ext. Coeff.) x dilution factor x (1000 µl / injection volume µl) (2.1) 
The absorbance at 280 nm was used to accurately determine the protein concentration of 
the NMR sample. From the NMR sample, 100 µl was taken and diluted to 1 ml and the 
absorbance at 280 nm measured. The molar extinction coefficient of Long-[Leu60]-IGF-I 
at 280 nm is 3270 M- 1cm-1 calculated using the method of Gill and von Rippel (1989). 
The concentration was determined from the relationship, A = £cl, where A is the 
absorbance at 280 nm, £ is the extinction coefficient in M-1cm- 1, c is the concentration (M) 
and 1 is the cell path length, 1 cm. 
2.3.6 Mass Spectrometry 
Positive electrospray ionisation was used to determine the mass of the protein fraction in 
order to verify the percentage incorporation of 15N into Long-[Leu60]-IGF-I. The protein 
sample concentration was 0.2 mM in H2O and 20 µl was injected at a solvent flow rate of 
10 µI/min. The raw data was transf armed using the standard instrument software, 
MASSLYNX. 
2.4 Results 
2.4.1 Overexpression of Long-[Leu60J.JGF-I 
T_he growth of cells was induced when the optical density had reached 1.5. Exponential 
growth continued until the optical density reached 7. The fermentation was terminated after 
two measurements were taken with the same optical density value, indicating no further 
growth. The pH did not rise significantly, as occurs when glucose becomes exhausted and 
nitrogen is still available, which is the case for the production of unlabelled protein using 
this procedure. Because nitrogen was exhausted, the inclusion body wet mass yield 
(6.16g) was lower than usually obtained for the same protein with unlimited nitrogen 
present. 
2.4.2 Purification of Long-[Leu60J-IGF-I 
The HPLC profile of the dissolved inclusion bodies is shown in Figure 2.1. Two major 
peaks are observed in the HPLC profile. The first peak, which elutes at approximately 18 
min contains the desired protein. The second peak is most likely an N-formyl-methionine 
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derivative of the fusion protein, a result of incomplete processing by E. coli which has 
previously been observed (Milner et al., submitted for publication). 
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Figure 2.1: HPLC trace of Long-[Leu60]-IGF-I inclusion bodies 
The HPLC profile of the fractions containing the refolded protein are shown in Figure 2.2. 
Although the HPLC profile is not clean, there was one major peak present arising from the 
protein of interest which was collected. This peak was then purified with an ion exchange 
column. The protein eluted in one repeat of the gradient. Reverse phase HPLC purification 
of Long-[Leu60]-IGF-I was then performed using the TFA/CH3CN buffer system 
followed by purification using a HFBA/n-propanol buffer system. The HPLC trace of the 
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purified protein is shown in Figure 2.3 and it is apparent that the sample is clean as a 
result of these steps. 
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Figure 2.2: HPLC profile of refolded Long-[Leu60]-IGF-I following ion exchange 
chromatography. 
2.4.3 Yield and Sample Concentration 
Prior to freeze drying the fractions containing protein, the amount of protein was estimated 
by analytical HPLC to be approximately 6 mg. The protein was freeze dried and an NMR 
sample made up to approximately 1 mM. The concentration was determined by measuring 
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the absorbance at 280 nm. The absorbance at 280 nm of a 1 in 10 dilution of the NMR 
sample at 280 nm was 0.4378 Absorbance Units. Using equation 2.1, the concentration of 
the NMR sample in 90% H2O/10% D2O was determined to be 0.96 mM. 
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Figure 2.3: HPLC trace of purified Long-[Leu60]-IGF-I 
2.4.4 N-terminal Sequence Analysis 
3JD 
~i 
" 
N-terminal sequence analysis was performed for the first 24 amino acid residues, i.e. the 
entire N-terminal extension and the first 11 residues of the IGF-I domain (Met-13 to 
Val11). The determined sequence was MFPAMPLSSLFVNGPEELHGAALV, which 
compares favourably with the expected sequence MFPAMPLSSLFVNGPETLCGAELV. 
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Residues four, six and nine differed in composition between the two sequences. Residue 
four, expected to be threonine was identified as a glutamic acid, although threonine was the 
second called amino acid type. Similarly, residue nine, expected to be glutamic acid was 
identified as alanine, though glutamic acid was the second called amino acid type. Residue 
six, expected to be a cysteine, was identified as a histidine and cysteine was not listed as 
either the second or third called residue. Table 2.1 shows the user sequence and the called 
sequence, including the second and third amino acid type for the first 24 residues of the 
protein. 
Table 2.1. N-Terminal Sequencing of Long-[Leu60]-IGF-I 
Called Sequence First Second Third 
Met -13 Met Thr Gly 
Phe -12 Phe Asp Trp 
Pro -11 Pro Asp Arg 
Ala -10 Ala Val His 
Met -9 Met Thr Gln 
Pro -8 Pro Asp Trp 
Leu -7 Leu Tyr Ser 
Ser -6 Ser Ala His 
Ser -5 Ser Thr His 
Leu -4 Leu Lys Trp 
Phe -3 Phe Ile Arg 
Val -2 Val Gln Asp 
Asn -1 Asn Asp Ala 
Gly 1 Gly Lys I Glu 
Pro 2 Pro Gln Lys 
Glu 3 Glu Lys Arg 
Thr 4 Glu Thr Ile 
Leu 5 Leu Glu Ser 
Cys 6 His Trp Lys 
Gly 7 Gly Ala Asp 
Ala 8 Ala Lys Gly 
Glu 9 Ala Glu Arg 
Leu 10 Leu Glu Arg 
Val 11 Val Trp Leu 
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Figure 2.4: Mass Spectrum of Long-[Leu60]-IGF-I 
2.4.5 Mass Spectrom.etry 
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Mass spectrometric analysis of the pooled fractions showed a major species with a 1nass 
of 9138.23 + 0.11 Da which is consistent with the expected mass of 100% 15N-labeled 
Long-[Leu60]-IGF-I. The mass spectrum (Figure 2.4) shows another smaller peak with a 
mass of 9154.47 + 0.10 Da. This is an increase in molecular mass of 16 Da compared to 
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15N-labeled Long-[Leu60]-IGF-I which could correspond to the oxidation of a 
methionine. 
2.5 Discussion 
Different recombinant proteins behave differently in the various protein production 
systems currently available, and no single production system is ideal for every protein. 
NMR spectroscopists require a range of protein expression systems from which to choose 
in order to evaluate the most efficient system for production of a particular protein. Due to 
the scope of this project, a choice was not available in the current recombinant production 
of Long-[Leu60]-IGF-I which was expressed and purified in close collaboration with the 
CRC for Tissue Growth and Repair, Adelaide at the premises of GroPep Pty Ltd. 
Standard protocol was established at this centre for the production of IGFs and their 
analogues based on methodology developed by King et al. ( 1992) and Francis et al. 
(1992). However, methodology has now been developed which enables the high-level 
production of uniformly l5N- and l3C-enriched fusion proteins of IGF-1 and IGF-II in E. 
coli (Jansson et al., 1998). The concept is based on intracellular production of the 
recombinant proteins in E. coli as fusions to an IgG-binding domain, Z, derived from 
Staphylococcal protein A. The production method provides yields of 40-200 mg/I of 
isotope-enriched fusion proteins in defined minimal media. In addition, the Z fusion 
partner facilitates the first purification step by IgG affinity chromatography. These yields 
were obtained in shaker flask, without the need to control dissolved oxygen and pH. 
Recently, an efficient and cost-effective isotope labelling protocol for proteins expressed in 
E. coli has been developed (Cai et al., 1998). Cells are initially grown in a medium 
containing nutrients at natural abundance and isotopically labeled nutrients are only 
supplied at the later stages of growth and during protein expression. This permits the 
accumulation of a large cell mass without the need to employ large amounts of expensive 
isotopically labeled nutrients. This method was not available at the commencement of the 
production of Long-[Leu60]-IGF-I. The aim of this project was not to evaluate the 
efficiency of the expression system used or to investigate other options, but to obtain 
milligram quantities of 15N-labeled Long-[Leu60]-IGF-I for NMR studies. 
It was initially hoped that both 15N-labeled Long-[Leu60]-IGF-I and 13C/15N-labeled 
Long-[Leu60]-IGF-I could be obtained, depending on the time available. Only one labeled 
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IGF sample had previously been expressed and purified in this laboratory, 15N-labeled 
Long-[Arg3]-IGF-I. The major problem with the production of 13C-labeled protein was 
that 30 g/L glucose is normally used in the fermentation using the protocol outlined above. 
Trial fermentations were performed using low glucose media, however, very low optical 
density measurements were reached, in the range of 0.8, prior to glucose exhaustion. 
Given the time constraints and the expense of 13C-glucose, only 15N labeled protein was 
produced. Yields of up to 1 g fusion protein/1 off ermentation broth are achieved using this 
expression system for the production of unlabelled proteins where nitrogen is not limited. 
With production of a 15N-labeled protein, nitrogen is limited and the yield of inclusion 
bodies is lower. However, milligram quantities of Long-[Leu60]-IGF-I were obtained, 
sufficient material for NMR spectroscopic studies. 
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CHAPTER3 
Resonance Assignments 
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3.1 Introduction 
The sequential assignment method (Wtithrich et al., 1982) has been described in section 
1.9.2. Obtaining sequential assignments is the essential first step toward three-dimensional 
structure determination for any protein using NMR. Each resonance must be associated 
with a specific nucleus in the protein. Resonance assignments must be sequence specific, 
that is, each resonance must be assigned to a spin in a particular amino acid residue in the 
protein sequence. These can be deduced from through-bond interactions (via scalar 
couplings), through-space interactions (via dipolar coupling), and chemical environment 
(via the chemical shift). 
The combination of 2D 15N-HSQC, 3D 15N-TOCSY-HSQC and 3D 15N-NOESY-
HSQC (Zhang et al., 1994) experiments provides most of the through-bond and through-
space connectivities necessary for sequential assignment of 15N-labeled proteins. This 
method of sequential assignment for 15N-labeled proteins was pioneered by Marion et al. 
(1989) and subsequently further developed by Ikura et al. (1990). Since praline residues 
do not have a backbone amide proton, neither the assignment of the praline spin systems 
or their connectivities to neighbouring residues can be established using these 
heteronuclear experiments alone. Homonuclear 2D NOESY and 2D TOCSY spectra 
(Oschkinat et al., 1989) are necessary for the assignment of praline proton resonances. 
Heteronuclear 2D 15N-HSQC-TOCSY, 2D 15N-HSQC-NOESY (Zhang et al., 1994) and 
3D 15N-HSQC-NOEY-HSQC (Zhang et al., 1994) experiments may also be used to 
resolve ambiguities remaining after complete analysis of the basic experiments. Resonance 
assignment, despite the advent of automated procedures, is still frequently the rate 
determining step of the three-dimensional structure determination. The determination of 
resonance assignments for Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I and the extent of 
these assignments are described in this chapter. 
3.2 Materials and Hardware 
Resonance assignment and the structure determination of Long-[Arg3]-IGF-I were 
achieved with two samples, unlabelled Long-[Arg3]-IGF-I at a concentration of 1.3 mM in 
100% D2O at pH 4.1 and l5N-labeled Long-[Arg3]-IGF-I at a concentration of 1.0 mM 
in 90% H2O/10% D2O at pH 3.0. One sample of Long-[Leu60]-IGF-I was used, i.e. 15N-
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labeled Long-[Leu60]-IGF-I at a concentration of 1.0 mM in 90% H2O/10% D2O at pH 
3 .0. The preparation of these samples was described in Chapter 2. 
Preliminary NMR experiments on the Long-[Arg3]-IGF-I sample were performed on a 
Varian VXR-500S NMR spectrometer. Subsequent NMR experiments were performed on 
a Varian INOV A-500 spectrometer operating at 500.058 MHz and 50.676 MHz for 1 H 
and 15N respectively and a Varian INOV A-600 spectrometer operating at 600.046 MHz 
and 60.809 MHz for 1H and 15N respectively. All NMR experiments on Long-[Leu60]-
IGF-I were performed on a Varian INOVA-600 spectrometer. 
3.3 Methods 
3.3.1 Heteronuclear NMR Experiments 
The following experiments were collected on the two 15N-labeled proteins: a 2D 15N-
HSQC (Kay et al., 1992), a 3D sensitivity-enhanced 15N-TOCSY-HSQC (Zhang et al. , 
1994) with a mixing time of 70 ms, two 3D sensitivity-enhanced 15N-NOESY-HSQC 
(Zhang et al., 1994) experiments with mixing times of 80 ms and 140 ms, a 2D 15N-
HSQC-TOCSY (Zhang et al., 1994) with a mixing time of 70 ms, 2D 15N-HSQC-
NOESY (Zhang et al., 1994) with a mixing time of 100 ms, a 3D sensitivity-enhanced 
15N-HSQC-NOESY-HSQC (Frenkiel et al., 1990) with a mixing time of 140 ms, and a 
3D sensitivity-enhanced 15N-HSQC-TOCSY-NOESY-HSQC (Zhang et al., 1994) with a 
NOESY mixing time of 100 ms and a TOCSY mixing time of 35 ms. Pulse sequences for 
the NMR experiments are shown in Appendix 1. 
The standard 15N-separated experiments ( outlined above) produced approximately 80% of 
the non-prolyl backbone assignments. The final 20% of the assignments were made with 
the 3D 15N-HSQC-NOESY-HSQC and 3D 15N-HSQC-TOCSY-NOESY-HSQC 
experiments. Dipolar couplings between two sequential amide protons, for example, HN(i) 
and HN(i+ 1) with the same HN shift, were identified by spreading the signals according to 
the nitrogen shift of N(i+l) with the 3D 15N-NOESY-HSQC experiment. However, if 
HN(i) and HN(i+l) themselves overlap, the 3D 15N-NOESY-HSQC experiment cannot 
resolve this NOE interaction between them. The 3D 15N-HSQC-NOESY-HSQC and 3D 
15N-HSQC-TOCSY-NOESY-HSQC experiments resolve NOEs between overlapping 
amide proton signals so long as the amide nitrogen shifts are not also degenerate (Pollock 
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et al., 1996). In each of these experiments, the 15N chemical shift of the nitrogen, which is 
one-bond correlated to the amide proton where magnetisation originates, is correlated with 
the lH and 15N chemical shifts of the destination amide (Zhang et al., 1994). The 3D 15N-
HSQC-NOESY-HSQC experiment is highly sensitive to helical regions since it relies on 
strong dipolar coupling between amide protons. By appending a TOCSY element to the 
NOESY element, the 3D 15N-HSQC-TOCSY-NOESY-HSQC experiment can be used to 
detect random sequences and P-structures which have efficient TOCSY transfers. 
The heteronuclear 2D spectra were acquired using 1 H and 15N sweep widths of 7002.8 
Hz and 1700 Hz respectively. Spectra were recorded with either 160, 200 or 256 t1 
increments and 2048 complex points in t2. All 3D heteronuclear spectra were acquired 
using 1 H and 15N sweep widths of 6489 .3 Hz and 1700 Hz respectively. The 
hypercomplex data were collected over 128 complex x 48 complex x 512 complex points 
in the F1, F2 (15N), and F3 dimensions respectively, with the exception of the 3D 15N-
HSQC-TOCSY-NOESY-HSQC which was recorded with a data size of 90, 80 and 512 
complex points in F1, F2 and F3 respectively. A l5N-filtered NOESY spectrum (Lee et al., 
1994) with 80 ms mixing time was acquired for Long-[Leu60]-IGF-I to obtain 1H 
assignments for praline residues. Information obtained from the 15N-filtered NOESY 
experiment was supplemented by a 2D NOESY with a mixing time of 120 ms on an 
unlabelled sample of [Leu60]-IGF-I. 
3.3.2 Homonuclear NMR Experiments 
The following experiments were collected on the unlabelled Long-[Arg3]-IGF-I sample; a 
2D NOESY with a mixing time of 150 ms and a 2D sensitivity-enhanced TOCSY with a 
mixing time of 80 ms. These experiments employed pulsed field gradients for artefact 
suppression and WATERGATE (Piotto et al., 1992; Sklenar et al., 1993) for solvent 
suppression. These 2D homonuclear spectra were acquired with a sweep width of 6002.4 
Hz and were recorded with 350 complex t1 increments. Each FID consisted of 2048 
complex points in t2. 
3.3.3 Spectral Processing 
All data were processed using VNMR software (versions 5.2 and 6.0) (Varian Associates, 
Palo Alto, CA). Typically, 3D experimental data were processed with a low frequency 
solvent filter and a 90° shifted sine bell in all three dimensions. Linear prediction was used 
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to extend the heteronuclear and homonuclear dimensions to improve their digital 
resolution (Olejniczak & Eaton, 1990). Typically, linear prediction was used to extend 48 
complex points to 96 in the nitrogen dimension and to extend 128 complex points to 256 
complex points in the proton dimension. The 15N chemical shifts were referenced directly 
to liquid NH3 at O ppm using the 15N/1 H frequency ratio of 0.101329118 (Wishart et al. , 
1995b). 
3.3.4 Spectral Analysis 
Spectral analysis and peak picking were performed using the program XEASY, version 
1.3.10 (Bartels et al., 1995). Firstly, each cross peak in the 2D 15N-HSQC spectrum was 
labeled. This peak list was loaded into the 3D 15N-TOCSY-HSQC spectrum which results 
in a list of peaks which lie on the diagonal of the proton planes. A strip was defined for 
each peak, the peak positions were adjusted and the strips were searched for additional 
overlapping peaks that could not be identified in the 2D 15N-HSQC spectrum. Cross 
peaks resulting from scalar coupling connectivities were picked and assigned to the 
sidechain atoms of the spin system. Notes regarding the probable type of spin system 
were kept as a comment entry in the peak edit window. The TOCSY peak list produced 
was then loaded into the 3D 15N-NOESY-HSQC spectrum and some peaks repositioned 
in the NOESY spectrum for which positions differed slightly in the NOESY and TOCSY 
spectra. Spectral correlations between the strips were calculated starting with a strip that 
corresponded to a spin system of a known amino acid type, e.g., Gly or Ala and potential 
sequential neighbours of the strip were displayed. The displayed strips were inspected 
visually to identify the one that most likely corresponded to the sequential neighbour. 
When deciding on the most probable sequential neighbour, detailed comparisons of the 
line-shapes of the intra residual peaks and the potential sequential peaks were made. These 
probable sequential neighbours were recorded as a comment entry. This procedure was 
repeated until a subsequence of spin systems could be mapped to the amino acid sequence 
and a strip list containing the assigned subsequence was saved. This procedure was 
repeated until the entire sequence of spin systems could be mapped onto the amino acid 
sequence. 
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3.4 Results 
3.4.1 Long-[Arg3]-IGF-I 
Identification of the spin systems in Long-[Arg3]-IGF-I was achieved by inspection of the 
scalar coupling connectivities within individual residues using the 2D 15N-HSQC, 2D 
15N-HSQC-TOCSY and 3D TOCSY-HSQC spectra. Praline residues were assigned 
from the homonuclear sensitivity-enhanced 2D TOCSY spectrum. Sequential resonance 
assignment followed procedures pioneered by Wtithrich and coworkers ( 1982) and 
utilised 3D NOESY-HSQC, 3D 15N-HSQC-NOESY-HSQC and 3D 15N-HSQC-
TOCSY-NOESY-HSQC spectra (Marion et al., 1989; Ikura et al., 1990). Connectivities 
from praline residues were assigned from analysis of the 2D NOESY spectra (NOEs 
from 8-CH2 protons to Ha of the preceding residue). A region of the 1H- 15N sensitivity-
enhanced 2D l5N-HSQC spectrum of Long-[Arg3]-IGF-I is presented in Figure 3.1 and 
the 1 H and 15N resonance assignments are given in Appendix 2. Of the non-prolyl 1 H and 
l 5N backbone resonances, 100% were assigned, while 92 % of 1 H sidechain resonance 
assignments were made. The 1H and 15N chemical shifts for Long-[Arg3]-IGF-I have 
been deposited in the BioMagResBank under BMRB accession number 4069 
(http://www.bmrb.wisc.edu). 
As well as the 76 major cross peaks in Figure 3.1, there is a subset of low intensity cross 
peaks that probably arise from a minor species in solution. None of these low intensity 
cross peaks gives rise to observable NOEs in the 3D NOESY-HSQC spectrum. Only one 
resonance, assigned to Gly42, is split into two distinct peaks of approximately equal 
intensity. Inspection of the 3D NOESY-HSQC spectrum revealed an identical NOE 
pattern for each of these diagonal peaks. Gly42 is close to Pro39 and the doubling of its 
cross peaks may be a result of cis-trans isomerism at this praline. Both the Leu IO and the 
Val11 cross peak in the 2D 15N-HSQC spectrum are broad and shifted upfield in the lH 
dimension. The Val 11 cross peak is shifted upfield also in the native IGF-I (Sato et al. , 
1992) suggesting a similar structural element that is retained near the start of helix 1. 
However, the 1H chemical shift of the amide proton of LeulO is shifted upfield in Long-
[Arg3]-IGF-I in comparison to its position in IGF-I. This may be a result of the close 
proximity of the N-terminal extension to the N-terminal end of helix 1. 
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Figure 3.1: The 2D 15N-HSQC spectrum of Long-[Arg3]-IGF-I at 30 °C and pH 3.0. 
Assignments for the backbone amides are labeled by the amino acid one letter code 
fo_llowed by the sequence number. 
The spin systems for the peptide seg1nent Glu46 to Phe49 were difficult to assign as was 
the spin system of Cys52_ The segment Glu46 to Phe49 is encompassed by helix 2 (Cooke 
et al., 1991; Sato et al., 1992), so it is surprising that it is not easily assigned. However, 
Jansson et al.(1998) in their chemical shift 1napping studies of IGF-I to IGFBP-1 also 
reported difficulties assigning the amino acid stretch of uncomplexed IGF-I from Asp45 to 
Phe49, even at 50 °c. 
Very few sequential NOEs were observed in the N-terminal extension, making this region 
quite difficult to assign, while intraresidue NOEs were lacking for Ser-5 and Leu-4. 
Intraresidue NOEs were also not observed for Ala 70, the C-terminal residue of the protein. 
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The 3D 15N-HSQC-NOESY-HSQC experiment was used to resolve overlapping amide 
proton resonances, particularly from Gly30 to Ala38 in the C-domain where three adjacent 
serine residues and two adjacent arginine residues with similar chemical shifts made 
assignment difficult. Fewer crosspeaks were observed in the 3D l5N-HSQC-TOCSY-
NOESY-HSQC spectn1m than the HSQC-NOESY-HSQC experiment. This may be 
attributed to the relatively small intraresidue 3 JHNHcx values (section 4.4.1) present 
throughout Long-[Arg3]-IGF-I, a 1nostly helical protein. Small 3JHNHcx values resulted in 
inefficient TOCSY transfer from HN to Hex. 
3.4.2 Long-[Leu60J-IGF-I 
In Long-[Leu60]-IGF-I, of the non-prolyl lH and 15N backbone resonances, 100% were 
assigned, while 92% of 1H sidechain resonance assignments were made. Figure 3.2 shows 
the 2D 15N-HSQC spectru1n of Long-[Leu60]-IGF-I. The lH and 15N chemical shifts for 
Long-[Leu60]-IGF-I have been deposited in the BioMagResBank 
(http://www.brmb.wisc.edu) under BMRB accession number 4278. Resonance 
assignments are included in Appendix 3. 
As with Long-[Arg3]-IGF-I, resonances from the peptide seg1nent Glu46 to Phe49 and 
Cys52 were difficult to assign though more difficulty was encountered in the assignment 
of Long-[Leu60]-IGF-I. It is possible that the mutation at position 60 of Long-[Leu60]-
IGF-I, which is close in space to Glu46-Phe49 in a-helix 2, disn1pts the stn1cture as 
compared with the parent protein and Long-[Arg3]-IGF-I. Very few sequential NOEs 
were observed in either the N-terminal extension or the C-tenninus and intra residue 
NO Es were not observed for some residues, namely Ser5, Leu-4 and Ala 70. These limited 
NOE data made assignment of both the N- and C-termini difficult, however assignments 
obtained for Long-[Arg3]-IGF-I could be used as a guide. No additional low intensity 
cross peaks were present in the 2D l5N-HSQC spectrum of Long-[Leu60]-IGF-I (Figure 
3.2) as were observed for Long-[Arg3]-IGF-I. 
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Figure 3.2: 2D 15N-HSQC spectrum of 1 mM 15N Long-[Leu60]-IGF-I at 30 °c and pH 
3.4 in 90% H2O/D2O. TI1e assignments are labeled by the amino acid one letter code 
followed by the sequence number. 
At 30 °c, no a1nide proton cross peaks were observed in the 2D 15N-HSQC spectrum for 
Leu4 , Asn-1 or Glyl. However, the amide proton cross peak of Leu-4 was observed in the 
3D NOESY-HSQC spectru1n at this temperature. Amide proton cross peaks for all three 
residues were observed in the 2D 15N-HSQC spectnun at 20 °c. This was not the case 
with Long-[Arg3]-IGF-I where amide proton cross peaks for all three residues were 
observed in HSQC spectra acquired at both 20 °c and 30 °c. This difference suggests 
that these three residues are undergoing exchange more rapidly in Long-[Leu60]-IGF-I 
than in Long-[Arg3]-IGF-I which may be a result of the reversal of the Glu3 to Arg3 
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mutation of Long-[Arg3]-IGF-I in Long-[Leu60]-IGF-I and the close proximity of Leu-4, 
Asn-1 and Gly1 to residue 3. 
1 H assignments of praline residues were made by inspection of an 15N-filtered NOESY 
spectrum of 15N-labeled Long-[Leu60]-IGF-I and supple1nented by a 2D NOESY 
spectrum of unlabelled [Leu60]-IGF-I since the resolution of the 15N-filtered NOESY 
spectrum was not sufficient to complete the assignments. An unlabelled sample of Long-
[Leu60]-IGF-I was not available. Therefore, the confidence in the 1H assignments of these 
residues is not as great. Aromatic spin systems were assigned from the 15N-filtered 
NOESY spectrum. 
A comparison of the 15N and lH chemical shifts in the 2D 15N-HSQC spectra of Long-
[Arg3]-IGF-I and Long-[Leu60]-IGF-I is shown in Figure 3.3. Local differences in the 
15N chemical shift are noted in the proximity of residue 60 and the N-terminal extension 
as well as variations in chemical shift in regions separated in sequence but close in space 
such as the C-domain and a-helix 1 (Cooke et al., 1991). Ha chemical shift differences 
will be discussed in Chapter 4. The mutation at residue 3 causes local changes at the C-
terminal end of the N-terminal extension and the beginning of the IGF-I domain. In Long-
[Leu60]-IGF-I, Leu-4, Val-2 and Leu5 all experience an upfield 15N shift, while Phe-3 and 
Thr4 experience a downfield shift in 15N compared with those residues in Long-[Arg3]-
IGF-I. This 15N che1nical shift difference is difficult to rationalise without knowledge of 
the arrangement of the N-terminal extension in 3D space. However this information, 
combined with the absence of cross peaks for Asn-1 and Gly 1 at 30 °c indicates that the 
N-terminal extension of Long-[Leu60]-IGF-I is likely to have undergone a minor change 
in average confonnation in comparison with Long-[Arg3]-IGF-I. 
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Figure 3.3: 2D 1H_l5N HSQC spectrum of 15N-labeled Long-[Leu60]-IGF-I. Arrows 
indicate those resonances shifted by more than 1 ppm in the 15N dimension when 
compared with the HSQC spectrum of Long-[Arg3]-IGF-I (Figure 3.1). The origin point 
of the arrow approximates the resonance position of the residue in the spectrum of Long-
[ Arg 3 J-IGF-I (Figure 3.1). 
From Figure 3.3 it is apparent that Phe16, Gly19 and Asp20 are all shifted slightly upfield 
in Long-[Leu60J-IGF-I compared to Long-[Arg3]-IGF-I. In IGF-I, Phe16 is part of helix 
1, while Gly19 and Asp20 form part of a ~-tum following helix 1 (Sato et al. , 1992). These 
residues are close in three dimensional space to residue 60 which is the C-terminal residue 
of helix 3 and the three helices enclose a hydrophobic core. Presumably, the 15N 
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resonances of Phe16, Gly19 and Asp20 are shifted upfield in Long-[Leu60]-IGF-I due to 
the absence of the ring current effect of Tyr60. 
The 15N shifts of two residues in the C-domain, Phe25 and Asn26 are shifted slightly 
downfield in Long-[Leu60]-IGF-I. This region is believed to be responsible for binding to 
IGF receptors (Bayne et al., 1988, 1989; Cascieri et al., 1988, 1989). Other studies have 
shown that a Tyr to Leu mutation increases the activity of the protein since [Leu60]-IGF-I 
binds with lower affinity to the type 1 IGF receptor than IGF-I and thus, promotes release 
of endogenous IGF-I from IGFBPs which then interact with the type 1 IGF receptor 
(Milner et al., submitted for publication). 
The region most affected by the Tyr60 to Leu60 mutation appears to be a-helix 2. Since 
helix 2 and helix 3 run roughly anti-parallel to each other in IGF-I (Cooke et al., 1991; 
Sato et al., 1992), residue 60 is close to the N-terminal end of helix 2. Several residues, 
Gln40, Gly42, Val44, Asp45 and Phe49, at this end of the helix all experience upfield 15N 
shifts due to the absence of the ring current effect of Tyr60 in Long-[Leu60]-IGF-I. 
Three residues in the D-domain (at the C-terminus) are also affected by substitution of 
Tyr60 by Leu. Leu64 and Ala70 have an upfield 15N shift, while Lys65 experiences a 
downfield shift. Although these residues are mobile, the time-averaged positions are within 
the influence of the ring currents generated by Tyr60. 
3.5 Discussion 
In the first solution structure determination of IGF-I by Cooke et al. (1991), resonance 
assignments were made for 87% of the backbone resonances and 72% of the proton 
resonances. Assignments could not be made for either the HN or the Ha protons of Ser34, 
Ser35, Arg36, Arg37, Arg50, Lys68 or Ser69, the HN protons of Glyl or Lys27 or the Ha 
protons of Pro28 or Pro63. All of these assignment ambiguities, with the exception of the 
HN proton of Gly1, were resolved by Sato et al. (1992) although two ambiguous 
assignments, the HN protons of Lys68 and Ala 70, were noted. A complete set of resonance 
assignments were obtained for mini-IGF-I (De Wolf et al., 1996). All three studies 
employed homonuclear NMR techniques using unlabelled samples. Although the solution 
structure of a protein of 70 amino acids residues is achievable under favourable 
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circumstances, using only homonuclear techniques, the helical structure and flexibility of 
these proteins suggested that 15N labelling will enable a more precise structure 
determination. Since the two analogues of IGF-I, Long-[Arg3]-IGF-I and Long-[Leu60]-
IGF-I both have 83 amino acid residues, the limitations of homonuclear NMR and the 
helical and flexible nature of these proteins, necessitated 15N labelling. 
Heteronuclear NMR experiments of Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I enabled 
many of the ambiguities associated with resonance assignments of IGF-I, e.g., residues of 
the D-domain, to be resolved. Information obtained from the 3D 15N-TOCSY-HSQC 
spectra was limited and some assignments were made using only the 3D 15N-NOESY-
HSQC spectra. Assignment of the 3D 15N-TOCSY-HSQC spectra beyond Ha was not 
possible for many residues, mainly due to the helical nature of the protein resulting in 
small 3 JNHa couplings which reduce the efficiency of magnetisation transfer. The 
presence of 20% dimer in Long-[Arg3]-IGF-I (see section 5.4) also has an adverse effect 
on resonance line width. 
The 3D 15N-HSQC-NOESY-HSQC experiment enabled resonances in the segment Ser33 
to Arg37 of both Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I to be assigned. The 
residues in this segment could not be assigned by a combination of 3D 15N-TOCSY-
HSQC and 3D 15N-NOESY-HSQC because of overlap of the HN protons of Ser33 and 
Ser34 and very similar 15N shifts. In addition, neither aN(i,i+ 1) nor ~N(i,i+ 1) NOEs 
between Ser33, Ser34 and Ser35 could be identified. 
The N-terminal extension and a segment in the A-domain, Glu46 to Phe49, of both Long-
[Arg3]-IGF-I and Long-[Leu60]-IGF-I were difficult regions to assign. In the resonance 
assignment of the N-terminal extension of both analogues, there was a paucity of 
sequential and medium range NOEs, and in Long-[Leu60]-IGF-I, intraresidue NOEs were 
not present for Leu-4. The C-terminal end of a-helix 2 (Cooke et al, 1991; and Sato et al. , 
1993) was also difficult to assign in the two IGF-I analogues. Interestingly, no particular 
difficulties with resonance assignments were noted in this region of IGF-I by either Cooke 
et al. (1991) or Sato et al. (1992). However, Jansson et al. (1998) could not make any 
assignments for the polypeptide segment Asp45_Phe49, neither could assignments be made 
for Gly 1 or Cys6. The segment Leu-4 to Thr4 in Long-[Leu60]-IGF-I was more difficult to 
assign than the same segment in Long-[Arg3]-IGF-I due to the absence of some 
resonances at 30 °C in this region (section 3.3.2). This suggests that there are some 
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differences in the conformation or flexibility of Long-[Arg3]-IGF-I and Long-[Leu60]-
IGF-I in this region, probably induced by the Glu3 to Arg3 mutation. The peptide segment 
Glu46_Phe49 was also more difficult to assign in Long-[Leu60J-IGF-I than in Long-
[Arg3]-IGF-I, which can be attributed to the proximity of this segment to Leu60 as 
determined by the solution structure of IGF-I (Cooke et al., 1991: Sato et al. , 1993). 
Jansson et al. (1998) made resonance assignments of IGF-I at 50 °C and pH 3.4 while 
Sato et al. (1992) used spectra obtained at both 40 °C and 50 °C and pH 3.0 to make 
resonance assignments, reporting that the spectral quality of IGF-I at 30 °C was not of 
sufficient resolution and only partial assignments were obtained. Specifically, Jans son et 
al. (1998) reported that at 30 °C the only residues for which assignments could be made 
unambiguously were Pro2-Glu3, Gly7, Gly19, Pro28_Thr41 , Ser51, Met59 and Pro63_Aia70_ 
The segments Pro28_Thr41 and Pro63_Aia70 are both unstructured regions of IGF-I 
(Cooke et al., 1991; Sato et al., 1992). This suggests that there are some differences in the 
conformation or flexibility of IGF-I and both Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-
I at this temperature and pH. 
The NMR chemical shift of a given nucleus depends on its electronic environment. It is 
sensitive to many atomic or molecular effects including the local electron distribution, 
bond hybridisation states, proximity to polar groups, nearby aromatic rings and local 
magnetic anisotropies (Wishart, 1992). The sensitivity of the H<X proton chemical shifts to 
the secondary structure of proteins has been used to deduce structural information. An 
analysis of the H<X chemical shift data for Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I is 
presented in Chapter 4 where the secondary structure of these two proteins is presented. 
Amide proton chemical shifts are much more sensitive to the experimental conditions, such 
as temperature and pH, than the H<X chemical shifts and the relationship between the amide 
proton chemical shift and hydrogen bond length has been established for amphipathic a-
helices (Zhou et al., 1992). A comparison of the amide proton chemical shifts of Long-
[Arg3]-IGF-I and Long-[Leu60]-IGF-I with IGF-I and mini-IGF-I indicates local changes 
in molecular conformation and environment. The amide proton resonances of the 
following residues in Long-[Arg3]-IGF-I were shifted in relation to both IGF-I and mini-
IGF-I by more than 0.3 ppm: Cys6, Gly7, Ala8, Leul0, Gln15, Vall 7, Glu46, Cys48, Cys52, 
Leu54 and Leu57_ The amide proton resonances of the following residues in Long-
[Leu60]-IGF-I were shifted relative to both IGF-I and mini-IGF-I by more than 0.3 ppm; 
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Cys6, Gly7, Ala8, LeulO, VaI17, Cys48, Cys52 and Leu54. The most significant amide 
nitrogen resonance shift differences observed in both Long-[Arg3]-IGF-I and Long-
[Leu60]-IGF-I in comparison with IGF-1 occur at Leu10 (far up field at 6.88 ppm) and 
Ala8 (far downfield at 8.98 pm). These unusually large shifts are attributed to the ring 
current effects due to the proximity of Phe25 to A1a8 and Leu 10 in Long-[Arg3]-IGF-I 
relative to IGF-1. Interestingly, none of the amide protons of residues in unstructured 
regions of either Long-[Arg3]-IGF-I or Long-[Leu60]-IGF-I are shifted significantly 
relative to IGF-1. The residues of Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I whose 
amide protons experience shifts relative to IGF-1 are located prior to helix 1, within helix 1, 
helix 2 and helix 3 and the link joining helices 2 and 3 in IGF-1. This suggests that there is 
some minor change in · the conformation or the environment of the amide protons of 
residues of Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I which are in structured regions 
of IGF-1. There may even be some disruption of the secondary structure in these two IGF-
1 analogues. 
Analysis of 15N chemical shifts of Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I indicates 
that there may be differences in conformation in the regions Leu-4-Thr4, Phe16, Glyl9_ 
Asp20, Phe25_Asn26, Gln40_Phe49 and Leu64_Ala70 between the two variants (discussed at 
length in chapters 4 and 5). A similar comparison is not possible between IGF-1 and the 
Long-IGF-1 analogues due to IGF-1 and mini-IGF-1 NMR studies being performed on 
unlabelled samples. 
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CHAPTER4 
Secondary Structure 
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4.1 Introduction 
The secondary structural elements of proteins can be identified from the chemical shift of 
the a protons, the relative intensities of NOE connectivities between HN, Ha and H~ 
protons and by three bond J-coupling information (Wtithrich, 1986). a-helices are 
characterized by strong NN(i,i+l) NOEs, weak aN(i,i+l) and NN(i,i+2) NOEs and the 
presence of aN(i,i+3) and ap(i,i+3) NOEs. Regions of P-sheet or extended structure are 
characterized by strong aN(i,i+ 1) and weak NN(i,i+ 1) NOEs. A sequential region of 
3JHNHa values < 6 Hz is indicative of a-helices, while regions of P-sheet have 3JHNHa 
values> 8 Hz. Antiparallel ~-sheet regions have long-range HN(i)-HN(j), HN(i)-HCX(j) and 
HCX(i)-HCX(j) crosspeaks, where i and j represent residues from different P-strands in the 
protein. Parallel P-sheet regions have weak interstrand HCX-HN and HN-HN crosspeaks. 
Tum structures are characterized by medium-range aN(i,i+2) NOEs and weak NN(i,i+ 1) 
NOEs. The following NOE crosspeaks may be present in tight turns:), aN(i,i+3), 
aN(i,i+2), NN(i,i+2) and NN(i,i+l). Weak and strong aN(i,i+l) and NN(i,i+l) 
crosspeaks are present in type 1 P-turns while the preferred position for praline in tight 
turns is position two. Reverse turns or loops which reverse the direction of the polypeptide 
chain at the surfaces of molecules, for example, P-hairpins and P-tums, are prevalent in 
globular proteins and are frequently classified as a third type of secondary structure in 
addition to helix and sheet. Tums can also be identified by amide proton exchange 
patterns and backbone dihedral angles, which will be discussed in Chapter 5. The NOE 
patterns and scalar couplings observed for the different types of secondary structure are 
shown in Table 4.1. 
Analysis of the deviation of the chemical shifts of the Ha protons from their random coil 
values can further support secondary structure information gained from NOE 
connectivities since Ha chemical shifts are strongly dependent on the character and nature 
of protein secondary structure (Wishart et al., 1992). The Ha proton experiences an 
upfield shift with respect to the random coil value when in a helical conformation and a 
downfield shift when in a P-sheet conformation. 
Hydrogen-deuterium exchange may be used to locate amide protons that are hydrogen-
bonded or inaccessible to solvent. In structured regions of proteins such as an a-helix or a 
P-sheet, the exchange of amide hydrogens with solvent can be greatly slowed due to 
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hydrogen bonding, even when the bond is at the surface of the protein. The exchange 
process in these structured regions requires hydrogen bond breakage which may occur in 
small concerted folding reactions (Englander, 1975). For 15N-labeled proteins with slow 
exchange (Kex < 0.01 s-1 ), the slowly exchanging amides are identified by rapidly 
exchanging the protein from H2O into D2O buffer solution and repeatedly acquiring 2D 
1H- 15N HSQC spectra to observe the decrease in amide proton resonance intensities with 
time. The observation of a slowly exchanging amide proton implies that the amide proton 
may be involved in a hydrogen bond, but does not identify the atoms acting as hydrogen-
bond acceptors. 
Table 4.1. Summary of NOE and scalar couplings characteristic of secondary structure 
types 
dNN(i, i+ 1) 
dexN(i, i+l) 
d~N(i, i+ 1) 
dexN(i, i+3) 
dex~(i, i+3) 
d~N(i, i+3) 
dexN(i, i) 
3JNHex 
Hex shifts 
ex-helix 
strong 
weak 
medium/strong 
present 
present 
present 
weak in 3D TOCSY-HSQC 
spectra 
< 6 Hz 
upfield of random coil shift 
~-sheet 
weak 
strong 
weak 
not present 
not present 
not present 
strong in 3D TOCSY-HSQC 
spectra, weak in 3D NOESY-
HSQC spectra 
> 7.5 Hz 
downfield of random coil shift 
The secondary structure, determined by analysis of NOE contacts, I-coupling information, 
chemical shift index analysis and amide proton exchange rates for both Long-[Arg3]-IGF-
I and Long-[Leu60]-IGF-I is presented in this chapter. 
4.2 Materials 
15N-labeled Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I and unlabelled Long-[Arg3]-
IGF-I samples were used for the secondary structure determination as described in 
Chapter 3. NMR experiments were performed on a Varian INOVA-600 spectrometer 
operating at 600.046 MHz and 60.809 MHz for lH and 15N respectively. 
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4.3 Methods 
4.3.1 NMR Experiments 
In addition to the suite of NMR experiments described in Chapter 3, two additional NMR 
experiments were performed to determine 3JNHcx values, the 15N-HMQC-J (Szyperski et 
al., 1992) and HNHA (Vuister and Bax, 1993). 3JNHcx values are used as confirmation of 
the type of secondary structure as determined by NOE patterns (discussed in section 4.1). 
Pulse sequences are shown for these experiments in Appendix 1. The technique of non 
linear fitting of J-modulated l5N-1H HMQC spectra for the determination of }-couplings 
decreases in accuracy when the line-width becomes significantly larger than the }-
coupling. This presents a problem for the measurement of small J couplings, such as 
typically encountered in predominantly a-helical proteins. The HNHA experiment which 
correlates intraresidue 1 HN, 15N and Hex resonances, relies on quantitative analysis of the 
diagonal-peak to cross peak intensity ratio in a l5N-separated HN-Hcx homonuclear J 
correlation experiment. This experiment correlates the intra residue 1 HN, 15N, and 1 Hex 
resonances (Vuister and Bax, 1993). 
4.3.2 Analysis of NOE Contacts 
The NOEs observed in 3D NOESY-HSQC spectra acquired with a mixing time of 120 ms 
were most extensively used in the determination of regions of secondary structure in 
Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I. 3D NOESY-HSQC spectra acquired with a 
mixing time of 80 ms were used to confirm these contacts and eliminate the possibility of 
NOEs arising as a result of spin diffusion. A homonuclear 2D NOESY experiment with 
mixing time 120 ms was used to determine the intensity of ap(i,i+3) NOEs which are 
characteristic of a-helices. 
Since the solution structure of IGF-I has been previously determined, the intensity of 
sequential and medium-range NOEs in the helical regions of the IGF-I domain were 
investigated first, followed by the less structured regions. The intensity of NOEs 
throughout the remainder of the protein was subsequently analysed. 
4.3.3 Coupling Constant Determination 
3JNHcx coupling constants were estimated from the splittings in the 15N-HMQC-J 
spectrum by }-deconvolution using an "in-house" software package. The active splitting 
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was removed by dividing the time-domain signals by sin (7t/*t), equivalent to 
deconvolution in the frequency domain with an antiphase doublet. A search algorithm was 
used to find the condition where the trial coupling l* = la, where la is the active coupling 
constant. Only a one-dimensional search is involved since la appears in both dimensions. 
Passive splittings were then eliminated by an analogous procedure involving cos (re l *t). 
3JNHa coupling constants were also measured from the HNHA experiment (Vuister & 
Bax, 1993). The cross-peak to diagonal-peak intensity ratios Cicrosslldiag) provides a direct 
measure of the magnitude of 3JNHa using the equation: 
Icrosslldiag = -tan2(21CJHHS) (4.1) 
where 31NHa is simplified to lHH ands is the pulse sequence delay, 12.6 ms in this case. 
3JNHa values were considered quantitative and accurate (Vuister and Bax, 1993). 
4.3.4 Amide Proton Exchange Rates 
Approximate amide exchange rates were measured by a modified saturation transfer 
method (Spera et al., 1991; Grzesiek & Bax, 1993) to ascertain whether amide proton 
exchange rates were measurable by persistence methods. In the saturation transfer method, 
the ratio of the peak intensities was taken between two 2D 15N-HSQC spectra, collected 
with and without weak irradiation of the water peak during recovery (Is and Io 
respectively). The smaller the Is/lo ratio, the more rapid the rate of amide proton exchange. 
Qualitative amide proton exchange rates were determined by acquiring a series of 2D 15N-
HSQC spectra. The first spectrum collected was on the l5N-labeled samples in 90% 
H2O/10% D2O. The protein was then lyophilised and reconstituted in approximately 400 
µl D2 0. The second spectrum was acquired as soon as possible ( 10-15 min) following 
dissolution in D2O. Further 2D 15N-HSQC spectra were acquired at 1, 4, 8, and 24 hours. 
All spectra were collected under the same conditions at a temperature of 20 °c, lower than 
the temperature of 30 °C used for other NMR measurements (Scholtz and Robertson, 
1995). Amide proton exchange experiments are sensitive to temperature, and acquiring the 
spectra at 20 °c was an attempt to slow the exchange of rapidly exchanging protons and 
assist in their identification. The acquisition time for each spectrum was 35 minutes . 
Spectra were acquired using 1H and l5N sweep widths of 6489.3 Hz and 1800 Hz 
respectively. Spectra were processed using a 90° shifted sinebell in both dimensions with 
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Varian VNMR version 5.2 software (Varian Associates, Palo Alto, CA). The 2D 15N-
HS QC spectra, taken at various elapsed times, were overlaid for inspection of the amide 
protons for which cross peaks remained. Amide protons, for which a cross peak in the 2D 
15N-HSQC experiment in D2O was still observed after 24 hours, were classed as slowly 
exchanging. Amide protons, for which a cross peak in the 2D 15N-HSQC experiment in 
D2O was still observed after 4 hours, were classed as undergoing intermediate exchange. 
4.3.5 Chemical Shift Index Analysis 
Wishart et al. ( 1992) have demonstrated that the chemical shift of the nuclei of the protein 
backbone can be used to identify regions of secondary structure. The chemical shift index 
(CSI) method is a technique for rapidly and accurately determining the type and location 
of secondary structures in proteins from Ha chemical shifts. As was discussed in section 
4.1, the Ha proton experiences an upfield shift with respect to the random coil value when 
in a-helical conformation and a downfield shift when in ~-sheet conformation. If the a-
proton chemical shift for a specific residue in the protein was greater than the random coil 
Ha proton chemical shift by 0.1 ppm for that particular amino acid (Wishart et al., 1992), 
it was assigned the label "1 ". If the a-proton chemical shift for a particular residue was 
less than the random coil Ha chemical shift for that particular amino acid by 0.1 ppm, it 
was labeled "-1 ". If the a-proton chemical shift for a particular residue was within the 
given range for the random coil Ha shift it was labeled "O". 
Any sequence of four or more "-1 s" that are not interrupted by a "1" is in an a-helical 
conformation (Wishart et al., 1992). Likewise, any sequence of three or more "1 s" not 
interrupted by a "-1" is in a ~-strand conformation. All other regions are designated as coil 
or unstructured. A local "density" of non zero chemical shift indices which exceeds 70% 
is required when defining regions of helical or extended structure. Termination points (at 
either end) of helices or ~-strands can often be recognised by the first appearance of 
chemical shift indices that are opposite to those of the corresponding secondary structure. 
Otherwise, the first appearance of two consecutive zero-valued chemical shift indices 
marks the termination point. 
Databases with random coil Ha chemical shift values have been developed by Wishart et 
al. (1992) and subsequently refined by Wishart and Sykes (1994) and Wishart et al. 
(1995a). In the latter study, the random coil 1H, 13C and 15N chemical shifts for the 20 
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common amino acids when followed by alanine or pro line were measured in addition to 
the random coil chemical shifts for alanine and pro line when preceded by one of the 20 
common amino acids. 
4.4 Results 
4.4.1 Long-[Arg3 J-IGF-1 
The secondary structure elements in Long-[Arg3]-IGF-I were identified from the relative 
intensities of sequential and medium-range NOEs and }-coupling information and were 
confirmed by analysis of the deviation of the chemical shifts of the Ha protons from their 
random coil chemical shift values. A diagrammatic summary of these results and amide 
proton exchange rates is presented in Figure 4.1. 
When compared to the solution structure of IGF-1 (Cooke et al., 1991; Sato et al., 1993) it 
is apparent from an examination of the pattern of NOEs of Long-[Arg3]-IGF-I that the N-
terminal extension Met-13 to Asn-1 has very little effect on the secondary structure of the 
IGF-1 domain (Gly1 to Ala70) (Figure 4.1). Medium to strong sequential NN(i,i+ 1) 
NO Es are observed for the segments Ala8 to Phe23, Ile43 to Arg50 and Leu54 to Aia62 and 
a series of medium-range aN(i,i+3) NOEs are detected for the segments Aia8 to Cys18, 
Ile43 to Arg50 and Leu54 to Met59_ Furthermore, some aN(i,i+4) NOEs are also observed 
in these regions (Figure 4.2). a~(i,i+3) NOEs are also observed for the segments Glu9 to 
Cys18, Ile43 to Cys48 and Leu54 to Met59. Such NOE patterns are typically found in 
helical regions of proteins and hence this places the three helices in the IGF-1 domain in 
approximately the same location as in the parent IGF-1 protein. Strong aN(i,i+ 1) NOEs 
are observed in the segments Thr4 to Leu5, Cys6 to Gly 7, and Gly30 to Aia38. These types 
of NOEs suggest that the region between Gly30 and Aia38 is in an extended conformation. 
Medium-range aN(i,i+2) NOEs are detected between Gly19 and Arg21 and between 
Asp20 and Gly22 indicating that the ~-turn observed in this region of IGF-1 is most likely 
preserved in Long-[Arg3]-IGF-I. 
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Figure 4.1: A summary of the NMR data defining the secondary structure of Long-
[Arg3]-IGF-I at pH 3.0 and 30 °c. The primary sequence is displayed at the top. 
Sequential NOE connectivities, dNN, daN and d~N, are indicated by bars linking the 
residues concerned and are classified as strong, medium or weak according to the 
thickness of the bar. Medium-range NOE connectivities, daN(i,i+2), daN(i,i+3) and 
daNO,i +4) are linked by lines. The chemical shift index ( defined as the deviation of the 
chemical shift value of the a proton from its random coil value) is classified as positive or 
negative by vertical lines above and below a baseline respectively. 3JNHa values greater 
than 7.5 Hz are indicated by an upright arrow, 3JNHa values less than 6 Hz are indicated 
by an inverted arrow. Unfilled circles indicate ainide proton resonances that are observable 
1 h after exchange of the solvent from H20 to D20. Filled circles indicate ainide proton 
resonances. that are observed 24 h after sol vent exchange. 
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The N-terrninal segment of the extension, from Met-13 to Ser-5, has little or no 
recognisable stn1cture, as judged by the paucity of non-sequential NOEs. Based on the 
pattern of NO Es, the seg1nent from Leu-4 to Gly 1 has features re1niniscent of a tum-type 
structure. Medium-range NOEs are observed between the amide protons of Leu-4 and Val-
2 and several "reversed" sequential NOEs are present between the ainide proton of Phe-3 
and the a, ~ and y protons of V al-2. After structure calculations, this tum structure was 
subsequently located in the three dimensional solution structure between Asn-1 and Arg3 
as described in Chapter 5. Interestingly, long-range NOEs are observed between Phe-3 and 
Gly7 and between Val-2 and Cys6 which place the segment Leu-4 to Glyl over the N-
terminal end of the IGF-I domain near the start of helix 1. Figure 4.3 shows lH-lH strips 
from the 3D sensitivity enhanced 15N NOESY-HSQC spectnun of Long-[Arg3]-IGF-I 
displaying the sequential and long-range contacts observed in the region Ser5 to A1a8. 
Figure 4.4 shows 1H-1H strips fro1n the 3D sensitivity enhanced 15N-NOESY-HSQC 
spectrum of Long-[Arg3]-IGF-I displaying the sequential and medium-range contacts 
observed in the region from Leu57 to Ala62. The C-terrninal region of the protein ( or D-
do1nain) has weak NN(i,i+ 1) NOEs and the absence of internal NOEs for some residues. 
This NOE pattern is also seen in the D-do1nain of the native IGF-I which is believed to 
exist in a random coil conformation. The magnitude of some NOEs were uncertain in 
previous homonuclear studies of IGF-I because of overlap of various regions. In this 
work, these regions are better defined, because the pulse sequences employed pulsed field 
gradients for coherence selection and solvent suppression and, the resonances were 
dispersed along a third heteronuclear dimension (15N). Rapidly exchanging protons are 
more readily observed because of these recent technological developments. Many of the 
long-range NOEs that are observed in native IGF-I are also observed in the IGF-I domain 
of Long-[Arg3]-IGF-I, for example, Val1Lyal44, Leul4_Tyr60, Leul4_Phe23, Phel6_Leu54 
and Ile43-Tyr60, suggesting that the addition of the N-terrninal extension has only minor 
local effects on the three dimensional fold of the parent IGF-I domain. 
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Figure 4.2: 1H-1H strips from the 3D sensitivity enhanced NOESY-HSQC spectrum of 
Long-[Arg3]-IGF-I displaying the sequential and medium-range contacts for part of helix 
1 encompassing residues Alal3 to Cysl8. 
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Figure 4.3: Strips from the 3D sensitivity enhanced 15N~NOESY-HSQC spectrum of 
Long-[Arg3]-IGF-I displaying the sequential and long-range contacts observed for the 
region Ser-5 to Ala8. Long-range contacts are shown by dashed lines. 
1H 
~pptrn) 
""\ -' 'lfl~ L,.L,'-~· 
1 
,1,., 
.iii! ,> .. , r:.'f.' ~,~, .. 
~\~i• Y. r,~••'f.,:;..,,,._r_....,,,.,,,..,.,~• ,.•,;,,.~.,;...:..-.~..,,-,...,.,:,,'.~."'j/i: ;i.,..,:·· . I . --
~o;;..;~~~ -
'l."z; 
"' 
Ii t',;;t ;:.;$, .'"' ~r~~:• 
rtJ\r 
·~)· 
!I. 
ti 
L 
! 
t1 
ii 
,1 
' 
!I' 1! I 
1, 
i! [ 
l' ~ 
(' 
d 
\ 
·1 
p 
(J= 
. ·- . -a ..,.. , , "<,,;;;,. .~., 1, ( ~':! i: 
, n 
, ..  
·'.'.1 r:c, -~ •. :-s.~ -~ , , 
. 4''. i . .1. 
$\ 
i• 
~: 
., 
,;/•'~ 
~~!J· :f· ... 
5 .tlJ ·iJ .,-;" 
f 
~ 
; Fi'~ i : 
.J,l., ..: 
-~ 
~ - lf''""'i ;'I': J .L.{,;! • 
Ji 
ii,'! f"Y:'~ 0 ~~~~\. .. 
~l(l"'J 
:~., ~~ 
t 
,.,; ~ 
,~. -~ i· 
·.i\, 
.9U57 
·124:.3 
-~: :t1S> 
·fjl 
'f~:11;) 
.. 
;.. 
...... r,-.,,_,_.,,1,,..,.,,_·<-i:--:n1f•~f 
'J ,,, 
'"'' ~ffe ;r · 
-:wipr · -.,.,,, .......... ". 
i~ 
-~~-
"<;,1,, -
~ .• 
H lu5B 
11'"" ~ 
~ - I 
~!J.19ffir9 
119.2 
!,;. 
,i, 
" i . 
'~1 ~; 
i. '<4' !:~ 
e--~· ... : ···-~· ~ II ~, -i~"-~-"· ... ,, __ -II 
,,,_ .... ~,.. ...... ,:,.::~• •.,.......:!••··• ... -,:_ .. .,..... 
·t, 
•~'t~ 
~· 
• t _~ -~rt. 
' 
'g· 
" ~ :I 
. ~ 
-C· 
1 ,>:~> •••.•. ·• '-···~-••·" .•. ,.....,,1,v.w ·'\,;~~lj'!:'Y'-! I I , 
! 
f' 
t,g•-
·~). 
:~ 
rn;i 
i 
I 
'I, 
; 
t· 
ii'..~-t~1·.::·"-'J.r-•1,~-t'):,:>;,1,, ... -.i.:..~:.::~· 
i :i 
Ii : I ( 
1., 
i 
i'11'' 
"'"" 
, .......... ...,,.,--···· • -·. ,•? ,~_,..,.......,,.,.,'?' •. \· 
:-; 
f 
-~J.,-. 
Tvrtirfi 
~-
118 .. 4 
\I• 
",j 
H 
I i · 20-L _1 _____ , , ·- .,,.. ;, ... -,---~- ,. __ 
~,a1 
"" 1~· !J . ~ ·ti,.,..: 
... ~.~ .. 
"' 
-~ 
,...·.i.-:. 
~;,, 
Ab52 
12tt8 
88 
Figure 4.4: Strips from the 3D sensitivity enhanced 15N-NOESY-HSQC spectnun of 
Long-[Arg3]-IGF-I displaying the sequential and medium-range contacts observed for the 
region Leu57 to A1a62. 
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3JNHa values for Long-[Arg3]-IGF-I < 5.0 Hz (indicated by a downward arrow in Figure 
4.1) were consistently found in the segments which display the NOE patterns typical of 
helical structure. Ha chemical shift data also support the location of the three a-helices in 
Long-[Arg3]-IGF-I, i.e. an upfield shift for these protons was consistently observed in 
helical regions, as represented by a downward stroke in Figure 4.1. Several residues 
between Gly30 and Ala38 had 3JNHa values> 7.5 Hz as indicated by an upward arrow in 
Figure 4.1. This observation suggests the possibility of a short segment of extended 
structure and is supported by the NOE data which show strong sequential aN(i,i+ 1) 
NOEs. However, only two residues in this C-domain loop have Ha proton chemical shifts 
downfield from the rando1n coil values, as indicated by an upward stroke in Figure 4.1. 
The chemical shifts of Ha protons of residues in the N-terminal extension deviate from 
random coil values, though these deviations are not consistent across the extension (Figure 
4.1). For example, Mer-13, Phe-12 and Met-9 have Ha chemical shifts downfield of the 
random coil values while Ala-10 and Leu-7 have Ha chemical shifts upfield of the random 
coil value. Generally, the shifts are of similar magnitude to those observed for Ha shifts in 
other regions of the protein. Likewise, there is no consistent NOE pattern within this 
region. Thus, it was not possible to ascribe a secondary structural motif to this region. 
Identification of slowly exchanging amide protons frequently locates the position of the 
more highly structured regions of the protein. A plot of Is/Io, determined by the saturation 
transfer method, as a function of residue number is shown in Figure 4.5 and gives an 
indication of the relative rates of amide proton exchange across the protein. The most 
rapidly exchanging amide protons are located in the C-do1nain loop. In contrast, there are 
several slowly exchanging amide protons located in the N-terminal extension which was 
unexpected because of the lack on 1H-1H NOEs observed in this region. Residues at the 
C-terminus CD-domain) are exchanging rapidly along with many in the N-terminal 
extension (Figure 4.1). The hydrogen exchange patterns in the IGF-I domain are in 
agreement with the secondary structural elements as determined by NOE patterns, J-
coupling data and supported by Ha chemical shift index analysis. Hydrogen exchange 
patterns in the IGF-I domain are also in agreement with previous homonuclear studies of 
wild-type IGF-I. Helix 1 shows consistent slow amide exchange along the whole length of 
the helix whereas only some of the protons within the two shorter helices are protected 
from the solvent. The only residues in helices 2 and 3 which have amide proton 
resonances still present 24 hours after sample preparation are Ile43, Glu46 and Phe49 in 
helix 2, and Arg55 and Arg56 in helix 3. Residues within the C-domain loop (Gly30 to 
90 
Ala38) are also protected from solvent. This region in native IGF-I was poorly defined in 
the homonuclear studies and did not display any solvent protection (Sato et al., 1992), thus 
it is not clear whether this is a real difference between Long-[Arg3]-IGF-I and IGF-I or is 
due to a limitation of the homonuclear NMR methods used in IGF-I studies. IGF-II has a 
similar stretch of residues in an extended conformation between helix 1 and helix 2 that 
are also protected from solvent exchange, however, compared to Long-[Arg3]-IGF-I, this 
region is off set five residues toward the N-terminus, i.e. from Gly25 to Phe28 (Torres et 
al., 1995). Residues Gly25 to Phe28 are involved with high affinity binding to the type 1 
IGF receptor (Cascieri et al., 1988, 1989). 
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Figure 4.5: Plot of Is / Io vs residue nu1nber which was used to estimate of the relative 
rates of amide proton relaxation. 
A long stretch of residues in the N-terminal extension (Met13 to Leu-4) is also protected 
from solvent (Figure 4.1). This is a surprising result since generally, most protected mnide 
protons are involved in hydrogen bonds ( discussed in section 4.2), but no well defined 
secondary structure exists in this part of the N-terminal extension. The pattern of solvent 
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protection may reflect the hydrophobic nature of the extension which arranges the residues 
in such a way as to exclude solvent. However, these structures must be transitory since this 
region has no well defined secondary structure as indicated by the paucity of sequential, 
medium-range, or long-range NOE contacts between this part of the N-terminal extension 
and the IGF-I domain (Figure 4.5). Insight into what type of transitory stn1ctures exist 
may be gained from the three-dimensional solution structure of Long-[Arg3]-IGF-I 
generated from the NOE data ( discussed in Chapter 5). However, information pertaining 
to the structure of this segment will be funited if no further long-range contacts can be 
extracted from the NMR data fallowing examination of the preliminary structures. 
4.4.2 Long-[Leu60J-IGF-I 
As with the Long-[Arg3]-IGF-I 1nutant, the secondary structural elements characteristic of 
the parent protein, IGF-I, are retained in the IGF-I domain of Long-[Leu60]-IGF-I. A 
diagrammatic summary of the relative intensities of sequential and medium-range NOEs, 
J-coupling information, chemical shift index values for the Ha protons and amide proton 
exchange rates is presented in Figure 4.6. 
Medium to strong sequential NN(i,i+ 1) NOEs are observed for the segments Ala8 to 
Phe23, Ile43 to Arg50 and Leu54 to Leu60 and medium-range aN(i,i+ 3) NOEs are detected 
for the seg1nents Ala8 to Cys18, Ile43 to Arg50 and Leu54 to Leu60. aN(i,i+4) NOEs are 
also observed for the region Ala8 to Cys18 (Figure 4.7). These NOE patterns are indicative 
of helices. The location of these three helices are the same as in I G F-I and Long-[Arg 3 ]-
I GF-I. Strong aN(i,i+ 1) NOEs are observed in the segments Glu3 to Thr4, Leu5 to Gly 7 
and Gly30 to Ala38, suggesting short seg1nents of extended confonnation exist in these 
regions. 
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Figure 4.6: A summary of the NMR data defining the secondary structure of Long-
[Leu60]-IGF-I at pH 3.0 and 30 °c. The primary sequence is displayed at the top. 
Sequential NOE connectivities, dNN, daN and d~N, are indicated by bars linking the 
residues concerned and are classified as strong, medi1un or weak according to the 
thickness of the bar. Medium-range NOE connectivities, daN(i,i+2), daN(i,i+3) and 
da.N(i,i+4) are linked by lines. The chemical shift index is classified as positive or negative 
by vertical lines above and below a baseline respectively. 3JNHa values greater than 7 .5 Hz 
are indicated by an upright arrow, 3JNHa values less than 6 Hz are indicated by an inverted 
arrow. Open circles indicate amide proton resonances that are observable 1 h after 
exchange of the solvent from H2O to D2O. Filled circles indicate amide proton resonances 
that are observed 24 h after solvent exchange. 
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A 1nedium-range aN(i,i+2) NOE was detected between Gly19 and Arg21 , which was also 
observed in Long-[Arg3]-IGF-I. However, another medium-range aN(i,i+2) NOE was 
observed between Asp20 and Gly22 in Long-[Arg3]-IGF-I which was not present in Long-
[Leu60]-IGF-L This suggests that the P-turn that is present in this region for IGF-I and 
Long-[Arg3]-IGF-I is preserved in Long-[Leu60]-IGF-I but is not as well defined. There 
are differences in 15N chemical shifts for residues Gly19 and Asp20 in Long-[Leu60]-
IGF-I compared with Long-[Arg3]-IGF-I. 
As with Long-[Arg3]-IGF-I, Met-13 to Ser-5 of the N-tenninal extension of Long-[Leu60]-
IGF-I has very few sequential NOEs and no non-sequential NOEs suggesting this 
seg1nent has little or no recognisable structure. A weak NN(i,i+ I) NOE was observed 
between Leu-4 and Phe-3 and the "reversed" sequential NOEs are observed between the 
ainide proton of Phe-3 and the a, p and y protons of Val-2 as in Long-[Arg3]-IGF-I. 
Long-range NOEs between Phe-3 and Gly 7 and between Val-2 and Cys6 are observed in 
Long-[Leu60]-IGF-I as in Long-[Arg3]-IGF-I, although there are so1ne differences in the 
intensities of the NOEs between the two proteins. Figure 4.8 shows 1H-1H strips from the 
3D l5N NOESY-HSQC spectrum of Long-[Leu60]-IGF-I displaying the sequential, 
medium- and long-range contacts observed in the region Ser-5 to Ala8. The Arg3 to Glu3 
mutation from Long-[Arg3]-IGF-I to Long-[Leu60]-IGF-I resulted in 15N chemical shift 
differences of the amide protons between Leu-4 and Leu5 indicating an altered 
conformation of this region in Long-[Leu60]-IGF-I, however, some important elements 
appear to be conserved. Figure 4.9 shows the 1 H-1 H strips fro1n the 3D 15N-NOESY-
HSQC spectrum of Long-[Leu60]-IGF-I displaying the sequential and medium-range 
contacts observed in the region Leu57 to Ala62, which are similar to those in Long-[Arg3]-
IGF-I (Figure 4.4). Only weak sequential NOEs are observed in the C-terminal region of 
Long-[Leu60]-IGF-I and internal NOEs are absent for Ala 70, as observed in Long-[Arg3]-
IGF-I. 
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Figure 4.7: Strips from the 3D sensitivity enhanced 15N-NOESY-HSQC spectn1m of 
Long-[Leu60]-IGF-I displaying the sequential and long-range contacts observed for the 
region Alal3 to Cys18. 
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The NOE pattern in the D-domain is similar for IGF-I, Long-[Arg3]-IGF-I and Long-
[Leu60]-IGF-I and suggests an unstn1ctured conformation for this region. There are no 
long-range NO Es between the C-tenninal region and other parts of the protein for either 
IGF-I (Cooke et al., 1991; Sato et al., 1993), Long-[Arg3]-IGF-I or Long-[Leu60]-IGF-I. 
Small 3 I NH a values, < 5 .5 Hz, were obtained for residues in segments which display the 
NOE patterns typical of helical structure, i.e. A1a8 to Cys18, Ile43 to Arg50 and Leu54 to 
Leu60. Two regions of the protein show 3JNHa values> 7.5 Hz, i.e. Met13, Met9, Ser-5 
and Leu-4 in the N-tenninal extension and a seg1nent in the C-domain loop, encompassing 
residues Tyr31, Ser35, Arg36 and Arg37. Some strong aN(i,i+ 1) NOEs were observed 
between residues Tyr31 to Arg37, consistent with data obtained for Long-[Arg3]-IGF-I. 
Ser5 and Leu-4 have 3JNHa > 7.5 Hz, as do residues Glu3, Thr4, and Cys6. The presence 
of large coupling constants for residues in the region from Glu3 to Cys6 is consistent with 
data obtained for IGF-I but this pattern was not as clear for Long-[Arg3]-IGF-I, which 
provides further evidence that the mutation at position 3 results in local conformational 
changes to the protein. The region Thr4 to Gly 7 also displayed strong aN(i,i+ 1) NO Es 
which suggests that the small seg1nent of extended structure identified in IGF-I is retained 
in Long-[Leu60]-IGF-I. 
Ha chemical shift data support the location of the three helices in Long-[Leu60]-IGF-I at 
positions Ala8 to Cys18, Ile43 to Arg50 and Leu54 to Leu60. No other regions of the 
protein had Ha chemical shifts which were consistently significantly shifted from random 
coil values. 
As discussed earlier (section 4.1), amide proton exchange rates are highly sensitive to 
changes in conformation and to variations in the stability of proteins. Changes in 
accessibility to solvent should be readily identified between Long-[Arg3]-IGF-I and Long-
[Leu60]-IGF-I. 
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Figure 4.8: Strips from the 3D sensitivity enhanced 15N-NOESY-HSQC spectrum of 
Long-[Leu60]-IGF-I displaying the sequential contacts observed for the region Ser 5 to 
Ala8. 
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Figure 4.9: Strips from the 3D sensitivity enhanced 15N-NOESY-HSQC spectrum of 
Long-[Leu60J-IGF-I displaying the sequential and medium-range contacts observed for 
the region Leu 57 to Aia62. 
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Some striking differences were noted in amide proton exchange data between Long-
[Leu60]-IGF-I and Long-[Arg3]-IGF-I. Only 12 arnide proton cross peaks for Long-
[Leu60]-IGF-I were observed in the 2D 15N-HSQC spectrum after 24 hours compared 
with 30 observed cross peaks for Long-[Arg3]-IGF-I (Figure 4.6). Similarly, after four 
hours, 20 cross peaks were observed for Long-[Leu60]-IGF-I compared with 32 for Long-
[Arg3]-IGF-I. For the entire 1nolecule, the arnide protons of Long-[Leu60]-IGF-I appear 
much more accessible to exchange than Long-[Arg3]-IGF-I. Surprisingly, the helices in 
Long-[Leu60]-IGF-I are more susceptible to solvent exchange than in Long-[Arg3]-IGF-I. 
After four hours, only 7 helical residues show cross peaks in the HSQC spectrum and 
after 24 hours only one helical residue (Leu60) shows an amide proton cross peak in the 
HSQC spectrum of Long-[Leu60]-IGF-I. Therefore Leu60, while it is itself protected fro1n 
solvent, appears to act as a destabilising influence on the hydrophobic core of the protein 
including the three helices and the receptor binding region. 
There is no apparent variation in the relative rate of exchange of the three helices in Long-
[Leu60]-IGF-I since there are two residues from each of the three helices which have 
amide proton resonances still observed after four hours. There are no solvent protected 
residues remaining in the centre of the helices after 24 hours. Much of the C-domain loop 
remains protected from solvent in Long-[Leu60]-IGF-I supporting the conservation of a 
small stretch of extended structure, with four residues (Ser33 to Arg36) in this region 
observed in the HSQC spectra after 24 hours. However, the extent of protection in this C-
domain loop region is smaller than Long-[Arg3]-IGF-I which has nine residues with 
ainide proton cross peaks still present in the HSQC spectrum after 24 hours (Figure 4.6). 
In Long-[Leu60]-IGF-I, the majority of residues for which cross peaks are observed in the 
HSQC spectrum after 24 hours are located in the N-terminal extension. This behaviour 
was also present in Long-[Arg3]-IGF-I and it was suggested that this solvent protection 
may reflect the hydrophobic nature of the extension which arranges itself in transitory 
structures so as to exclude solvent. However, in Long-[Leu60]-IGF-I, the extent of 
protection of the N-terminal extension is not as great since the amide proton resonances of 
only five residues in the N-terminal extension of Long-[Leu60]-IGF-I were present 24 
hours after exchange compared with eight N-terminal amide proton resonances in Long-
[ Arg 3 ]-I GF-I. 
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4.5 Discussion 
A detailed comparison of the NOEs, amide proton exchange rates, }-couplings and H<X 
proton chemical shifts used to determine secondary structure in IGF-I, mini-IGF-I, Long-
[Arg3]-IGF-I and Long-[Leu60]-IGF-I is presented in this section. Subtle differences in 
the structural regions or length of secondary structural elements between IGF-I and the 
analogues may provide partial explanation for differences in biological activity and altered 
affinity for receptors and binding proteins. 
In the first published IGF-I structure (Cooke et al., 1991), the authors identified that helix 
1 extended from Alas to Val17, helix 2 from Val44 to Phe49 and helix 3 from Leu54 to 
Met59. The authors also noted that a-helix 3 is less well defined than the other two, 
especially at Arg55. A more recent structure of IGF-I (Sato et al., 1992) identified the first 
helix as encompassing residues Alas to Cys18, one residue longer at the C-terminal end 
than identified by Cooke et al. (1991). Helix 2 extended from Gly42-Cys48, while helix 3 
extended from Leu54 to Cys61, with the length of two turns. For mini-IGF-I, helix 1 was 
found to extend from Alas to Cys18, the same length as identified by Sato et al. (1992), 
helix 2 extended from Gly42 to Phe49, one residue longer at the C-terminus than IGF-I 
(Sato et al., 1992) while helix 3 extended from Leu54 to Cys61, encompassing the same 
residues as identified by Sato et al. (1992). 
The three helices of Long-[Arg3]-IGF-I encompass residues Alas to Cys18, IIe43 to Arg50 
an.d Leu54 to Tyr60 respectively. Helix 1 of Long-[Arg3]-IGF-I encompasses the same 
residues as helix 1 of IGF-I (Sato et al., 1992) and mini-IGF-I (De Wolf et al., 1996), 
helix 2 of Long-[Arg3]-IGF-I is the same length as helix 2 in mini-IGF-I though shifted 
by one residue toward the C-terminus. Helix 3 of Long-[Arg3]-IGF-I is one residue 
shorter than helix 3 in both IGF-I (Sato et al., 1992) and mini-IGF-I (De Wolf et al. , 
1996). The three helices of Long-[Leu60]-IGF-I are located in the same positions as the 
helices of Long-[Arg3]-IGF-I, though helix 2 of Long-[Leu60]-IGF-I is not as well 
defined as in Long-[Arg3]-IGF-I, especially the segment Cys47 to Arg50_ 
In all IGF structural studies, the start and end points of the a-helices were defined by 
strong dNN (i,i+ 1), daN(i,i+3), daN(i,i+4) and da~(i,i+3) connectivities for IGF-I (Sato et 
al., 1992), mini-IGF-I (De Wolf et al., 1996), Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-
I. The differences in the start and end points of helices between IGF-I and the analogues 
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are small and may be explained by differences in sample and NMR experimental 
conditions. The magnitude of some NOEs were uncertain in previous homonuclear studies 
of IGF-I (Cooke et al., 1991; Sato et al., 1992) because of overlap in some regions. In this 
work, these regions are better defined because of more advanced NMR technology and 
pulse sequences. 
Hydrogen-deuterium exchange experiments are quite sensitive to conformational changes 
and variations in solvent exposure between proteins. Identification of slowly exchanging 
backbone amide protons was used to confirm the location of secondary structure in IGF-I 
(Sato et al., 1992), mini-IGF-I (De Wolf et al., 1996), Long-[Arg3]-IGF-I and Long-
[Leu60]-IGF-I. Cooke et al. (1991) did not report hydrogen-deuterium exchange rates in 
their publication of the IGF-I structure. Sato et al. (1992) identified 17 backbone amide 
protons in IGF-I as slowly exchanging, all of which were in helical regions with the 
exception of Gly22, which is involved in a hydrogen bond in the ~-turn following helix 1. 
In mini-IGF-I, 18 amide proton resonances were still observed 30 min after sample 
preparation, all of which were in helical regions with the exception of Gly22 (De Wolf et 
al., 1996). In addition, a further 11 amide proton resonances were noted as undergoing 
slow exchange. Only one of these residues, Ala8, was in a helical region. The others were 
Gly1, Thr4, Leu5, Gly7, Tyr24, Ser51, Asp53, Leu64, Lys65 and Ser69. 
Long-[Arg3]-IGF-I showed a different pattern of solvent exchange with 30 backbone 
amide proton resonances still present 24 hours after solvent preparation, 12 of these in 
helical regions. Eight residues in the C-domain of Long-[Arg3]-IGF-I (Gly30_AJa38) had 
slowly exchanging amide protons, none of which were slowly exchanging in IGF-I. IGF-
II has a smaller stretch of residues in an extended conformation between helix 1 and helix 
2 that are protected from solvent, although, compared to Long-[Arg3]-IGF-I, this region is 
offset five residues toward the N-terminus at Gly25 to Phe28 (Torres et al., 1995). An 
additional 12 residues of Long-[Arg3]-IGF-I had backbone amide protons still observed 
after four hours, with seven of these in helical regions. Slowly exchanging amide protons 
were observed for Leu5, Gly 7, and Leu64 of Long-[Arg3]-IGF-I, consistent with the amide 
exchange patterns for mini-IGF-I. 
In contrast to Long-[Arg3]-IGF-I, overall only 12 residues of Long-[Leu60]-IGF-I have 
amide proton resonances still observed after 24 hours, suggesting that the analogue is less 
protected from solvent than Long-[Arg3]-IGF-I, with fewer residues participating in 
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hydrogen bond interactions. The helical regions of Long-[Leu60]-IGF-I are more exposed 
to solvent than the same regions of Long-[Arg3]-IGF-I with the resonance of only one 
backbone amide proton still observed after 24 hours. Residues in the C-domain of Long-
[Leu60]-IGF-I are strongly protected from solvent with the backbone amide proton 
resonances of four residues (Ser33_Arg36) still observed after 24 hours. 
3JNHa values were not obtained for IGF-I or mini-IGF-I. This is unfortunate since it 
would have been useful to know if the series of 3JNHa values> 7.5 Hz observed for the 
C-domain segment (Gly30 to Ala38) of both Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I 
were observed in IGF-I. This region of IGF-I did not display the same solvent protection 
as Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I. The analogous solvent protected region 
in the C-domain of IGF-II did not have 3 JNHa values > 7 .5 Hz. 
Chemical shift index analyses for the H<X protons were not performed by Cooke et al. 
(1991) or Sato et al. (1992) for IGF-I since the chemical shift index tables of Wishart et 
al. ( 1991) were not available at the time. However, tables of 1 H chemical shift resonances 
including H<X proton chemical shifts for IGF-I were provided by both research groups 
(Cooke et al., 1991; Sato et al., 1992), allowing chemical shift index analyses to be 
performed for the purposes of comparison with Long-[Arg3]-IGF-I and Long-[Leu60]-
IGF-I. 
Upfield H<X chemical shifts are generally observed in the helical regions for IGF-I, mini-
IGF-I, Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I. However, a number of exceptions are 
noted. The H<X resonance of Ala8 is shifted downfield in mini-IGF-I relative to the random 
coil value, whereas this resonance is shifted upfield in the two Long-IGF-I analogues. The 
H<X resonances of Cys18, the C-terminal residue of helix 1, is shifted downfield relative to 
the random coil value in IGF-I and mini-IGF-I ) but not in either of the Long-IGF-I 
analogues (Cooke et al., 1991; Sato et al., 1992; De Wolf et al., 1996). The H<X resonance 
of Cys47 also experiences a downfield shift in IGF-I (Cooke et al., 1991; Sato et al., 
1992), mini-IGF-I (De Wolf et al., 1996) and Long-[Arg3]-IGF-I. The Tyr60 Ha 
resonance experiences a downfield chemical shift with respect to the random coil value in 
IGF-I (Sato et al., 1992), mini-IGF-I (De Wolf et al., 1996) and Long-[Arg3]-IGF-I. In 
addition, the H<X resonances of two other Cys residues, Cys52 and Cys61 experience 
downfield chemical shifts with respect to the random coil value in IGF-I, mini-IGF-I and 
Long-[Arg3]-IGF-I (Cys61 only). The H<X resonance of Leu57 (helix 3) in Long-[Arg3]-
102 
IGF-I is shifted downfield with respect to the random coil value. Similarly, the Ha 
resonances of Glu46 and Arg50 (helix 2) in Long-[Leu60]-IGF-I are shifted downfield, 
indicating that helix 2 of Long-[Leu60]-IGF-I has experienced some disruption when 
compared with IGF-I, due to the Tyr60Leu mutation. 
Residues in the segment Phe23 to Phe25 of IGF-I have been identified as important for 
IGF receptor binding (Cascieri et al., 1988). In Long-[Arg3]-IGF-I, the Ha resonances of 
Phe23 to Asn26 all experience a downfield shift with respect to their random coil values. 
However, in Long-[Leu60]-IGF-I, the Ha resonances are shifted upfield with respect to the 
random coil values for the segment Tyr24 to Lys27. These chemical shift differences are 
presented in Table 4.2. Long-[Leu60]-IGF-I binds less well to the type 1 IGF receptor 
than IGF-I (Milner et al., 1999). The Tyr60Leu mutation is the major contributing factor to 
decreased binding of Long-[Leu60]-IGF-I to the type 1 IGF receptor. However, it is 
difficult to distinguish the ring current effect from a structural effect. 
Table 4.2. Ha chemical shift deviations from random coil Ha shifts 
Residue 
Phe23 
Tyr24 
Phe25 
Asn26 
Lys27 
Long-[Arg3]-IGF-I 
+0.52 
+0.22 
+0.15 
+0.25 
0.00 
Long-[Leu60]-IGF-I 
+0.28 
-0.11 
-0.16 
-0.26 
-0.20 
The stability and biological activity of globular proteins are dictated by the close packing 
of amino acids. Disruption of the packed core of a protein, even in the form of quite subtle 
mutations, can result in dramatic effects (reviewed by Shortle ( 1989), Fersht & Serrano 
( 1993) and Sturtevant ( 1994)). Rearrangements of the main chain of proteins can allow 
accommodation of substituted residues. Major disruptions in the packing interactions 
occur when polar charged residues are introduced into or removed from the protein core 
(Ladbury et al., 1995). In this study, neither IGF-I substituted residues, Glu3 or Tyr60, are 
buried in the protein core, although Tyr60 is positioned at the C-terminal end of a-helix 3. 
The Glu3 Arg substitution in Long-[Arg3]-IGF-I, despite involving a change in charge, 
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does not result in a large structural reorientation of the IGF-I domain. Rather, the 
substitution results in local conformational changes at the N-terminus (see section 5.4.5). 
From the NMR data presented herein, the Tyr60Leu substitution in Long-[Leu60]-IGF-I 
does result in some chemical shift changes in nearby secondary structure elements but this 
does not disrupt the protein core. This was also observed for a mutant of thioredoxin, 
Leu 78Lys, in which structural changes caused by the mutation were localized within 12 A 
of the altered sidechain (De Lorimier et al., 1996). However, this mispacking of the protein 
core was reported to affect the local dynamics and stability throughout the protein. The 
mobility and dynamics of the Long-IGF analogues were investigated by NMR 
spectroscopy and the results are discussed in Chapter 6. 
The analysis of NOE contacts, J-coupling information, amide proton exchange rates and 
chemical shift index data confirms that the location of the secondary structure elements of 
the Long-IGF analogues is essentially unchanged from the parent IGF-I molecule. 
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CHAPTERS 
Three-Dimensional Solution Structure of Long-[Arg3]-IGF-I 
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5.1 Introduction 
Three-dimensional solution structure calculations were performed for the Long-[Arg3]-
IGF-I analogue but not for the Long-[Leu60]-IGF-I analogue for the following reasons. 
Firstly, the binding studies between Long-[Leu60]-IGF-I and IGFBP-2 (described in 
chapter 7) were considered to be a priority for this analogue. Secondly, the resonance 
assignments and secondary structure of Long-[Leu60]-IGF-I were not sufficiently 
different from Long-[Arg3]-IGF-I (section 4.4.2) to indicate that the three-dimensional 
structure would be substantially changed. Finally, no unlabelled Long-[Leu6°J-IGF-I was 
available, meaning that unambiguous identification of long-range contacts between 
sidechain protons could not be completed. Thus, all subsequent sections of this chapter 
refer only to the structure of Long-[Arg3]-IGF-I. 
The major interest in the structure of Long-[Arg3]-IGF-I resides in the effects that the 
thirteen amino acid extension and the Glu3 Arg mutation have on the three-dimensional 
structure of the IGF-I domain. As discussed in section 1.8, Long-[Arg3]-IGF-I is among 
the most potent of the IGF-I analogues with N-terminal modifications. Enhanced 
biological activity is observed despite a lower affinity for the type 1 IGF receptor 
compared to wild-type IGF-I. The increased potency has been attributed to reduced 
binding to IGFBPs, which increases the concentration of free Long-[Arg3]-IGF-I available 
to the receptor. A three-dimensional model of Long-[Arg3]-IGF-I (presented in this 
chapter) enables a partial rationalisation of a wealth of experimental data collected over the 
past decade with regard to the binding of IGF-I and its analogues to IGFBPs, the IGF 
receptors and the insulin receptor. 
5.2 Materials and Hardware 
5.2.1 Software 
Three-dimensional NOESY cross peaks were integrated using the program SPSCAN 
(R.W.Glaser and K.Wiithrich, http://www.biol.ethz.ch/wuthrich/software/spscan/). 
CALIBA (part of the DY ANA suite of programs) was used to convert NOESY cross peak 
volumes and disulfide bonds into upper and lower distance bounds. Automatic calibration 
was performed by the macro CALIBA. ~, \If and X 1 angle restraints and H~ assignments 
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were created from experimentally derived 3JHNHa and 3JHNH~ values using the program 
HABAS (Guntert et al., 1989). Structures were generated using the program DY ANA 1.5 
(Guntert et al., 1997) which employs simulated annealing combined with molecular 
dynamics in torsion angle space. DY ANA calculates structures by adjusting torsion angles 
to fit conformational restraints derived from experimental data while all covalent structure 
parameters (bond lengths, bond angles, chiralities and planarities) are kept at their 
optimum values. The quality of the structures were analysed using the programs AQUA 
and PROCHECK-NMR (Laskowski et al., 1996). 
5.2.2 Sedimentation Equilibrium Apparatus 
A Beckman Optima XL-A analytical centrifuge (Beckman Instruments, Fullerton, CA) 
located at the John Curtin School of Medical Research, Australian National University, 
was used for the sedimentation equilibrium experiments. 12 mm path length cells with 
aluminium filled double sector centrepieces were used. 
5.3 Methods 
5.3.1 Sedimentation Equilibrium 
The solution sector of the analytical centrifuge contained 100 µl of a 1 mM sample of 
Long-[Arg3]-IGF-I dissolved in H2O while the solvent sector contained 110 µl of H2O as 
a reference. Experiments were performed at 25 °C. The equilibrium profile of absorbance 
of the protein, A, at 280 nm as a function of the radial distance (in cm) from the axis of 
rotation at the centre of the rotor, r, was recorded. The attainment of sedimentation 
equilibrium was checked by collecting and superimposing scans at two hourly intervals. 
Scans at 360 nm were collected and subtracted from the equilibrium scans to correct for 
anomalies arising from the cell windows. 
5.3.2 NMR Experimental 
The HNHA experiment (Vuister and Bax, 1993) was used to determine 3 J NHa coupling 
constants and was described in section 4.3.1. The HNHB experiment (Archer et al., 1991) 
was used to correlate amide proton (HN) and l 5N resonances with those of intraresidual 
sidechain H~ proton signals. Measurement of the cross-peak intensity provides qualitative 
information on the size of 3 JNH~- In this experiment, H~ cross peaks have negative 
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intensities while HN diagonal cross peaks have positive intensities. This yields information 
about the sidechain torsion angle X 1 and aids in the stereospecific assignment of non 
equivalent methylene protons. The pulse scheme is presented in Appendix 1. A 3D 15N-
NOESY-HSQC spectrum with mixing time 80 ms and a 2D NOESY spectrum with 
mixing time 120 ms were used for assigning upper and lower distance restraints. 
5.3.3 Experimental Restraints 
Angular restraints, derived from 3JHNHcx via the Karplus relation (equation 5.1), were used 
to restrict the sampling of conformational space by the protein backbone during structure 
refinement. The magnitude of the 3 JHNHa values is related to the backbone dihedral 
angle of a protein, 8 (shown in Figure 1.5). 
3J = A cos28 + Bcos8 + C (5.1) 
The constants A, B, and C depend on the particular nuclei that form three adjoining 
covalent bonds. Accurate parameterisation of the Karplus equation is necessary in order to 
relate measured 3J values to dihedral angle ranges. The most accurate values for the 
constants A, B, and C have been derived by correlation of observed 3 J values with the 
corresponding dihedral angles measured in protein structures determined by X-ray 
crystallography or NMR spectroscopy (Pardi et al., 1984; Ludvigsen, 1991 ). Different 
conformations can yield the same value of 3JHNHcx, although some of the possible 
orientations may be sterically unfavourable. Dihedral angle constraints enforced during 
structural calculations must include all of the valid solutions to the Karplus curve 
(Cavanagh et al., 1996). 3JHNHcx values observed in the range 6-8 Hz generally are not 
used as protein structural restraints because they may reflect motional averaging of 
multiple conformations. 
Two methods were used for restraining phi ( <j>) and psi ('V) angles. Firstly, for 3 JNHcx < 
5.0 Hz, <j> was restrained to -60 + 30°, for values 5.0 Hz < 3JNHcx < 5.5 Hz, <j> was 
restrained to -60 + 40° and for values of 3 JNHcx > 7 .5 Hz, <j> was restrained to -120 + 30°. 
<j> was not restrained for 3JNHcx values between 5.5 and 7 .5 Hz. The second method 
employed HABAS which determines the allowed conformation for the 
<j>, 'V, and XI dihedral angles using a grid search on the basis of local distance restraints 
and scalar coupling constants. The upper and lower dihedral angle restraints generated by 
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both methods were inspected to ensure that they were self consistent. 
X 1 angle restraints and H~ stereospecific assignments were made using the program 
HABAS via estimates of the 3JNH~ values obtained from the relative HN-H~ cross peak 
intensities in a 3D HNHB spectrum. 3 JNH~ values were treated qualitatively and given the 
limits of+ 2.0 Hz. If one of the HN-H~ cross peaks is stronger than the other in the 
HNHB experiment, this reflects the presence of a large and small coupling constant. A 
difference in strength of the cross peaks was defined as one cross peak being three times 
as intense as the other cross peak. The larger cross peak was assigned a 3 JNH~ value of 
5.0 Hz while the smaller coupling constant was assigned a 3JNH~ value of 1.5 Hz. If only 
one HN-H~ cross peak was observed, 3 JNH~ was assigned a value of 5 Hz. If weak or 
vanishing HN-H~ correlations were observed for both ~-protons or both cross peaks were 
equally intense, no input was given for these results. These 3JNH~ values were assigned in 
accordance with the Karplus relationship (equation 5.1). 
Slowly exchanging backbone amide protons were identified as described in section 4.3.3. 
Hydrogen bond restraints were included for slowly exchanging NH groups, for which a 
single hydrogen bond acceptor was identified in preliminary structure calculations, and 
was consistent with the secondary structure determined previously. Lower distance 
restraints between the hydrogen bond donor and acceptor and the hydrogen bond donor 
0 0 
antecedent and the acceptor of 1.5 A and 2.3 A respectively were added. Upper distance 
0 0 
restraints for the same bonds were 2.3 A and 3.3 A respectively. 
Upper distance bounds were calculated from the integration of three-dimensional NOESY 
cross peaks using the program SPSCAN as described earlier (section 5.2.1). 
5.3.4 Structure Calculations 
An iterative process of calculation was employed where successive rounds of structure 
calculations were used to make further NOE assignments. During preliminary rounds of 
structure calculations, typically 50-100 structures were generated using 10000 simulated 
annealing steps fallowed by 1000 energy minimisation steps, with 15 or 25 structures 
being retained for analysis of hydrogen bonds and long range NOEs. The 15 sets of 
coordinates with the lowest target functions were selected from 100 coordinate sets in the 
final cycle of calculations. 
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5.3.5 Evaluation of the Quality of the Structure 
AQUA is a suite of programs for analysing the quality of biomolecular structures 
determined by NMR spectroscopy. PROCHECK-NMR is a suite of programs that 
produce PostScript plots of the restraint violations computed by AQUA together with 
various analyses of the stereochemical quality of the models in the NMR ensemble. The 
PDB file (Bernstein et al., 1977) with the coordinates of Long-[Arg3]-IGF-I, a restraint 
file listing NOEs, hydrogen bonds, disulphides and torsion angle restraints were input for 
the two programs AQUA and PROCHECK. The angular order parameters give an 
indication of how well defined the backbone dihedral angles are. An angular order 
parameter close to one represents a well-defined backbone dihedral angle, while low 
angular order parameters indicate poorly defined backbone dihedral angles. Angular order 
parameters for Long-[Arg3]-IGF-I were determined using MOLMOL (Koradi et al., 
1996). 
5.4 Results 
5.4.1 Sedimentation Equilibrium 
Sedimentation equilibrium was reached after seven hours at a speed of 3000 rpm. The 
resulting absorbance (A) vs radial distance (r) in cm from the axis of rotation data were 
analysed using the program XLAEQ (Beckman Instruments, Fullerton, CA), employing 
the sedimentation equilibrium equation: 
M=2RT/(l-vp )co . d(lnA)/(dr2) (5.2) 
where M is the molecular weight, R is the gas constant, T is the absolute temperature, co is 
the angular rotation in rad/sec, vis the partial specific volume of the protein, 0.73 ml/g in 
this case, and d is the density of the buffer. For a non-associating, monodisperse system, 
the plot of In A vs r2 will be linear. The data could not be fitted to a single straight line 
using equation (5.2), the plot of the data was curved upwards, indicating a heterogenous 
protein (Figure 5.1). The apparent heterogeneity in molecular weight of the protein was 
examined to determine if this could be attributed to association of the protein. If the 
system is self-associating or involved in 'heterologous' association (i.e. complex 
formation) the In A vs r2 plot can be used to measure the stoichiometry and strength of the 
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interaction. Assuming a mixture of monomer and dimer, using the pro gram MUL TMXl 
(Beckman Instnunents, Fullerton, CA), a good fit was obtained for a mixture of 80% 
monomer (mol. wt. 9000) and 20% dimer (mol. wt. 18000). 
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Figure 5.1: Plot of lnA vs r2 for a 11nM solution of Long-[Arg3]-IGF-I. 
5.4.2 Experiniental Restraints 
The input restraints were obtained from 3D 1H-15N NOESY-HSQC and 2D 1H NOESY 
experiments. Initially, structures were calculated using only 389 unambiguous 
experilnentally derived distance restraints, 90 restraints derived from coupling constants 
and 12 restraints to maintain the three disulfide bridges. Subsequently, 24 upper bound 
and 24 lower bound hydrogen bond restraints were added to maintain 12 hydrogen bonds 
that were deduced from 12 very slowly exchanging amide protons. These hydrogen bonds 
were primarily within the three a-helices with one restraint added for a hydrogen bond in 
the type 1 ~-tum following a-helix 1 (Glyl9_Gly22). An additional 107 NOEs were 
unainbiguously assigned and added as restraints after inspection of the preliminary 
111 
structures. The stereospecific assignments of nine methylene ~ protons were deduced by 
inspection of the relative crosspeak intensities in the 3D HNHB, 1H- 15N NOESY-HSQC 
and 1H- 15N TOCSY-HSQC spectra. There was no evidence f intermonomer NOEs and 
so no restraints were expected to be due to dimerization. 
The final structures were calculated on the basis of 524 distance restraints, 90 dihedral 
angle restraints and 48 hydrogen bond restraints. Interproton distance restraints could be 
divided into 177 intraresidue, 167 sequential, 78 interresidue medium-range (i to i + j < 4) 
and 63 interresidue long-range (i to i + j > 5). An average of 5.9 restraints per residue 
were used. Distance and dihedral angle restraints used in the calculation of the three-
dimensional structure of Long-[Arg3]-IGF-I are presented in Appendix 4. The maximum 
number of restraints occurred at residue Leu14, located in a-helix 1, with 41 NOE 
restraints. There were no restraints imposed on residues Pro-8, Pro2, Pro63, Pro66 or Ala70, 
which clearly were experiencing substantial motion, and very few intra- or interresidue 
NOEs were observed. 
5.4.3 Results of Structure Calculations 
One hundred structures were calculated, each starting from a different random 
conformation. The final 15 structures, selected on the basis of overall energy, are displayed 
in Figure 5.2. Each structure satisfies the experimental restraints with no upper-bound 
0 0 
violations greater than 0.6 A, no lower-bound violations greater than 0.1 A and no dihedral 
~ngle violations greater than 5°. The backbone conformations are well defined except for 
the first nine residues of the N-terminal extension, the final eight residues of the C-
terminus and residues Asn26 to Pro39 in the C-domain loop between the first and second 
helices. The overall mean global backbone rmsd value for the 15 best structures is 3.5 + 
0 
0.9 A (excluding the N-terminal nine residues and the C-terminal eight residues) and 0.82 
0 
+ 0.14 A for the helical regions. The heavy atom rmsd values for the equivalent regions 
0 0 
are 4.4 + 0.9 A and 1.38 + 0.33 A respectively. The backbone dihedral angles (<p and \jl) 
are well defined, with angular order parameters (S > 0.8) for residues comprising the 
hydrophobic core of the protein (Figure 5.3), i.e. Ala8 to Phe23, Gln40 to Cys52 and Leu54 
to Ala62, as well as Ser6 to Sers, Phe-3, Leu4, Cys6, Lys27, Thf29, Gly32 and Ser35_ A 
survey of the structural statistics and residual violations of the experimental restraints is 
displayed in Table 5.1. 
Table 5.1. Structural statistics and root mean square deviations for the 
15 lowest energy solutions of human Long-[Arg3]-IGF-I 
Structural Restraints 
Distance restraints 
total 
intraresidue 
sequential 
medium-range li-jl < 5 
long-range li-jl > 5 
Dihedral angle restraints 
Hydrogen bond restraints 
Disulfide bond restraints 
Statistics for Structure Calculations 
Average restraint violations 
NOE violation (A) 
dihedral angle violation (0 ) 
Atomic rmsd values, all residues (A) 
backbone 
range 
all heavy atoms 
range 
0 
Atomic rmsd values, residues fi3 to 62 (A) 
backbone 
all heavy atoms 
0 
Atomic rmsd values, a-helices (A) 
backbone 
all heavy atoms 
Target Function (A 2) 
5.4.4 Quality of the Structure 
485 
177 
167 
78 
63 
90 
48 
18 
0.17+0.22 
1.63 + 0.52 
5.3 + 1.6 
3.16-9.66 
6.0 + 1.4 
3.67-9.99 
3.5 + 0.9 
4.4 + 0.9 
0.82 + 0.28 
1.71 + 0.34 
55.16 + 1.93 
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A distribution of the NOE restraints as a function of residue number, the rmsd value as a 
function of residue number and the distribution of angular ( cp and \{I) order parameters for 
Long-[Arg3]-IGF-I are shown in Figure 5.3. The Ramachandran plot of the average 
minimised structure (Figure 5.4) shows that 43% of the meaningful residues fall into the 
most favoured regions and 41 % of residues are in other allowed regions. The average 
structure was calculated using molmol. The remaining 16% of residues, all of which are in 
the disordered terminal and loop regions of the protein, fall in the so-called generously 
allowed region of the Ramachandran plot. No angular values occur in the disallowed 
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5.4.5 Description of the Solution Structure 
The solution structures of Long-[Arg3]-IGF-I display good convergence to a single fold 
in the hydrophobic core region containing the three a-helices (Figure 5.2). A file 
containing the coordinates of the ensemble of the 15 structures with the lowest target 
functions have been submitted to the Protein Data Bank. The coordinates entry for Long-
[Arg3]-IGF-I has the PDB ID code 3lri and the NMR restraints entry has PDB ID code 
3lrimr. The structured regions in the IGF-I domain of Long-[Arg3]-IGF-I are retained 
from the parent protein, in which helix 2 and helix 3 run approximately anti-parallel to 
each other and roughly perpendicular to helix 1, the three helices enclosing a hydrophobic 
core (Figure 5.6). This arrangement arises because several long-range NOE interactions 
were observed between the three a-helices ( 49% of the long-range NOEs connected pairs 
of helices) or between residues identified as important for receptor binding, at the C-
terminal end of the B-domain. 
Overall, the long-range NOEs observed between elements of recognisable secondary 
structure are almost identical to those observed by Sato et al. ( 1992) in IGF-I. However, 
some long-range NOEs were observed in Long-[Arg3]-IGF-I that were not reported for 
IGF-I which contribute to subtle changes in the orientation of helix 3 with respect to helix 
1. These long-range contacts include NOEs between Val1 1 and Val44 and between Leu14 
and Leu57 which were also detected in mini-IGF-I (De Wolf et al., 1996). A related long-
range NOE is observed between Leu14 and Ile43 in Long-[Arg3]-IGF-I whereas the 
equivalent NOE for IGF-I is between Ala13 and Ile43 and in mini-IGF-I this NOE is 
between Leu14 and Val44. In Long-[Arg3]-IGF-I, an NOE is observed between Asn26 and 
Tyr60 whereas NOEs between Tyr24 and Tyr60 and between Gly22 and Tyr60 were 
observed in IGF-I (Sato et al., 1992) but not in Long-[Arg3]-IGF-I. The retention of the 
hydrophobic core of the IGF-I domain of Long-[Arg3]-IGF-I indicates that modifications 
at the N-terminus have a minimal impact on the overall protein conformation except for a 
slight reorientation of the three helices and a realignment of residues near the N-terminus. 
The sidechains of all polar and charged residues of helices 1, 2 and 3 face the solution, i.e. 
Glu9, Asp12, Gln15, Asp45, Glu46, Arg50, Arg55, Arg56 and Glu58 although Glu46 and 
Arg55 do not point directly away from the hydrophobic core. Most of the helical residues 
in Long-[Arg3]-IGF-I prefer helical locations in proteins, with the exception of Tyr6°, as 
Tyr is a poor helix former (Richardson & Richardson, 1988). However, the aromatic ring 
of Tyr60 faces away from the hydrophobic core. 
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Figure 5.2: Stereo superposition of the backbone heavy-atoms N, ca, C' and O from the 
fb}al ensemble of 15 structures for Long-[Arg3]-IGF-I. View a) shows all the residues. In 
view b), the residues in the C-domain loop (Asn26-Gly42) and the C-tenninus (Cys61_ 
Ala 70) are deleted for clarity. 
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Figure 5.3: a) Distribution of NOE restraints for Long-[Arg3]-IGF-I. The height of each 
bar denotes the number of NOEs. b) The nnsd value per residue of the heavy atom 
backbone coordinates for the 15 best structures of Long-[Arg3]-IGF-I relative to the 
average structure. c) Distribution of <j> angular order parameters, S(<j>) , for Long-[Arg3]-
IGF-I. d) Distribution of 'ti angular order pararneters, S('tf), for Long-[Arg3]-IGF-I. 
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Figure 5.4: Ramachandran plot of the <p and 'V dihedral angles for the average structure of 
the family of the final 15 structures of Long-[Arg3]-IGF-I. The plot, generated by the 
program PROCHECK-NMR (Laskowski et al., 1996), displays the most favoured, 
additional allowed, generously allowed and disallowed regions as red, yellow, light pink 
and white respectively. Glycine residues are shown as triangles. Residues with rmsd < 4.0 
are indicated by an open circle. Residues with rmsd > 4.0 are indicated by a filled square. 
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It is not possible to distinguish whether these small variations in structure between IGF-I 
and Long-[Arg3]-IGF-I are due to a greater number of medium-range distance restraints 
obtained from the enhanced resolution of the 15N-edited experiments or from a real 
change in structure imposed by the N-terminal modifications in Long-[Arg3]-IGF-I. The 
15N-edited experiments used in the structure detennination of Long-[Arg3]-IGF-I 
primarily provide short- and medium-range restraints whereas the global fold of a protein 
is determined by long-range restraints. 
There is a ~-tum between Gly19 and Gly22 which was also observed in IGF-I and IGF-II. 
The <I> and ~ angles in this turn most closely fit those of a type 1 tum which is supported 
by a slowly exchanging amide at Gly22. A small stretch of extended structure exists 
between Gly30 and Ala38 which was not detected in IGF-I as was discussed previously 
(Chapter 4) but was observed in IGF-II and is also consistent with a number of slowly 
exchanging amide protons in this stretch of amino acids. 
There is no well defined secondary structure in the N-terminal extension of Long-[Arg3]-
IGF-I as reflected by the large nnsd values for most residues in the extension. As might 
be expected, there are substantial changes in the confonnation of the residues Gly 1 to 
Cys6, which are adjacent to the extension, compared with IGF-I. In particular, NOEs 
between Gly 1 and residues in the loop between helices 2 and 3 (i.e. Arg50_ Asp53), 
observed in IGF-I, are not present in the spectra of Long-[Arg3]-IGF-I. Instead, several 
long range NOEs are observed from Phe-3 and V al-2 to residues immediately prior to helix 
1 (Cys6 and Gly 7) which places the N-terminal extension near the beginning of helix 1. In 
Long-[Arg3]-IGF-I, the residues Asn-1, Glyl, Pro2 and Arg3 form a tum-like structure. 
Analysis of the <I> and ~ angles showed that this tum did not belong to any of the 
published ~-turns. The paucity of 1nedium- and long-range NOEs for residues Gly1 to 
Thr4 is reflected in an increase in the nnsd values for these residues (Figure 5.3). Most 
significant is the drainatic change in orientation of the sidechain of the residue at position 
3. In IGF-I, Glu3 is located in a region bounded by helix 1, helix 3 and the link between 
helix 2 and helix 3 (Figure 5.5). In Long-[Arg3]-IGF-I, the sidechain of Arg3 is located in 
an exposed position on the surface of the protein (Figure 5 .5). 
The solution structure of Long-[Arg3]-IGF-I suggests that the N-terminal extension may 
fold back over the hydrophobic core of the protein, however, no long-range NOEs are 
identified between the N-terminal extension and this helical region of the IGF-I do1nain. 
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As discussed previously (Chapter 4), there are several slowly exchanging amide protons in 
the N-terminal extension despite the lack of NOEs, suggesting that these residues arrange 
themselves in such a way as to exclude solvent. These structures must, however, be 
transitory because of a lack of medium- and long-range NOEs. The equivalent region of 
porcine growth hormone, from which the stretch of residues in the N-tenninal extension is 
derived, forms an a-helix (Abdel-Meguid et al., 1987). Thus, the N-terminal extension 
may retain some of the structure of the corresponding segment of growth honnone and 
fold into a molten helix in Long-[Arg3]-IGF-L The amide protons of Phe49 and Arg50 
near the C-terminus of helix 2 and Arg55 and Arg56 at the N-tenninus of helix 3 are 
strongly protected from exchange with the solvent, unlike the equivalent residues in native 
IGF-I (Sato et al., 1992), further supporting the notion that the N-terminal extension does 
have some order and 1nay form transitory hydrophobic contacts between this region and 
the N-terminal extension. 
5.5 Discussion 
5.5.1 Comparison of Long-[Arg3]-IGF-I with IGF-1 and mini-IGF-1 
The number of restraints used in the refinement of the structure of Long-[Arg3]-IGF-I is 
greater than the number of restraints used for the original IGF-I structures (Cooke et al., 
1991; Sato et al., 1993) and is co1nparable to the number of restraints used for subsequent 
work with IGF-II (Torres et al., 1995) and mini-IGF-I (De Wolf et al., 1996). The paucity 
of NOEs in the N-terminal extension contributed to an inflated rmsd value for the entire 
protein. This is supported by the obvious flexibility in the N-terminal extension (discussed 
in chapter 6). The data, however, were sufficient to define the global fold, including the 
position of the three helices and the less mobile part of the N-terminal extension. There 
was no evidence of intermonomer NOEs. 
The fold of the IGF-I domain of Long-[Arg3]-IGF-I does not substantially differ from 
IGF-I. However, there are some variations worth noting. A comparison of Long-[Arg3]-
IGF-I with the IGF-I structure of Cooke et. al. (1991) is displayed in Figure 5.5. 
Immediately obvious is the variation in the orientation of the axes of helix 1 and helix 3. 
The angles between helices were calculated using MOLMOL (Koradi et al., 1996). The 
angle between helices 1 and 3 in Long-[Arg3]-IGF-I is 63.2° while in IGF-I the same 
interhelical angle is 87 .4°. The angles between helices 1 and 2 and between helices 2 and 3 
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are similar in the two proteins, i.e. the angle between helices 1 and 2 is 109. 6° in Long-
[ Arg 3 ]-I G F-I and 106.0° in IGF-I and the angle between helices 2 and 3 is 160.3° in 
Long-[Arg3]-IGF-I and 166.4° in IGF-I. 
Long- [Arg3]- IG F-1 
c-domain loop 
IGF-1 
c-domlln loop 
H2 
---- Glul 
H1 
Figure 5.5: Schematic representation of the average NMR structures of Long-[Arg3]-
IGF-I and IGF-I (Cooke et al., 1991). The locations of the sidechains of Arg3 in Long-
[Arg3]-IGF-I and Glu3 in IGF-I are shown in blue to indicate the different orientations. 
120 
The orientation of the loops in Long-[Arg3]-IGF-I is not always the same in the various 
structures, however, the sidechain of Arg3 is always pointing outwards. 
It is unlikely that the orientational shift between helices 1 and 3 is solely a result of 
additional distance restraints from the 15N-edited experiments because these experiments 
provide mostly short-range and medium-range distance restraints. Thus, the change is 
most likely a real structural reorientation resulting from the removal of the free N-terminus 
at Gly 1 which has been shown to interact with Arg55 and Arg56 in IGF-I (Cooke et al., 
1991). In Long-[Arg3]-IGF-I this interaction cannot occur, although the N-terminal 
extension does orient in the same general direction with an average location just above 
helix 2, helix 3 and the C-domain loop. A change in interhelical angles was also noted for 
E. coli DnaJ, a heat shock protein, upon addition of a C-terminal extension, a conserved 
"G/F" region which is rich in glycine and phenylalanine residues (Huang et al., 1999). 
Local conformational changes were also noted in the loop region of DnaJ connecting the 
two central helices. 
Most significant though, is the change in location and orientation of the sidechain of the 
residue at position 3, which is removed from its location between helices 1 and 3 in IGF-I 
to a highly exposed location in Long-[Arg3]-IGF-I (Figure 5.5). A number of factors 
influence this reorientation including the removal of the N-terminal charge at Gly1, the 
advantageous alignment of three residues that favour a turn structure (Asn-1, Gly 1 and 
Pro2) and the interaction of four nearby hydrophobic residues (Phe-3, Val-2, Gly1 and 
Leu5). The Val-2-Asn-1 dipeptide linker between the N-terminal extension derived from 
porcine GH and the IGF-I domain was introduced to enable facile cleavage by 
hydroxylamine for obtaining IGF-I or analogues. Asn has a preference for assuming 
position 1 in turn structures, Gly has a preference for turns, while Pro has a preference for 
occupying position 3 in turns. This tripeptide sequence, favourable for assuming tum 
structures, provides a unique structural element of Long-[Arg3]-IGF-I which distinguishes 
the binding affinities and biological activities of this protein from other members of the 
IGF family. 
5.5.2 Implications of Long-[Arg3]-IGF-I Structure for Binding to IGF Receptors 
and IGFBPs 
Several studies have shown that Arg21, Phe23, Tyr24, Phe25 and Val44 are crucial for type 
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1 IGF receptor binding and Cooke et. al. ( 1991) established that these residues are located 
in a cleft on one face of IGF-I separating the A- and B- domains from the C-domain. 
Figure 5.6 shows the relative locations of the N-terminal extension and this cleft in Long-
[Arg3]-IGF-I. It is evident that the N-terminal extension may limit access to Val44 and 
there does appear to be some variation (compared to IGF-I) in the relative positions of 
Arg21, Phe23 and Tyr24, which are crucial to the binding of the type 1 receptor, between 
the two models. 
The three N-terminal residues of IGF-I, in particular Glu3, are crucial for effective 
association of IGF-I and IGF-I analogues with the IGFBPs. Mutation of Glu3 to Arg3 
substantially reduces the affinity of IGF-I analogues for IGFBPs which is logically 
attributed to an electrostatic effect. The addition of a 13 amino acid extension to the N-
terminus of IGF-I and its analogues, [Gly3]-IGF-I and [Arg3]-IGF-I further reduces the 
affinity for the IGFBPs. The amino acid at position 3 is not masked from the IGFBPs by 
the N-terminal extension, because the "Long" analogues of IGF-I, i.e. Long-IGF-I, Long-
[Gly3]-IGF-I and Long-[Arg3]-IGF-I, follow the same trend for the binding affinity for 
IGFBPs as IGF-I, [Gly3]-IGF-I and [Arg3]-IGF-I. The solution structure of Long-
[Arg3]-IGF-I agrees with these binding affinity data and indeed shows that Arg3 in Long-
[Arg3]-IGF-I is even more exposed than Glu3 in IGF-I (Figure 5.5). 
The solution structure of the IGF binding domain of IGFBP-5 has recently been 
determined and the association of this domain with IGF-II investigated by NMR 
techniques (Kalus et al., 1998). The authors propose that Glu6 and Phe48 in IGF-II are 
crucial for the binding of IGF-II to IGFBP-1. By analogy, one can conclude that the 
spatial location and proximity of the corresponding residues in IGF-I, Glu3 and Phe49, are 
important for the binding of IGF-I to IGFBPs. Figure 5.7 shows space-filling models of 
the location and proximity of Glu3 and Phe49 in IGF-I and Arg3 and Phe49 in Long-
[Arg3]-IGF-I. It is immediately clear that there is a substantial change in the relative 
positions of these residues, particularly for residue 3, between the two proteins. Thus, the 
reduced binding of Long-[Arg3]-IGF-I to IGFBPs may not simply result from the 
electrostatic effect of the Glu3 to Arg3 mutation but also from a spatial effect caused by 
conformational relocation of the residue at position 3. This would explain the further 
reduction in affinity for the IGFBPs for the long analogues that is observed in the binding 
studies. The specific binding determinants of IGF-I analogues for IGFBP-2 are discussed 
further in chapter 7. 
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Figure 5.6: A co1nparison of CPK models of the average NMR structures of Long-
[Arg3]-IGF-I and IGF-I (Cooke et al. , 1991). Crucial residues for the interaction with the 
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type 1 receptor (Arg21, Phe23, Tyr24 and Val44) and the N-terminal extension are 
highlighted. The location of Arg3 in Long-[Arg3]-IGF-I is also shown but Glu3 is 
obscured in this view of IGF-I. 
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Figure 5.7: A comparison of the CPK 1nodels of the average NMR structures of Long-
[Arg3]-IGF-I and IGF-I (Cooke et al., 1991) with the residues ilnplicated in the 
association with IGFBPs (Arg3 and Phe49 in Long-[Arg3]-IGF-I and Glu3 and Phe49 in 
IGF-I) highlighted. 
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CHAPTER6 
Backbone Dynamics Studies of IGF-1 Analogues 
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6.1 Introduction 
Analysis of the backbone dynamics of proteins is a useful adjunct to structural studies 
because it provides information about the mobility of distinct regions of a protein that 
cannot be obtained directly from the 1 H-1 H NOE data. This is particularly important for 
regions of a protein which have a paucity of 1 H-1 H NOEs. Both IGF-I analogues, Long-
[Arg3]-IGF-I and Long-[Leu60]-IGF-I, have specific regions which have very few 1 H- 1 H 
NOEs i.e. the N-terminal extension, the C-domain loop and the C-terminus (D-domain) 
(sections 4.4.1 and 4.4.2). Heteronuclear NMR spin relaxation spectroscopy constitutes a 
powerful experimental approach for globally characterising conformational dynamics of 
proteins in solution. The measurement of 15N relaxation rates is particularly useful for 
obtaining dynamic information since the relaxation of 15N nuclei is governed 
predominantly by the dipolar interaction with directly bound protons and, to a much 
smaller extent, by the chemical shift anisotropy mechanism (Allerhand et al., 1971). 
Investigations of intramolecular dynamics of proteins by solution NMR spectroscopy 
involve measurement of the longitudinal relaxation rate constant, R 1, the transverse 
relaxation rate constant, R2, and the steady state { 1 H} l 5N nuclear Overhauser Effect 
(NOE). These relaxation data are analysed by the model-free approach formulated by 
Lipari and Szabo ( 1982a,b ). Data can be analysed assuming either isotropic or anisotropic 
motion. The number of proteins for which backbone and/or sidechain spin relaxation data 
have been measured in solution is large enough such that comparisons between 
homologous or related proteins are now possible. Some examples of proteins for which 
relaxation data have been obtained include interleukin 3 (Feng et al., 1996), the A domain 
of HMG 1 (Broadhurst et al., 1995), hen egg white lysozyme (Buck et al., 1995), and SH2 
(Kay et al., 1996) and SH3 (Farrow et al., 1997) domains. 
The intramolecular backbone dynamics of both Long-[Arg3]-IGF-I and Long-[Leu60]-
IGF-I are presented in this chapter, giving the first example of a member of the IGF family 
for which this information has been determined. 
6.1.1 Theory of Model-free Formalism 
The T1 and T2 relaxation times and the NOE enhancement of an amide l5N nucleus are 
dominated by the dipolar interaction of the l5N nucleus with its attached proton and by 
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chemical shift anisotropy as described by Abragam (1961). 
l/f 1 = d2 [ J(WH - WN) + 3J(CDN) + 6J(WH + WN)] + c2J(CDN) (6.1) 
l/T2 = (l/2)d2 [ 4J(0) +J(WH - WN) + 3J(CDN) + 6J(WH) +6J(WH + WN)] + 
(l/6)c2 [ 3J(CDN) + 4J(0) ] (6.2) 
NOE= 1 + ( YNIYH) d2 [ 6J(WH +WN) - J(CDH - WN)] T1 (6.3) 
The constants d2, and c2, are defined as 
d2 = 0.1 'YH2 'YN2 h2 / (4n2)<1/r3NH>2 (6.4) 
c2 = (2/15) YN2 Ho2 (cr11 - cr1_)2 (6.5) 
where 'YH and 'YN are the gyromagnetic ratios of the 1H and 15N nuclei, respectively, WH 
and WN are the 1 H and 15N Larmor frequencies, rNH is the internuclear 1 H- 15N distance 
0 (1.02 A), H 0 is the magnetic field strength, J is the spectral density function, and the 
parallel and perpendicular components of the assumed axially symmetrical 15N chemical 
shift tensor are represented by cr11 and cr 1_ respectively. The assumption of an axially 
symmetric chemical shift tensor has been shown to be valid for peptide bonds with ( cr11 -
cri) = -160 ppm (Hiyama et al., 1988). 
The 15N relaxation data are analysed according to the model-free approach developed by 
Lipari and Szabo (1982a,b). This approach interprets relaxation phenomena in terms of the 
minimum number of parameters required to describe the overall tumbling motion of a 
macromolecule and the internal motions of the 1 H- 15N bond vector, in the following 
expression: 
J(w) = S2'tm I (l + w2'tm2) + (1-S2)'t / (1 + w2't2) (6.6) 
J(w) is the spectral density function and CD is the 15N Larmor frequency. The order 
parameter S2 describes the degree of spatial restriction of the internal motion of the 1 H-
l5N bond vector. 'tm is the correlation time of the tumbling motion of the entire molecule. 
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The effective correlation time of the internal motions is described by 'te, where 1/'t = 1/'tm 
+ 1/'te. 'te is an effective correlation time for the reorientation of the N-H vector due to the 
internal motion. Isotropic overall tumbling of the molecule is assumed in Equation 6.6. 
An extended form of the model-free spectral density function has been developed (Clore et 
al., 1990 a,b) to describe internal motions that take place on two distinct time scales, 
differing at least by an order of magnitude. Assuming that the term containing the 
correlation time describing the faster of the two time scales contributes a negligible amount 
to the relaxation, the modified spectral density function becomes (Clore et al., 1990b ): 
J ( ro) = S2'tm I ( 1 + ro2tm2) + (Sf2 - S2)'t / ( 1 + ro212) (6.7) 
where the order parameter S2 is expressed as the product of two order parameters 
characterising the fast and slow internal motions, Sf2 and Ss2, respectively. The effective 
correlation time for the slow internal motions, 'ts, is included using the relationship 1/'t = 
1/'ts + 1/'tm. 
An additional term, Rex, is required when modelling observed transverse relaxation rates to 
account for the contributions from processes other than from dipole-dipole and chemical 
shift anisotropy. In many cases, these contributions are due to conformational exchange 
averaging (15N exchange broadening during T2 measurements). The additional term, Rex, 
may be included to modify the calculated value using the relationship: 
l/T2 = l/T2(DD) + l/T2(CSA) + Rex (6.8) 
in which the DD and CSA subscripts represent contributions from dipole-dipole and 
chemical shift anisotropy to transverse relaxation (Farrow et al., 1994). 
The tumbling of a protein in solution is characterized by a single rotational correlation time 
only if rotational diffusion is isotropic; an accurate description of anisotropic motion may 
require up to five correlation times (Woessner, 1962). Preliminary calculations for Long-
[Arg3]-IGF-I revealed a longer than expected global correlation time and suggested some 
degree of anisotropy. The model-free spectral density function affords a natural separation 
between isotropic or axially symmetric overall rotational diffusion and the internal motions 
that are particularly useful for globular protein·s. Rotational diffusion anisotropy has a 
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profound effect on the physics of spin relaxation and on the interpretation of experimental 
studies of intramolecular dynamics because the spectral density power function depends 
on the relative orientations of the principal axis systems of the contributing mechanisms 
and the diffusion tensor (Woessner, 1962). Experimental know ledge of the rotational 
diffusion tensor is essential for a detailed analysis of intramolecular motions in non-
spherical proteins. There are two methods of determining the diffusion tensor: direct 
fitting of the R2/R 1 ratios for a set of nuclear spins (Tjandra et al., 1995; Zheng et al. , 
1995) and analysis of local diffusion coefficients that are derived from relaxation rate 
constants (Briischweiler et al., 1995). 
For a symmetric top with an axially symmetric diffusion tensor, D .l = Dxx = Dyy and D11 
= Dzz are the two unique diffusion coefficients, Diso = (D11 + 2D .1)/3 and; 
Ji(ro) = I Aji [ 'tj I (l + ro21j2)] (6.9) 
where l/11 = 6D .l, l/12 = 5D .1 +D11, l/13 = 2D .1 + 4D11, Ali = (3cos20i -1), A2i = 
3sin28icos28i, A3i = (3/4)sin48i, and Si is the angle between the X-H bond of the ith spin 
and the unique axis of the principal frame of the diffusion tensor. For the axially 
symmetric model, the angles 8 and <t> define the orientation of the unique axis of the 
diffusion tensor frame relative to the arbitrary molecular frame (Lee et al., 1997). 
6~2 Materials 
6.2.1 Sample 
15N-labeled Long-[Arg3]-IGF-I and 15N-labeled Long-[Leu60]-IGF-I were 1 mM and pH 
3.0 in 90% H20/10% D20. The preparation of samples was described in Section 2.3.4. 
6.2.2 Software 
Varian VNMR 6.0 (Varian Associates, Palo Alto, CA) and XEASY software were used to 
measure crosspeak intensities in the T1, T2 and NOE experiments. Modelfree 3.1 and 
Modelfree 4.0 software packages (A.G.Palmer ill, Columbia University, Palmer et. al. , 
1991) were used for the analysis of 15N relaxation data employing the model-free 
approach of Lipari and Szabo ( 1982a,b ). 
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6.3 Methods 
6.3.1 Heteronuclear NMR Experiments 
R1(lff1) and R2(lff2) relaxation rates and { lH} 15N steady state NOEs were determined 
from a series of 2D 1H-15N correlation spectra at 14.1 Tesla as described by Farrow et al. 
(1994). The experiments are variations of a sequence originally proposed for the recording 
of 1H-15N correlation spectra (Bodenhausen & Ruben, 1980). In order to measure T1 or 
T2 relaxation rates of the heterospin, net magnetisation transfer between the protons and 
the coupled heteroatom must occur, requiring slightly more complicated pulse sequences 
than necessary for a normal single quantum heteronuclear correlation experiment. Two 
refocussed INEPT-type sequences (Morris & Freeman, 1979; Burum & Ernst, 1980) 
were used to transfer magnetisation from the directly bound protons to the low y 
heteronucleus and back to the protons for detection. For the measurement of 1H- 15N 
NOEs, correlation spectra were recorded separately in the presence and absence of 1 H 
saturation. Since the longitudinal magnetisation of the heteroatom is to be measured for 
calculating the heteronuclear NOE, magnetisation must originate on the 15N spin. 
Magnetisation is subsequently transferred via a refocussed INEPT sequence to the directly 
coupled HN proton for observation. The pulse sequences implemented are shown in 
Appendix 1. 15N T 1 values were measured from spectra recorded with increasing 
relaxation delays of 5.5, 66, 143, 247.5, 363, 528, 759 and 1144 ms. 15N T2 values were 
determined from spectra using a 15N Carr-Purcell-Meiboom-Gill (CPMG) spin-echo 
sequence with delays of 6, 32, 47, 63, 79, 94, 110 and 142 ms applied during the transverse 
relaxation period, T, of the T2 experiment (Carr & Purcell, 1954; Meiboom & Gill, 1958). 
{ 1 H} 15N steady state NOE values were obtained by recording spectra with and without 
1 H presaturation of duration 3 s. 
R1(l/f 1) and R2(lff2) relaxation rate constants were determined by non-linear least 
squares fits of the resonance intensities assuming a single exponential decay. 1 H { 15N} 
NOE values were obtained from the ratio of intensities of cross peaks in the reference and 
NOE spectra following the relation NOE=Isatllnosat where Isat is the intensity of the cross 
peak when presaturation is applied and Inosat is the intensity of the cross peak in the 
spectrum with no presaturation. 
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6.3.2 Initial Estimate of Overall Correlation Time 
The overall isotropic correlation time of the protein ( 'tm) was estimated from the average 
T1/f2 ratio for residues located in secondary structural elements. An initial estimate of 'tm 
is usually obtained from the average T1/f2 ratio of nuclear spins that do not exhibit slow 
internal motion and with T2 values not significantly shortened by chemical or 
conformational exchange processes (Kay et al., 1989; Clore et al., 1990a). Internal motion 
results in a reduction in both the T1/f2 ratio and the NOE, whereas a significant 
contribution from exchange processes leads to an increase in the T1/f2 ratio. Alternative 
methods have been used to identify nuclear spins for the estimation of 'tm values. Nuclear 
spins with slow internal motion can be identified by their small NOE values. Rapid 
internal motion results in negative NOEs (e.g. in the N- and C-termini of Long-[Arg3]-
IGF-I. A lower limit in the range of 0.6-0.7 for steady state NOE values is frequently 
adopted for exclusion of nuclear spins in the estimation of 'tm. Nuclear spins having a 
significantly shortened T2 value due to chemical or conformational exchange are identified 
by a T1/f2 ratio greater than the average (over the nuclear spins with NOE larger than the 
preselected value) plus one standard deviation (Kay et al., 1989). Alternatively, nuclear 
spins exhibiting either slow internal motion or chemical or conformational exchange can 
be identified exclusively from the T1ff2 ratio. For example, only nuclear spins with a 
T 1 ff 2 ratio within one standard deviation of the averaged value are used for the 'tm 
estimation (Clore et al., 1990a,b), or, a trimmed weighted average value of the T1/f2 ratio 
can be used (Mandel et al., 1995). 'tm is also estimated by making use of structural 
information, for example, the T1/f2 ratios of nuclear spins located in regions that are well 
defined in the solution structure (Cheng et al., 1993). All of the above methods were used 
in obtaining an estimate of 'tm for both Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I. For 
both proteins, the latter method of using the T1/f2 ratio of nuclear spins in structured 
regions was found to result in the least number of nuclear spins requiring optimisation of 
'te and Rex• 
6.3.3 Model-free Analysis 
The 15N relaxation data were initially analysed using the model-free approach of Lipari 
and Szabo (1982a,b) with the "Modelfree 3.1" software package (A.G.Palmer ID, 
Columbia University, Palmer et al., 1991; Mandel et al., 1995). Selection of the spectral 
density functions were based on NOE, T1 and T2 values using the protocol of Stone et al. 
( 1992). A preliminary calculation was performed in which 'tm was fixed at the estimated 
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value, Rex was held at 0, and S2 and 'te were optimised for each resonance. In cases where 
the optimized value of 'te was non-zero (within 95% confidence limits), 'te was optimised in 
the final calculation. Otherwise, 'te was assumed to be zero in the final calculation. A 
second preliminary calculation was performed in which 'tm was held at the estimated value 
and 'te was held at zero, while S2 and Rex were optimised for each resonance. In cases 
where the optimised value of Rex was non-zero, Rex was optimised in the final calculation. 
Otherwise, Rex was assumed to be zero. A final calculation was performed by optimising 
'tm for the whole molecule, S2 for each resonance, and 'te and/or Rex for the resonances 
selected in the two preliminary calculations outlined above. 
Subsequently, the relaxation data for Long-[Arg3]-IGF-I were analysed using Modelfree 
4.0 (A.G.Palmer ill, Columbia University, Palmer et al., 1998) which optionally utilises an 
axially symmetric rotational diffusion tensor in the calculations. An initial estimate of this 
tensor was obtained from the T1/f2 ratio and the three-dimensional model of the protein 
(Chapter 5) using the program, R1R2_diffusion (A.G.Palmer III, Columbia University). 
The coordinate origin of the three-dimensional structure was translated to the centre of 
mass using the program, pdbinertia (A.G.Palmer III, Columbia University). Both 
programs are available at: 
http://cpmcnet.columbia.edu/dept/gsas/biochem/labs/palmer/software/modelfree.html 
Long-[Leu60]-IGF-I could not be analysed employing an axially symmetric rotational 
diffusion tensor model since the three-dimensional structure was not determined for this 
analogue. Selection of the spectral density functions were based on NOE, T1 and T2 
values using the protocol of Stone et al. (1993). Briefly, preliminary calculations were 
performed in which first S2 and 'te and then S2 and Rex were optimised for each amide 
nitrogen. In the final calculation, 'tm was optimised for the whole molecule, S2 was 
optimised for each amide nitrogen and 'te and Rex were optimised only for those amide 
nitrogens for which non-zero values for these parameters were found in the preliminary 
calculations (i.e. outside 95% of set bounds). 
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6.4 Results 
6.4.1 Long-[Arg3]-IGF-I 
A total of 200 relaxation parameters were used as input for the analysis. The T1, T2 and 
T1/f2 values were obtained for 74 of the 76 protonated amide nitrogens and are displayed 
in Figure 6.1. No data were obtained for the nuclear spins of either Cys47 or Lys68 due to 
the low intensity of these cross peaks. The mean 15N T1, T2 and T1/f2 values for residues 
in helical conformation are 0.74 + 0.15 s, 0.092 + 0.046 s and 8.7 + 2.7 respectively, 
while the mean T1, T2 and T1/f2 values for the whole protein are 0.72 + 0.17 s, 0.13 + 
0.09 sand 6.6 + 3.2 respectively. 
The T1/f2 ratio is particularly informative because it can be used to distinguish regions 
undergoing slow conformational exchange. The mean T1/f2 ratio for residues in regions 
of secondary structure can be used to derive an initial estimate for the overall correlation 
time for the protein, while deviations from this average identify residues which move in a 
way that is not entirely correlated with the rest of the molecule. An above average T1/f2 
ratio indicates T2 line broadening from conformational exchange. A below average T1/f2 
ratio suggests that the amide group undergoes motion on a timescale faster than the global 
correlation time. The value of 'tm estimated in this way of 8.90 + 0.02 ns, is longer by a 
factor of two than expected for a globular 9 kDa protein using the Stokes-Einstein 
relationship. Wagner (1997) provides a plot of 'tm versus molecular weight for a set of 39 
proteins or protein complexes. The largest values of 'tm recorded for a protein or protein 
complex of approximately 10 kDa are 8-9 ns. 
The possibility of dimerization of Long-[Arg3]-IGF-I at the concentration used for the 
NMR experiments ( ~ 1 mM) was investigated and discussed in Chapter 5. At this 
concentration, the presence of dimer was found to be 20% at most. Thus, the long 'tm value 
does not arise from large-scale aggregation of Long-[Arg3]-IGF-I. Anomalously high 
values of 'tm, estimated from T1/f2 ratios may be indicative of anisotropic motion and/or a 
slow conformational exchange contribution to T2. The refined model of Long-[Arg3]-
IGF-I indicates that the protein approximates a cylinder with dimensions in the ratio 
1.5: 1.1: 1.0. There is also evidence of conformational exchange in the secondary structural 
elements that were used to estimate the average T1/f2 ratio since an Rex term was required 
for many of the residues in the a-helical regions of the protein. This is caused in part by 
slow relative motion of some a-helical regions. Subsequent analysis of 
(A) 
1''1 Ht T2 
'I .c- bA-··"•WlZ""'"'I ' .,. JPF? I 
••~¾ '"1,''N..., l 
t: [,,· 
, n ~ : 
1 .. 4 .. E .
~ 
. ,-
·''t' i t11· 00 .....,.  
-r-·, 
i..:... 
'8) \ . .!i 
·~ ij 
...... 
s;.;:,. 
~ -
~t,; 
·11· .II i -1, -~, 
\i 
f.10 . 
ilS ---r 
O~it ~- . 
0.3 ">• ,!.' 
(12 - • ~· 
o.·• 
. ..,!i ~--•:?! 15 :!lfi as 
H:2 H~ 
iil5 
I 
,56 
t•. 
ilt""' ti~ 
' 
i• 
. 65 ,;i ,r;; 6$. ~11:· ~-I-ii.I- ;//!,. • •::I.I:'~ ~:!< CL~· ·•· - t ,= ,,5 ,,::,,,. ' r- ,.st) -~ 
. - ,;). 
(C} me -~ 
llio.J~.. I! 
' [ ! \ 
-~:. ·. ~ ' i &i.·1111 • ~ 1!10 - .:- . • 11111 ~ __ ' J.dl J-':· :a.1: 
qm: 71 ' ! !..It: ffl5. ms '' ,~ ~ 'Oil!ld :; ,. 1 . ~ '"1Y CLO -~ ~S 1,5 25 · 
(D) ·1JJ.,.,V 
~-~ 
5 ~. U,, ~ 
t ·1•1, • • • 
~ - IH.I< I 1: 7 
_ -1,·. 1 / 1 ~ - ' ' '. 0.5 . 
·1 .0 ""i "" 
~-
!· 
r 
'1 . 5 ··{---·-'"~·r~·-·----·1·"·~•m, .. -~.-r-"'"'"'-'"~·,-----'"'~·"r------'"r""~'-~'---1·--~····~·---1-·"'~' 
-6 5 HJ. 25 ~ 4i 55 ffi 
Reaidua Nurnbar 
133 
Figure 6.1: Plots of the experimentally determined T1, T2, T1/T2 and { 1H} 15N NOE as a 
function of residue number for Long-[Arg3]-IGF-I. T1, T2, T1/T2 and the { 1H} 15N NOE 
values are shown in panels (A), (B), (C) and (D) respectively. The error in T1, T2 and 
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NOE is no greater than 10%. 
the T1, T2 and { 1H} 15N NOE data using Modelfree 4.0 and the associated programs 
RlR2_diffusion and pdbinertia (A.G.Palmer ill, Columbia University) confirmed that the 
rotational diffusion is anisotropic with a D111D 1_ ratio of 1.58 + 0.05 and the axis of 
diffusion tilted at 8 = 75° and cp = 131 ° with respect to the magnetic field direction. Spins 
of residues extending away from the axis of symmetry were excluded when calculating the 
degree of anisotropy since inclusion of these flexible residues may overestimate the 
anisotropy (Tjandra et al., 1995). Spins in the N- and C-termini with small or negative 
NOE values were omitted from the calculations. The calculated overall correlation time of 
7 .58 + 0.07 ns from Modelfree 4.0 is lower than the estimate obtained from the T1/T2 
ratio and the value obtained assuming isotropic tumbling but is still high for a protein of 
this size. 
Heteronuclear NOEs are more sensitive to the effects of internal motion than T1 or T2 
values, hence the regions of fast internal motion in the protein are more apparent from 
inspection of the plot of { 1H} 15N NOE values as a function of residue number (Figure 
6.1). Heteronuclear NOEs were obtained for 72 of the 76 (95%) protonated backbone 
nitrogens. Residues in elements of secondary structure show positive NOEs (average 0.55 
+ 0.12) but this average value is significantly less than the theoretical maximum of 0.82 
(Kay et al., 1989) indicating that there is substantial motion within the helices, in particular 
within helix 2 and helix 3. The residues in the poorly defined region of extended structure 
between helix 1 and helix 2 (Asn26 - Gln40) have NOEs near zero indicating substantial 
conformational reorientation is occurring in this section of the protein. This increased 
flexibility of this C-domain loop is also supported by an increase in the T2 relaxation 
times for several residues in the loop. Negative NOEs are observed for each non-prolyl 
residue in the N-terminal ten amino acids of the extension, which is indicative of large 
amplitude motions and is in agreement with the paucity of medimn- and long-range 
homonuclear NOEs in this region of the protein. Positive heteronuclear NOEs are 
observed at Phe-3 and Val-2 in agreement with the observation of some long-range 
homonuclear NOEs in this section of the N-terminal extension (Figure 6.1). 
The generalised order parameter, S2, derived from the relaxation data using the model-free 
approach (Lipari & Szabo, 1982a,b) describes the degree of spatial restriction of rapid 
internal motions of the 1 H-15N bond vector of each residue of the protein for which data 
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Figure 6.2: Plots of the (A) order parameter (S2), (B) effective correlation time (te) and 
(C) exchange contribution (Rex) as a function of residue number for Long-[Arg3]-IGF-I 
calculated using Modelfree 4.0 assuming an axially sym1netric rotational diffusion model. 
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are obtained. S2 values range from zero for completely isotropic tumbling to unity for 
completely restricted motions. Residues in secondary structural regions therefore 
generally have higher values of s2. The effective correlation time resulting from the 
internal motions is described by 'te, In cases where internal motions are extremely fast, a 'te 
term is not required, in all other cases 'te must be included to account for internal motions 
(Farrow et al., 1994). The values of s2, 'te and Rex presented in Figure 6.2 were calculated 
using Modelfree 4.0, assuming an axially symmetric rotational diffusion tensor and are a 
reasonable guide to the relative flexibility of different sections of Long-[Arg3]-IGF-I. The 
mean value of S2 for residues in helical conformation is 0.81 + 0.12 indicating a high 
degree of order with respect to rapid internal 1notions. Residues in the N-terminal 
extension are considerably less ordered (mean s 2 = 0.40 + 0.17). Similarly, the C-
tenninal part of the C-domain loop from Asn26 to Gln40 shows a sharp drop in order 
(mean S2 = 0.56 + 0.14). The D-domain (C-terminus) is also less ordered. These flexible 
regions also have non-zero 'te values which are shorter in the N-terminal extension (1nean 
'te = 186 + 76 ps) than in the C-domain loop (mean 'te = 446 + 288 ps). 
The interpretation of Rex has to be treated with care, particularly when the protein is 
tumbling anisotropically because T1ff2 values are sensitive to the orientation of the NH 
bond vector with respect to the axes of rotational diffusion. The analysis assu1ning either 
an isotropic or an anisotropic rotational diffusion tensor required non-zero Rex values for 
most of the residues in helical segments of Long-[Arg3]-IGF-I. The residues (nuclei) that 
required an Rex term and the magnitude of that Rex term did not significantly depend on 
the assmnption of an axially sym1netric rotational diffusion tensor. 
6.4.2 Long-[Leu60J-IGF-I 
A total of 201 relaxation parameters were used as input for model-free analysis. T1, and T2 
values were obtained for 73 of the 76 protonated amide nitrogens (96%) (Figure 6.3). 
Residues for which no data were obtained are Mer-9, Ser-6 and Leu 10, due to overlap of the 
Met-9 and Ser-6 resonances and the low intensity of tl1e Leu 10 resonance. The mean 15N 
T1, T2 and T1ff2 values for residues in helical conformation are 0.60 + 0.16 s, 0.09 + 
0.06, and 8.95 + 4.85 respectively, while the mean T1, T2 and T1ff2 values for the entire 
protein are 0.67 + 0.24, 0.20 + 0.09 and 6.32 + 4.51 respectively. The mean T1/T2 ratio 
for residues in regions of secondary structure was used to derive an initial estimate for the 
overall correlation time of the protein. 
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Figure 6.3: Plots of the experimentally determined (A) T1, (B) T2, (C) T1/f2, and (D) 
{ 1H}-15N NOE as a function of residue number for Long-[Leu60]-IGF-I. Error in T1, T2 
and NOE does not exceed 10%. 
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The value of 'tm estimated in this way, 9.03 + 0.88 ns, is longer than expected for a 9 kDa 
globular protein by a factor of two. It is highly probable that this anomalously high value 
of 'tm is indicative of anisotropic motion and/or a slow conformational exchange 
contribution to T2. However, since no three-dimensional structure has been determined for 
Long-[Leu60]-IGF-I, an initial estimate of the axially symmetric rotational diffusion tensor 
could not be obtained using the program, RlR2_diffusion, and thus, relaxation data could 
not be analysed using the axially symmetric diffusion model. Therefore, the overall 
correlation time for Long-[Leu60]-IGF-I is likely to be an overestimate for this protein as 
relaxation data were analysed with an isotropic model using Modelfree 3.0. 
Heteronuclear NOE values for Long-[Leu60]-IGF-I are shown in Figure 6.3. The regions 
of fast internal motion, the N-terrninal extension, the C-domain loop and the C-terrninal 
extension, are apparent from inspection of Figure 6.3. The internal motion in the N-
terminal extension of Long-[Leu60]-IGF-I is more rapid than the N-terminal extension of 
Long-[Arg3]-IGF-I as indicated in Figure 6.3 by the larger negative NOE values in this 
region. Heteronuclear NOEs were obtained for 74 of the 76 protonated backbone 
nitrogens (97% ). Residues in elements of secondary structure show positive NO Es 
(averageO.69 +0.15) which is larger than the average value in Long-[Arg3]-IGF-I but is 
still significantly less than the theoretical maximum of 0.82 indicating that there is some 
motion within the helices, particularly within helix 2 and helix 3. In particular, the C-
terrninal end of helix 2 has low NOE values in comparison with other helical residues. 
These residues are affected by the mutation at residue 60 as seen by altered 15N chemical 
shifts (section 4.2.2). The residues of the C-domain loop (from Asn26 to Gln40) have 
NOEs close to zero or negative values. This increased flexibility in the C-domain loop is 
also seen in Long-[Arg3]-IGF-I (Figure 6.1). Negative NOEs are observed for each non-
prolyl residue in the N-terminal ten amino acids of the N-terrninal extension, Met-13 to 
Leu-4. This is in agreement with the paucity of medium- and long-range homonuclear 
NOEs in this region of the protein. Phe-3 has a heteronuclear NOE of near zero while the 
segment Val-2-Gly1 all have small positive NOEs, while in Long-[Arg3]-IGF-I the NOE 
observed for Phe-3 was positive. This suggests that the mobility of the tum structure 
involving residues Asn-1 to Arg3 in Long-[Arg3]-IGF-I is affected by the replacement of 
Arg3 by Glu3 in Long-[Leu60]-IGF-I and this supports the chemical shift data in this 
region for the two analogues (Chapter 4). 
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Figure 6.4: Plots of the calculated Modelfree 3.1 parameters, (A) s2, (B) 'te and (C) R ex 
as a function of the residue number for Long-[Leu60]-IGF-I. 
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The values of S2, 'te and Rex presented in Figure 6.4 were calculated using Modelfree 3.1 , 
assuming isotropic motion and these are a reasonable guide to the relative flexibility of 
different sections of Long-[Leu60]-IGF-I. The assumption of isotropic motion for an 
anisotropic protein does not substantially affect the relative values within a peptide chain of 
S2 and 'te derived using the model-free formalism, although some care must be taken when 
comparing these values to other proteins and the optimised overall correlation time will be 
overestimated. The mean value of S2 for residues in helical conformation is 0.83 + 0.21 
indicating a high degree of spatial restriction of rapid internal motions of the 1 H-15N bond 
vector. Residues in the N-terminal extension are considerably less ordered (mean S2 = 
0.29 + 0.23). Similarly, the C-domain loop shows less order (mean S2 = 0.34 + 0.27). 
These more flexible regions also have non-zero 'te values, with a mean 'te in the N-terminal 
extension of 253 + 217 ps, and a mean 'te of 280 + 209 ps in the C-domain loop. 
An Rex term was required for nineteen residues and most of these were in the helical 
segments of Long-[Leu60]-IGF-I. The requirement of these non-zero Rex values has to be 
interpreted with care when the protein is tumbling isotropically because T 1/f 2 values are 
sensitive to the orientation of the NH bond vector with respect to the axes of rotational 
diffusion. A decrease in T 2 values is observed for these residues, resulting in a T 1 ff 2 ratio 
which is larger than anticipated from the overall correlation time. Table 6.1 presents a 
summary of spectral density models used to fit T1, T2 values and NOE data for both 
Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I. A large number of 'te and Rex parameters 
were necessary to improve the fit for Long-[Leu60]-IGF-I. 
Table 6.1. Summary of Spectral Density Models Used to Fit T1, T2, and NOE Data for the 
Two IGF-I Analogues 
Parameters Optimised 
s2 
s2 and 'te 
s2 and Rex 
s2, 'te and Rex 
not fitted 
Number of Residues 
Long-[Arg-']-1 G F-1 
0 
46 
10 
18 
9 
Long-[Leu 0 U]-IGF-I 
30 
22 
13 
6 
12 
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6.5 Discussion 
Spectral crowding and low peak intensities were the major cause of difficulties in 
measuring peak intensities in the T1, T2 and NOE spectra. Quantitative analysis of the 
relaxation data according to the model-free approach is complicated by the presence of 
20% Long-[Arg3]-IGF-I dimer in solution since aggregation systematically increases T1 
and decreases T2 values. A thorough analysis is only possible when detailed knowledge of 
the shape and dimensions of the Long-[Arg3]-IGF-I dimer is known. Qualitative analysis 
of the relaxation and heteronuclear NOE data in a variety of proteins has provided valuable 
information about the backbone dynamics. For example, a qualitative analysis of backbone 
dynamics is adopted for proteins possessing aggregation tendencies, e.g. HIV-1 Nef 
which exists as approximately 50% monomer and 50% dimer at a concentration of 0.6 
mM (Grzesiek et al., 1997). A quantitative analysis using the model-free approach has also 
been presented in the results employing the most appropriate data-analysis protocol ( as 
discussed below). 
Shurr et al. ( 1994) investigated the effects of anisotropy of rotational diffusion and the 
extent of dimerisation on the performance of the simple and extended model-free 
formulas. Fitting to the simple model-free formalism was accomplished by adjusting a 
single common global correlation time, and also by an alternative protocol, in which the 
global correlation time was adjusted separately for each nucleus. Anisotropic global 
rotational diffusion (in the absence of dimerisation) was handled best with the simple 
model-free formalism adjusting the global correlation time independently for each nucleus, 
although analysis using the simple model-free formalism adjusting a single overall global 
correlation time, also gives accurate internal motion parameters. When the degree of 
dimerisation was between 20% and 90%, none of the model-free approaches tested yields 
reliable internal motion parameters, although employing the simple model-free formalism 
with adjustment of a single correlation time, yielded the most accurate internal motion 
parameters. Thus, in the case of Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I, the 
relaxation data were analysed using the protocol which yields the most accurate results 
given that Long-[Arg3]-IGF-I is subject to both dimerisation and anisotropy of rotational 
diffusion. Backbone dynamics can be investigated with greater accuracy if 13C-labeled 
protein is available. The simultaneous analysis of 13c and 15N relaxation data reduces the 
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bias in the distribution of bond vector orientations used to determine the diffusion tensor 
(Lee at al., 1997). 
The residues of both Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I undergo non-uniform 
and complicated backbone dynamics. The N-terminal eight residues of the N-terminal 
extension are not well defined in the solution structure of Long-[Arg3]-IGF-I (chapter 5) 
and the order parameters, with an average of less than 0.4, suggest a certain degree of 
disorder. However, the amide protons of several residues in the N-terminal extension do 
exhibit slow exchange with the bulk solvent ( chapter 4 ), which suggests that the dynamic 
disorder is correlated to protect the hydrophobic residues in the N-terminal extension from 
contact with the aqueous solvent. These eight N-terminal residues in the N-terminal 
extension also have long T2 values but the T1 values are only slightly longer when 
compared with the rest of the protein, indicating these residues are undergoing low 
frequency motions. Likewise, the N-terminal eight residues of Long-[Leu60]-IGF-I, with 
average order parameters of less than 0.3, also display a degree of disorder. The amide 
protons of several of the same residues of Long-[Leu60]-IGF-I are also slowly 
exchanging (chapter 4), indicating that the same type of dynamic disorder is occurring in 
both analogues. In Long-[Arg3]-IGF-I, the T2 values shorten markedly at Phe-3 and Val-
2, which correlates with the observation of several long-range NOEs to these residues. 
However, in Long-[Leu60]-IGF-I, the T2 values shorten for the segment VaI-2 to Gly1 
implying variation in the structure of this region between the two analogues. Most residues 
in the C-domain loop (Tyr24 to Gln40) have S2 values less than 0.5 and T2 values greater 
than 200 ms for both Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I. This degree of 
disorder for the C-domain loop is consistent with the segment being poorly defined in the 
solution structure of Long-[Arg3]-IGF-I. The C-terminal CD-domain) is disordered in 
both Long-[Leu60]-IGF-I and Long-[Arg3]-IGF-I. However, a detailed comparison 
between the two analogues cannot be made due to the paucity of some of the relaxation 
parameters in this region. Regions of mobility of Long-[Arg3]-IGF-I are mapped onto the 
structure of Long-[Arg3]-IGF-I in Figure 6.5. 
The most ordered regions of both Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I are the a-
helices. Although the helical regions are highly ordered on the picosecond time scale, the 
exchange contribution necessary to obtain a good fit to the data suggests that there are 
slow internal motions that contribute to T2 (Figures 6.1 and 6.3). This exchange process 
in all the regions of recognisable secondary structure makes it difficult to estimate 'tm for 
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both Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I. Although accurate estimates of 'tn1 are 
not possible, the trend of s2 does not vary over a wide range of overall correlation time. 
Analysis of the data for Long-[Arg3]-IGF-I assuming either isotropic rotational diffusion 
or axially symmetric rotational diffusion provides an estimate of 'tm that is longer than 
expected for a protein of 9 kDa although the anisotropic model estimates a 'tm that is 
shorter by 20% compared to the isotropic model. Anomalously long values of 'tm, 
estimated from T1ff2 ratios, have been observed in other proteins, for example, in several 
HMO box proteins (Broadhurst et al., 1995; Jones et al., 1994) and are indicative of 
anisotropic motion and/or a slow conformational exchange contribution to T2. Rotational 
diffusion anisotropies for several proteins have been determined from 15N relaxation 
measurements (Brilschweiler et al., 1995; Tjandra et al., 1995; Zheng et al., 1995; Mackay 
et al., 1996). However, due to the constraints imposed by hydrogen bonding in secondary 
structures, the orientations of the N-H bond vectors are not distributed isotropically in 
many proteins. 
833 
R36 
A70 
Figure 6.5: Long-[Arg3]-IGF-I regions with increased 1notion mapped onto the surface of 
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Long-[Arg3]-IGF-I. Residues with low order parameters (S2 < 0.6) are shown in blue. 
Correlations between the orientations of the N-H bond vectors compromise the accuracy 
and precision of the diffusion tensor derived from NMR relaxation measurements (Lee et 
al., 1997). Lee et al. (1997) demonstrate that simultaneous analysis of 13ca and 15N 
relaxation rate constants improves the reliability of the diffusion tensor determination. 
Tjandra et al. ( 1995) observed a higher degree of anisotropy of ubiquitin if the flexibility 
of the C-terminal residues was not taken into account. The flexibility of the N- and C-
terminal residues of Long-[Arg3]-IGF-I may result in an overestimate of the anisotropy of 
rotational diffusion. Residues in the N- and C-termini of Long-[Arg3]-IGF-I with small or 
negative NOEs were excluded from the calculations when employing the anisotropic 
rotational diffusion model. Another method of accounting for the flexibility in the N- and 
C-termini is to calculate the moments of inertia for a number of models of Long-[Arg3]-
IGF-I in which the N-terminal and/or C-terminal region are moved relative to the rest of 
the model (Hyre & K.levit, 1998). 
There is restricted motion in the vicinity of residue 60 in both proteins. The Tyr60Leu 
mutation in Long-[Leu60]-IGF-I does not disrupt the local helical structure (section 4.4.2) 
and therefore a large reduction in order was not expected. The only large differences 
between the two analogues occur for residues Glu58 (S2 of 0.47 in Long-[Leu60]-IGF-I 
and s2 of 0.85 in Long-[Arg3]-IGF-I) and Aia62 (S2 of 0.17 in Long-[Leu60]-IGF-I and 
S2 of 0.63 in Long-[Arg3]-IGF-I). Motion of the N-H bond vector for all other residues 
between Leu57 and Aia62 in both Long-[Leu60]-IGF-I and Long-[Arg3]-IGF-I is 
restricted (S2>0.7). The two residues for which a difference in mobility is observed (Glu58 
and Aia62) both experience a reduction in order induced by mutating Tyr60 in Long-
[Arg3]-IGF-I to Leu60 in Long-[Leu60]-IGF-I. It is not surprising that the local motion is 
more restrained in the molecule with the native local amino acid sequence. However, care 
must be taken in the interpretation of these results since model-free analysis of relaxation 
data can result in overestimated order parameters in the presence of dimerisation (Shurr et 
al., 1994). Backbone dynamics studies have not been performed on any other members of 
the IGF family, so no conclusions on the effect of the N-terminal extension or the 
mutations at positions 3 and 60 on the flexibility of the proteins can be made. 
Both Long-[Arg3]-IGF-I and Long-[Leu6°]-IGF-I, despite having three well-defined a-
helices, are clearly flexible molecules. Long-[Arg3]-IGF-I retains much of the broad 
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biological activity of IGF-I except for the reduced affinity for the IGFBPs which also 
results in enhanced potency in most cultured cell systems. Long-[Leu60]-IGF-I also 
exhibits reduced binding to IGFBPs due to the 13 amino acid extension and reduced 
binding to the type 1 IGF receptor, though it displays enhanced potency due to competing 
endogenous IGF-I from IGFBPs. It has been suggested that a broad specificity of protein 
interaction with ligands or receptors is correlated with a certain degree of flexibility (Carr 
et al., 1997). Indeed, it may be necessary for IGF-I to be sufficiently flexible in order to 
interact with the insulin and the type 1 IGF receptor as well as a family of at least six 
IGFBPs. 
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CHAPTER7 
Insulin-Like Growth Factor Binding Protein 2 Interaction with 
Long-[Leu60J-IGF-I 
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7.1 Introduction 
In vivo, IGFs bind to insulin-like growth factor binding proteins present in extracellular 
fluids. As a result of this interaction, the half-life of IGFs is prolonged by minimising IGF 
interaction with receptors. Mutagenesis studies have addressed the localisation of IGFBP 
binding determinants on the IGFs. The addition of a thirteen amino acid extension at the 
N-terminus reduces the IGF-I binding to IGFBPs, while residue 3 in IGF-I is critical for 
high affinity binding of IGF-I to IGFBPs (see section 1.8). In addition, residues Phe49, 
Arg50 and Ser5 1 in IGF-I have been implicated in binding to IGFBPs (Luthi et al., 1992; 
Bach et al., 1993; Jansson et al., 1998). Dubaquie and Lowman (1999) systematically 
investigated the binding contribution of each IGF-I amino acid sidechain towards IGFBP-
1 and IGFBP-3 by alanine screening mutagenesis. Glu3 and Phe49 of IGF-I were 
identified as major specificity determinants for IGFBP-1. No IGF-I sidechain specificity 
determinant was found for IGFBP-3, instead, the backbone atoms of the N-terminal region 
of IGF-I were found to be important for binding to IGFBP-3. Clemmons et al. (1992) 
showed that Glu3, Thr4, and Phe49-Ser51 of IGF-I are important for binding of IGF-I to 
both IGFBP-1 and IGFBP-2. The similar binding pattern of IGF-I for both IGFBP-1 and 
IGFBP-2 suggests that the structural conformation of IGFBP-2 is similar to IGFBP-1 , 
enabling it to use the same contact points for IGF-I binding. 
The NMR chemical shift of a given nucleus is sensitive to its magnetic environment. 
P~rturbations of the electron cloud around a nucleus by an approaching ligand is reflected 
in a change in the chemical shift. Variations of chemical shifts upon the addition of a 
ligand are a reliable indication of intermolecular interaction (Omichinski et al., 1993). 
Jansson et al. (1998) investigated the 15N and 13c shifts of 15N!13C-labeled IGF-I in the 
presence and absence of IGFBP-1. Many backbone NMR chemical shifts were found to 
be affected by IGFBP-1 binding, chiefly in the N-terminal region, C-domain loop and the 
C-terminal region (D-domain). These include residues Pro2, Glu3, Cys6, Gly7, Pro28, 
Thf29, Gly30, Gly32, Arg36, Arg37, Gln40, Thr41, Gly42, Ser51, Pro63, Lys65, Pro66, Lys68 
and Ala 70. In addition, three arginine sidechains (Arg36, Arg37 and Arg50) were found to 
participate in IGFBP-1 binding. In the case of Long-[Leu60]-IGF-I, it is of particular 
interest to determine what effect the N-terminal extension of thirteen amino acids has on 
the structural binding epitope, since the N-terminal extension decreases the affinity of 
IGFs for IGFBPs (Francis et al., 1992). The binding affinity of Long-[Leu60]-IGF-I for 
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IGFBP-2 is investigated at the same pH as for all other NMR work described in this 
thesis ( Chapter 3). 
IGFBP-2 binds to Long-[Leu60]-IGF-I and with similar affinity to Long-IGF-I but, with 
ten times lower affinity than IGF-I itself (Francis et al., 1992; Milner et al., 1999). Thus, 
the Tyr60Leu mutation does not affect the strength of the binding interaction with IGFBP-
2. Since the NMR structural work in this thesis had been performed at pH 3.0, it was 
necessary to investigate the strength of binding interactions at this pH. The BIAcore TM 
instrument developed by Pharmacia enables visualisation of macromolecular interactions 
directly and in "real time" (Fagerstam et al., 1992), and was used to investigate the binding 
interaction of Long-[Leu60]-IGF-I and IGFBP-2 at pH 3.0. The BIAcore is a biosensor-
based instrument that uses surf ace plasmon resonance as the detection principle. One 
molecule of the interaction system to be studied is immobilised covalently to a sensor chip, 
and the other interactant in solution is then passed over the chip. The detection system 
measures and displays a signal proportional to the mass of protein bound to the surface. 
In this way, the association phase can be directly visualised as the ligand-containing 
solution flows over the surface, and the subsequent dissociation is similarly displayed after 
the flow switches to buffer containing no ligand (Fagerstam et al., 1992). 
Chemical shift mapping experiments, that exploit the sensitivity of the NMR chemical 
shifts to the local environments, have found recent widespread application for defining the 
binding epitopes of proteins particularly if the protein is labeled with stable isotopes 
(Grzesiek, et al., 1997; Jansson et al., 1998; Kalus et al., 1998). Recently, Jansson et al. 
(1998) used the 13c and 15N chemical shift perturbations of twenty residues on one face 
of IGF-I to define the binding interface with IGFBP-1. Kalus et al. ( 1998) performed 
similar experiments but in this case a mini-IGFBP-5 was labeled with 15N and 13c and 
the complexed ligand was IGF-II. 
In order to gain a more detailed understanding of the nature of interactions between the 
insulin-like growth factors and their binding proteins, the 15N chemical shifts of Long-
[Leu60]-IGF-I in the presence and absence of IGFBP-2 have been compared to identify 
the IGFBP-2 structural binding epitope. 
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7.2 Materials and Methods 
7.2.1 Binding Protein 
Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) (10 mg) was purchased from 
GroPep Pty. Ltd. (Adelaide, Australia). IGFBP-2 was produced following a procedure 
adapted from Szabo et al. (1988). 
7.2.2 BIAcore Binding Studies 
Binding studies were performed on a BIAcore 2000 with BIAevaluation software (version 
3.0.2). BIAcore analyses were performed with Long-[Leu60]-IGF-I as the immobilised 
ligand. All analyses were performed at 25 °C and followed the protocol of Hobba et al. 
(1998). Covalent attachment of Long-[Leu60]-IGF-I to the CMS biosensor chip was 
achieved by the amine coupling method via the £-NH3 + groups of lysine (Lofas and 
Johnson, 1991). Long-[Leu60]-IGF-I (226 µg/ml in 50 mM sodium acetate, pH 7.4) was 
injected onto the activated CMS surface at 5 µI/min with HBS (10 mM HEPES, 150 mM 
NaCl, 3 mM EDTA, pH 7.4) as the running buffer. Long-[Leu60]-IGF-I was immobilised 
such that the final resonance value was approximately 400 above the resonance value of 
the activated but underivatized chip. Residual binding sites were quenched with 
ethanolamine. 
In order to estimate the dissociation constant (Kn) prior to a kinetic study, two or three 
co.ncentrations of IGFBP-2 were injected for 5 min at a flow rate of 40 µI/min with HBS 
as the running buffer. For a kinetic study, ten concentrations were chosen based on the 
trial: 2, 5, 8, 11, 15, 20, 30, 50, 100 and 150 nM. The dissociation phase, initiated by 
switching from the stream of IGFBP-2 to HBS, was carried out over a period of 10 min. 
The Long-[Leu60]-IGF-I surfaces were regenerated by a 90 second injection of 0.1 M 
HCl to dissociate bound IGFBP-2. The binding procedure was repeated at pH 3.0 (10 
mM citric acid, 150 mM NaCl and 3 mM EDTA) and pH 4.0 (10 mM formate, 150 mM 
NaCl and 3 mM EDTA). Trials were performed at both pH 3.0 and pH 4.0 with IGFBP-2 
injected for 5 min at a flow rate of 40 µI/min. Concentrations used for the kinetic study 
were based on trials in which two or three concentrations were used to determine the 
approximate Kn, and concentrations were chosen around this for the kinetic study. The 
concentrations chosen for the kinetic study at both pH 3.0 and pH 4.0 were 5, 10, 25, 50, 
75, 100, 200 and 400 nM. The apparent association and dissociation rates of IGFBP-2 
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were derived by fitting the experimental data to a one-site association and dissociation 
model with the BIAevaluation software (version 3.0.2). 
7.2.3 Formation of the Long-[Leu60J-IGF-I/IGFBP-2 Complex for NMR 
Spectroscopy 
1 mg of IGFBP-2 was dissolved in 150 µl 10 mM citrate buffer, pH 3.0. This solution 
was added to 325 µl of 0.34 mM Long-[Leu60]-IGF-I at pH 3.0, to give a Long-[Leu60]-
IGF-I concentration of 0.23 mM in 475 µl and a IGFBP-2 concentration of 0.066 mM. 
The IGFBP-2 concentration was at a 0.28: 1.0 molar ratio relative to Long-[Leu60]-IGF-I. 
IGFBP-2 was then progressively added to the solution as a dry powder to obtain 
concentrations of IGFBP-2 relative to Long-[Leu60]-IGF-I of 48%, 83% and 100%. No 
precipitation of either Long-[Leu60]-IGF-I or IGFBP-2 was observed at pH 3.0. 
7.2.4 NMR Experimental 
The Long-[Leu60]-IGF-I/IGFBP-2 complex was studied by NMR spectroscopy at pH 
3.0. 2D 15N-HSQC spectra (Chapter 3) were successively recorded for mixtures of Long-
[Leu60]-IGF-I and IGFBP-2 with IGFBP-2 concentrations of 0: 1.0, 0.28: 1.0, 0.48: 1.0, 
and 0.83:1.0 molar ratio relative to Long-[Leu60]-IGF-I. The lHN and 15N chemical shifts 
of all cross-peaks were measured at each IGFBP-2 concentration. 
7.'3 Results 
7.3.1 BIAcore Analysis 
Kinetic analyses of the association and dissociation of IGFBP-2 with immobilised Long-
[Leu60]-IGF-I at pH 3.0, pH 4.0 and pH 7.4 were performed in the BIAcore. The purpose 
of performing these binding studies was to determine if the binding affinity of Long-
[Leu60]-IGF-I for IGFBP-2 was sufficiently strong to perform NMR studies of the 
complex. This was confirmed, with a Ko in the nanomolar range at pH 3.0. 
Binding experiments at pH 7 .4 were performed to enable comparison with a previously 
obtained dissociation constant (Ko 10.3 + 3.0 nM) for IGFBP-2 binding to Long-
[Leu60]-IGF-I (Milner et al., submitted for publication) and to confirm that results were 
reproducible. The dissociation constant obtained for Long-[Leu60]-IGF-I of 14.3 + 0.1 
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nM was close to the value obtained by Milner et al. (submitted for publication). Kinetic 
analyses for Long-[Leu60]-IGF-I binding to IGFBP-2 at pH 7.4 are shown in Figure 7.1. 
The interaction between IGFBP-2 and Long-[Leu60]-IGF-I at pH 7.4 was difficult to 
resolve to a single binding site. Similar behaviour was also found by Hobba et al. (1998) 
when using IGF-I and IGF-II as the immobilised ligands and monitoring their interactions 
with IGFBP-2 and IGFBP-2 mutants. 
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Figure 7.1: Association and dissociation curves for IGFBP-2 binding to immobilized 
Long-[Leu60]-IGF-I at pH 7.4. The plot shows the relative response in resonance units 
(RU) plotted against time for different IGFBP-2 concentrations; 2 nM cyan, 5 nM red, 8 
nM dark green, 11 nM light blue, 15 nM pink, 20 nM yellow, 30 nM light green, 50 nM 
dark blue, 100 nM burgundy, 150 nM grey. 
The binding curves for IGFBP-2 to Long-[Leu60]-IGF-I at pH 3.0 indicated that 
saturation of binding sites occurred prior to the end of the association phase. However, for 
four of the chosen concentrations, the response decreased prior to initiating dissociation 
by switching fro1n the IGFBP-2 stream to the buffer to initiate dissociation. The analyte 
dissociation rate was calculated by plotting response at the end of the association phase 
(approxilnately 300 s) against concentration for a point on each of the curves during the 
association phase (Figure 7.2). The Kn measured in this way was 200 + 100 nM, an 
approximately ten-fold higher value than at pH 7.4. Binding data for IGFBP-2 to Long-
[Leu60]-IGF-I at pH 4.0 was irregular and the data could not be fitted to a model to derive 
the association and dissociation constants. Jansson et al. ( 1998) reported that between pH 
3.4 and pH 4.8 (the pl of IGFBP-1) IGFBP-1 precipitates, providing an explanation for 
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this behaviour. However, the pl of IGFBP-2 has been calculated as 7 .15 using "Pepstats" 
on ANGIS (Australian National Genomic Information Service, 1998). 
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The plot shows the relative response in resonance unit (RU) plotted against time for 
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7.3.2 Mapping the Long-[Leu60J-IGF-I Binding Site 
2D 15N-HSQC spectra of Long-[Leu60]-IGF-I complexed to IGFBP-2 were acquired at 
30 °c and pH 3.0 for compatibility with the previously described HN and 15N 
assignments of free Long-[Leu60]-IGF-I (Chapter 3). Furthermore, Jansson et al. (1998) 
reported that the spectral quality of the IGF-I/IGFBP-1 complex was improved at 30 °c 
compared with spectra acquired at 50 °c. 
Figure 7.3 shows 15N HSQC spectra of Long-[Leu60]-IGF-I in the absence of IGFBP-2 
and with 0.28:1.0 IGFBP-2:Long-[Leu60]-IGF-I and highlights the cross peaks of 
residues that display the largest 15N/HN chemical shift changes between the two spectra. 
At higher concentrations of IGFBP-2 relative to Long-[Leu60]-IGF-I, the quality of the 
15N HSQC spectra of Long-[Leu60]-IGF-I is reduced (Figure 7.4). Figure 7.5 shows the 
15N and the HN chemical shift differences for each residue between free Long-[Leu60]-
IGF-I and Long-[Leu60]-IGF-I complexed with 25% IGFBP-2. While the HN chernical 
shift changes between the complexed and uncomplexed forms are predominantly not large 
enough to be particularly infonnative, large chemical shift perturbations (> 0.08 ppm) are 
noted for Phe16, Asp20, Tur29, Gly42 and Ala70 upon interaction with IGFBP-2. The 
average Long-[Leu60]-IGF-I 15N chemical shift deviation upon cornplexation of IGFBP-2 
is 0.23 ppm, with values ranging from 0.0 ppm to 2.4 ppm. Significant 15N chemical shift 
differences (> 0.15 ppm) between the complexed and uncomplexed fonns of Long-
[Leu60]-IGF-I were observed for Met-13, Leu-7, Ser-5, Phe-3, Glu3, Cys6, Ala8, Glu9, 
Leul0, Ala13, Leu 14, Asp20, Arg21, Gly22, Tur29, Arg37, Gm40, 'fhr41, Gly42, Ile43, Glu46, 
Cys47, Cys48, Phe49, Arg50, Ser51, Leu54, Arg55, Arg56, Leu57, Glu58, Lys65 and Ala 70. 
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Figure 7.4: 2D l5N-HSQC spectra of Long-[Leu60]-IGF-I with; (A) 0.25: 1.0 molar ratio 
IGFBP-2:Long-[Leu60]-IGF-I, and (B) 0.83:1.0 1nolar ratio IGFBP-2:Long-[Leu60]-
IGF-I. Comparison of the 2D 15N-HSQC spectra of Long-[Leu60]-IGF-I shows 
increased line broadening and decreased spectral resolution upon addition of IGFBP-2. 
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Figure 7.5: a) 15N chemical shift changes in Long-[Leu60]-IGF-I induced upon binding 
of IGFBP-2 to Long-[Leu60]-IGF-I as a function of residue number at a molar ratio of 
0.28:1.0 IGFBP-2:Long-[Leu60]-IGF-I. b) Amide proton chemical shift changes in Long-
[Leu60]-IGF-I induced upon binding of IGFBP-2 to Long-[Leu60]-IGF-I as a function of 
residue number at a molar ratio of 0.28: 1.0 IGFBP-2:Long-[Leu60]-IGF-I. 
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Residues which experience chemical shift perturbations are localized in three mam 
regions; (a) the N-terminus and the N-terminal end of helix 1, (b) the ~-tum, and (c) the 
C-terminal end of helix 2 and some residues in helix 3. These residues are mapped to the 
molecular surface of Long-[Arg3]-IGF-I. (Figure 7.6). Overall, 15N and HN resonances 
were not shifted further upon increasing the IGFBP-2 concentration to molar ratios of 
0.48: 1.0, 0.83: 1.0 or 1: 1 compared with 0.28: 1.0 IGFBP-2 relative to the concentration of 
Long-[Leu60J-IGF-I. The chemical shifts of all residues involved in the binding have been 
affected upon addition of 0.28:1.0 molar ratio of IGFBP-2:Long-[Leu60J-IGF-I. However, 
many lower intensity cross-peaks were not observed as the IGFBP-2 concentration was 
increased due to the mass increase from 9 to 40 kDa upon complexation of the two 
proteins. With increasing protein concentration, the spectra were essentially unchanged, 
other than progressive line broadening, indicating that the binding of IGFBP-2 to Long-
[Leu60]-IGF-I is in the slow chemical exchange limit on the NMR time scale. 
7.4 Discussion 
In circulation, IGFBPs bind IGFs with a 1: 1 stoichiometry (reviewed in Baxter et al., 
1994) and therefore, a single site kinetic model should provide a valid approximation of 
the IGFBP-2/IGF interaction. The apparent dissociation constants calculated for Long-
[Leu60J-IGF binding to IGFBP-2 correspond well with published dissociation constants 
for IGFBP binding to IGF-I and IGF-I analogues generated by competition solution 
binding assays (Heding et al., 1996; Milner et al., submitted for publication). However, the 
interactions of IGFBP-2 with Long-[Leu60J-IGF-I deviated fro1n pseudo-first order 
kinetics in the BIAcore. This behaviour was also observed by Hobba et al. (1998) and 
Heding et al. (1996). 
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Figure 7.6: Molecular surface of Long-[Arg3]-IGF-I with the residues of Long-[Leu60]-
IGF-I for which chemical shift perturbations are detected upon complexation with IGFBP-
2 at 3O°C shown in red. 
Jans son et al. ( 1998) formed the IGF-I/IGFBP-1 co1nplex at dilute concentrations with an 
excess of IGFBP-1, in 7 ml of 1 mM sodium citrate buffer at pH 3.4 and subsequently 
concentrated by reduction of the sample vohune to minimise the previously noted 
aggregation tendencies of both IGF-I and IGFBP-1 when in free solution (Cooke et al., 
1991; Sato et al. , 1992; Jansson et al., 1998). Sodiu1n acetate buffer was used to maintain 
the complex at pH 3.0. Sato et al. (1992; 1993) reduced the self association of IGF-I at 2-
10 mM protein concentration and unproved the spectral quality by the addition of 10% or 
20% acetic acid. In the study by Jansson et al. (1998) and the present study, acetic acid 
was not used as it affects the binding affinity of IGFs for IGFBPs (Jansson et al. , 1998). 
In the work reported herein, no precipitation occurred on formation of the Long-[Leu60]-
IGF-I/IGFBP-2 co1nplex. Titrating IGFBP-2 into the NMR sample containing Long-
[Leu60]-IGF-I to form the Long-[Leu60]-IGF-I/IGFBP-2 complex simplified the 
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assignment procedure for the complex since most chemical shift assignments could be 
directly transferred from those determined for uncomplexed Long-[Leu60]-IGF-I (Chapter 
3). 
Recent studies, in which chemical shift perturbations were used to identify structural 
binding epitopes (Grzesiek et al., 1996; Craven et al., 1996) have involved a small molecule 
(Mr 500-2000) binding to a relatively large labeled protein (Mr 20,000 - 25,000), i.e. 
chemical shift changes were observed on the larger molecule. Recently, mini-IGFBP-5 
(Ala40_ne92 of the N-terminal domain of IGFBP-5) was complexed to IGF-I and IGF-II 
by successively adding IGF-I and IGF-II and NMR resonances of the larger 15N-labeled 
mini-IGFBP-5 were measured (Kalus et al., 1998). This work with Long-[Leu60]-IGF-I 
and IGFBP-2 presents the successive docking of the IGFBP family to an IGF-I analogue 
where the NMR resonances of the IGF-I analogue were measured. 
The structural binding epitope of IGF-I for IGFBP-1 binding was defined by the 
comparison of 15N and 13C chemical shifts of IGF-I in the presence and absence of 
IGFBP-1 (Jansson et al., 1998). For the work presented in this thesis, 13C-labeled Long-
[Leu60]-IGF-I was not available for studying the interaction between Long-[Leu60]-IGF-I 
and IGFBP-2, thus, only 15N chemical shifts of Long-[Leu60]-IGF-I in the absence and 
presence of IGFBP-2 were used to define a structural binding epitope of Long-[Leu60]-
IGF-I. The lack of 13C-labeled material is unfortunate since four of the five pralines in 
IGF-I were determined to have chemical shifts affected by IGFBP-1 binding (Jansson et 
a1:, 1998) and any chemical shift perturbations of these residues in Long-[Leu60]-IGF-I 
cannot be observed. It should be noted that Jans son et al. ( 1998) encountered difficulties 
in making assignments for free IGF-I at 30 °C and that additional, but not all, IGF-I 
resonances could be assigned unambiguously in the complex with IGFBP-1, despite the 
increase in monomer molecular mass from 7 to 30 k.Da. Assignments of Long-[Leu60]-
IGF-I could be made with similar levels of confidence for the protein in both the free and 
complexed state at 30 °C. 
The chemical shift differences found in Long-[Leu60]-IGF-I when comparing the 
molecule alone and in complex with IGFBP-2 are mapped onto the Long-[Arg3]-IGF-I 
structure in Figure 7 .6 since the three-dimensional solution structure of Long-[Leu60]-
IGF-I was not determined. Long-[Arg3]-IGF-I is a valid model for mapping the perturbed 
residues of Long-[Leu60]-IGF-I since the pattern of secondary structure observed in 
160 
Long-[Leu60]-IGF-I was almost identical to that of Long-[Arg3]-IGF-I and many of the 
same long-range NOEs were observed (Chapter 4). For comparison, the chemical shift 
differences found in IGF-I between the free and IGFBP-1 complexed forms (Jansson et 
al., 1998) are mapped onto the IGF-I structure (Cooke et al., 1991) in Figure 7.7. The 
IGF-I resonances perturbed by IGFBP-1 binding include Pro2, Glu3, Cys6, Gly7, Pro28, 
Thf29, Gly30, Gly32, Arg36, Arg37, Gln40, Thf41, Gly42, Ser51, Pro63, Lys65, Pro66, Lys68 
and Ala 70. The perturbed resonances of Long-[Leu60]-IGF-I on IGFBP-2 binding which 
are also perturbed resonances of IGF-I upon IGFBP-1 binding are Glu3, Cys6, Thr29, 
Arg37, Gln40, Thr41, Gly42, Ser51, Lys65 and Ala70 (Figure 7.5). Interestingly, no residues 
in helix 2 of IGF-I (Ile43 to Arg50) experienced chemical shift perturbations upon IGFBP-
1 binding, while six residues of a-helix 2 of Long-[Leu60]-IGF-I experienced chemical 
shift changes. This difference between IGF-I and Long-[Leu60]-IGF-I upon IGFBP 
binding may reflect a different conformation of helix 2 between the two proteins due to the 
Tyr60Leu mutation, or subtle differences between how IGFBP-1 and IGFBP-2 interact 
with IGFs, or even the difficulties Jans son et al. ( 1998) encountered in assigning this 
segment of uncomplexed IGF-I. 
The amino acid residues Glu3, Phe49, Arg50 and Ser51 of IGF-I were identified by 
Dubaquie and Lowman ( 1999) in alanine screening studies as affecting IGFBP-1 affinity. 
These residues are a small portion of the interaction surface identified by the present 
NMR study, with some residues outside this surface. The structural binding epitope 
encompasses those residues whose structural orientation is altered by the IGFBP 
interaction, while the functional binding epitope encompasses those residues which are 
directly involved in binding to sites on the IGFBPs. It is likely that the functional binding 
epitope is significantly smaller than the structural binding epitope in line with findings 
from IGF-I/IGFBP-1 interaction (Jansson et al., 1998) and the interaction of human 
growth hormone with the soluble form of its receptor (Clackson et al., 1995). 
An interesting observation in the present study is that the chemical shifts of some residues 
in the N-terminal extension and the C-terminus of Long-[Leu60]-IGF-I are perturbed by 
the association of IGFBP-2 (Figures 7.5 and 7.6). Jansson et al. (1998) also noted that 
residues Lys68-Ala70 of IGF-I were perturbed by the association of IGFBP-1, and the 
authors attributed this as being due to two alternative conformations adopted by the C-
terminus of IGF-I, one of which is "frozen out" upon complexation. The chemical shift 
changes in the residues in the N-terminal extension and the C-terminus of Long-[Leu60]-
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IGF-I on IGFBP-2 binding may result from a different conformational population or 
indirect structural changes, rather than direct contact with the binding protein. There are 
two proline residues in both the N-terminal extension and the C-terminus, which suggests 
the possibility of altered conformations arising from cis-trans isomerism of these four 
prolines. In order to make a detailed comparison of the effect the N-terminal extension of 
Long-[Leu60]-IGF-I has on the IGFBP-2 binding affinity it would be necessary also to 
investigate the chemical shift perturbations resulting from IGFBP-2 complexation with 
either [Leu60]-IGF-I or IGF-1. Asp20 of Long-[Leu60]-IGF-I also experiences a large 15N 
chemical shift change on IGFBP-2 complexation along with smaller perturbations 
experienced by Arg21 and Gly22, which comprise the ~-turn at the end of helix 1. It is 
possible that these chemical shift changes are also the result of an altered conformation of 
the tum, however direct contact with the binding protein cannot be ruled out. This may also 
partially explain the ambiguity associated with categorising the type of ~-tum in this 
region, which was discussed in Chapter 4. 
Jans son et al. ( 1998) could not assign the disulfide-connected residues, Cys6 and Cys48 in 
free IGF-I, however, cross peaks were observed for Cys6 after the addition of IGFBP-1. 
The authors attributed this to a conformational exchange between the cis and trans 
isoforms of the disulfide bond upon IGFBP-1 binding. The authors propose that this 
exchange between the cis and trans isoforms may be responsible for the two observed C-
terminal conformations. In contrast, both Cys6 and Cys48 could be assigned in free Long-
[Leu60]-IGF-I and the intensity of the cross peaks in the 2D 15N HSQC spectrum was 
not significantly altered upon the addition of 25% IGFBP-2. In support of the proposed 
cis-trans isomerism of IGF-I (Jansson et al., 1998), both Cys6 and Cys48 in Long-
[Leu60]-IGF-I experience 15N chemical shift perturbations upon the addition of IGFBP-2 
with the shift change experienced by Cys48 being quite substantial at 0.84 ppm. 
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Figure 7.7: Molecular surface of IGF-I (Cooke et al., 1991) showing the residues for 
which chemical shift perturbations were detected upon complexation with IGFBP-1 
(Jansson et al., 1998) in blue. IGF-I is rotated by approximately 90° about the z-axis 
relative to the orientation of Long-[Arg3]-IGF-I in Figure 7.6. 
Arginine sidechain guanidino groups are often found to be important in stabilising 
interactions between proteins (Pascal et al., 1994; Jansson et al., 1998). Jansson et al. 
(1998) identified Arg50, Arg36 and Arg37 of IGF-I, by 1nutation of these arginine residues 
to alanines, as being functionally involved with IGFBP-1 binding, while Arg21, Arg55 and 
Arg56 were found not to be functionally involved in binding. No 1nutations of arginine 
residues were explored in the present study. However, the backbone 15N resonance of 
Arg50 of Long-[Leu60]-IGF-I was perturbed by the addition of IGFBP-2 (Figure 7.5), 
suggesting a stabilising role for the Arg50 sidechain upon IGFBP-2 complex formation. 
The IGF-I arginines are highly conserved in vertebrates with the only co1nmon variant 
being an arginine to glutainine substitution at position of 50 in chicken, frog and salmon 
suggesting important functions for these residues. Arginine residues 36, 37, 21 and 56 are 
also involved with binding to the type 1 IGF receptor. The importance of these arginine 
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residues in both IGFBP and IGF receptor binding explains the competitive binding of 
IGFBP-1 and the type 1 receptor for IGF-I, since the presence of either will partially block 
the other's binding surface on IGF-I (Jansson et al., 1998). 
The Tyr60Leu mutation of Long-[Leu60]-IGF-I does not affect binding to IGFBP-2 but 
greatly reduces binding to the type 1 IGF receptor and the insulin receptor (Milner et al., 
submitted for publication). Long-[Leu60]-IGF-I selectively displaces IGF-I from its 
association with IGFBPs, since Long-[Leu60]-IGF-I has a much lower affinity for the 
type 1 IGF receptor, and thus promotes biological activity through action of endogenous 
IGF-I at the type 1 IGF receptor. Although the affinity of Long-[Leu60]-IGF-I for 
IGFBPs is not significantly affected, residues which have been identified as important for 
both IGFBP and type 1 IGF receptor binding of IGF-I may not show identical chemical 
shift changes on binding of IGFBP-2 to Long-[Leu60]-IGF-I because of local 
conformational changes induced by the Tyr60Leu mutation e.g., in a-helix 2. Residues 
Arg36 and Arg37 are two such residues that are important for the binding of IGF-I to 
IGFBPs and the IGF receptor (Jansson et al., 1998). Upon IGF-I/IGFBP-1 complex 
formation, the resonances of both Arg36 and Arg37 of IGF-I are perturbed (Figure 7.7). 
However, upon complexation of IGFBP-2 with Long-[Leu60]-IGF-I, the Arg37 resonance 
of Long-[Leu60]-IGF-I was perturbed, but not the Arg36 resonance. This difference may 
be attributed to an altered conformation in this C-domain segment induced by the 
Tyr60Leu mutation (see section 4.5). 
A . structural binding epitope on Long-[Leu60]-IGF-I for IGFBP-2 has been defined by 
chemical shift mapping studies. Most of the residues involved in the binding interaction 
are located on one face of the molecule, however, Long-[Leu60]-IGF-I has quite broad 
specificity determinants for interaction with IGFBP-2. 
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The work presented in this dissertation adds to the wealth of structural knowledge of IGFs 
with the NMR studies of two IGF-I analogues, Long-[Arg3]-IGF-I and Long-[Leu60]-
IGF-I. In particular, the first examples of the analysis of backbone dynamics for any 
member of the IGF-I family are presented. IGF-I and IGF-II are important mitogenic 
agents, while Long-[Arg3]-IGF-I shows increased mitogenic activity and Long-[Leu60]-
IGF-I promotes the release of endogenous IGF-I from its association with IGFBPs and, 
thereby indirectly, the action of IGF-I through the type 1 IGF receptor. 
Improvements in the resolution of NMR spectroscopy have enabled high quality spectra to 
be obtained at relatively low protein concentrations. 2D l5N-HSQC spectra were obtained 
with sample concentrations of Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I as low as 0.4 
mM, while 3D 15N-NOESY-HSQC and 3D 15N-NOESY-HSQC and 3D 15N-TOCSY-
HSQC spectra were obtained with protein concentrations of between 0.5 and 1.0 mM. 
Homonuclear NMR studies of IGF-I have, in the past, been hindered by the tendency of 
IGF-I to aggregate in solution at concentrations of 3-10 mM and pH above 5 (Cooke et 
al., 1991; Sato et al., 1992). In the work presented in this thesis, the amount of protein 
necessary to obtain a high resolution structure was reduced, enabling cost effective 
production of 15N-labeled protein, while the lower sample concentrations used reduced the 
prevalence of aggregation. Despite working with Long-[Arg3]-IGF-I concentrations of 
around 1.0 mM, sedimentation equilibrium experiments revealed the presence of 20% 
dimer. The effects of dimerisation, however, were not manifest in NOESY spectra nor did 
they affect the interpretation of the backbone dynamics, since there is no evidence of 
iritermonomer peaks. 
A central feature of all IGF structures determined thus far is retention of the three a-
helices that enclose a hydrophobic core. The three dimensional structure determination of 
Long-[Arg3]-IGF-I and the secondary structure determination of Long-[Leu60]-IGF-I 
supports the retention of the hydrophobic core of the IGF-I domain. Despite the addition 
of a 13 amino acid extension at the N-terminus of the protein, the approximate relative 
alignment of the three helices remains unaltered in comparison with IGF-I, with the 
exception of a slight reorientation of the helices. The major variations in the structure of 
Long-[Arg3]-IGF-I, compared with IGF-I, occur at the N-terminus with a substantial 
reorientation of the N-terminal three residues of the IGF-I domain. The sidechain of the 
residue at position three is removed from its location between helices 1 and 3 in IGF-I to a 
highly exposed location in Long-[Arg3]-IGF-I. Thus, the reduced binding of Long-
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[Arg3]-IGF-I to IGFBPs does not simply result from the electrostatic effect of the 
Glu3 Arg mutation, but also from a spatial effect caused by a conformational relocation of 
the relative positions of Arg3 and Phe49 compared with the positions of Glu3 and Phe49 in 
IGF-I, residues involved in binding to IGFBPs. 
Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I undergo non-uniform and complicated 
backbone dynamics. The most ordered parts of Long-[Arg3]-IGF-I and Long-[Leu60]-
IGF-I are the a-helices. Nevertheless, the average heteronuclear NOEs for Long-[Arg3]-
IGF-I and Long-[Leu60]-IGF-I of 0.55+0.12 and 0.69+0.15 respectively, are significantly 
less than the value observed in well defined secondary structure of rigid proteins (>0.75). 
The reduced heteronuclear NOEs suggest that the helices are not completely rigid and this 
is supported by the relatively rapid amide proton exchange rates compared to the helices of 
other proteins. Despite having three well-defined a-helices, Long-[Arg3]-IGF-I and Long-
[Leu60]-IGF-I are clearly more flexible than most proteins. 
The residues of the N-terminal extension of both Long-[Arg3]-IGF-I and Long-[Leu60]-
IGF-I have negative heteronuclear NOEs, with the exception of Phe-3 and Val-2, 
suggesting a degree of disorder. However, the amide protons of several residues in the N-
terminal extension of Long-[Arg3]-IGF-I and Long-[Leu60]-IGF-I exhibit slow exchange 
with the bulk solvent, which suggests that any dynamic disorder is correlated to protect the 
hydrophobic residues in the N-terminal extension from contact with the aqueous solvent. 
The C-domain loop (Gly30_Gln40) has heteronuclear NOEs indicative of substantial but 
restricted motions as might be expected in a long loop. 
Quantitative analysis of the relaxation data according to the model-free approach is 
complicated by the presence of 20% dimer, since aggregation systematically increases T 1 
and decreases T2. However, analysis performed using an axially symmetric rotational 
diffusion tensor is sufficient to show that the overall correlation time is longer by 
approximately a factor of two than other proteins of similar size. It has been suggested that 
a broad specificity of protein interaction with ligands or receptors is correlated with a 
certain degree of flexibility (Carr et al., 1997). It may be necessary for IGF-I to be 
sufficiently flexible in order to interact with the insulin and the type 1 IGF receptors as 
well as a family of six binding proteins. 
Specific binding determinants of Long-[Leu60]-IGF-I for IGFBP-2 were probed by 
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acquiring 2D 15N-HSQC spectra with and without IGFBP-2 present. Long-[Leu60]-IGF-
I residues involved in the binding interactions with IGFBP-2 were identified by a 
significant 15N chemical shift change upon complex formation with IGFBP-2. A number 
of residues were perturbed upon complex formation, including Glu3, Cys48, Phe49, Arg50 
and Ser51, residues previously identified as involved in IGFBP complex formation 
(Jansson et al., 1998; Dubaquie and Lowman, 1999). These residues are all located on one 
face of the protein that is composed of the N-terminus of IGF-I, the N-terminal end of a-
helix 2 and the region between a-helices 2 and 3, with the sidechains exposed to solvent. 
The choice of the Val-2-Asn-1 linker between the remainder of the N-terminal extension 
derived from pGH and the IGF-I domain was purely fortuitous. The primary reasons for 
choosing this dipeptide were to introduce a location susceptible to cleavage by 
hydroxylamine at Asn-LGlyl, while Val-2-Asn-1 provides a restriction enzyme cleavage 
site in the DNA construct.. However, Asn has a preference for being in the first position in 
turn structures, Gly has a preference for being in turns and Pro has a preference for being 
at position 3 in turns. This introduces the unique structural element of a turn incorporating 
residues Asn-1, Gly 1, Pro2 and Arg3. Research is in progress to find alternative linker 
sequences which can be cleaved proteolytically to give IGF-I or IGF-II or analogues of 
these proteins without the "long" N-terminal extension (G.L. Francis and S. Lien, personal 
communication). If an alternative linker is used with the fusion peptide for production of 
an IGF analogue with the extension intact, the turn is not likely to be maintained unless 
residues are used in the linker sequence which also have a propensity to form turn 
structures. The turn between Asn-1 and Arg3 in Long-[Arg3]-IGF-I is a crucial component 
in altering the affinity of Long-[Arg3]-IGF-I for IGFBPs and the receptors , since it brings 
the extension close to the IGF domain and alters the sidechain conformation of residue 3. 
NMR spectroscopy will prove an important tool for future IGF research. Rapid growth 
has taken place in the field of NMR spectroscopy in the last few years and its application 
to the study of macromolecules. The present work has provided an important structural 
basis for future work. The structure determination of the family of IGFBPs, crucial for 
understanding their interactions with IGFs, is now feasible. NMR methods will, in the 
future, be able to identify residues of IGFs, IGFBPs or IGF receptors involved in the 
structural and functional binding sites. The flexibility of the IGFs and the conformational 
changes undergone to accommodate an approaching ligand can be investigated using 
backbone dynamics. The mobility of the IGFs is perhaps more significant than site 
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directed mutations in defining the specificity of interactions. The availability of 13C/15N 
double labeled samples would result in structures of higher precision enabling more 
detailed comparison of the orientation of key sidechains and improved backbone dynamics 
analyses. 
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Pulse sequences are shown for each of the NMR experiments performed with the exception of 
the following ; 2D NOESY and 2D TOCSY which are standard experirnents, 2D 15N-HSQC-
TOCSY and 2D 1SN-HSQC-NOESY which are 2D variants of the 3D experilnents shown, and 
the 3D 15N-HSQC-NOESY-HSQC. The same pulse scheme was used for the 3D 15N-HSQC-
NOESY-HSQC and the 3D 15N-HSQC-TOCSY-NOESY-HSQC with the TOCSY element 
disabled while acquiring the 3D l5N-HSQC-NOESY-HSQC spectrum. 
Pulses for which the phases are not labeled are applied along the x-axis. Pulses labeled with 
rc/2 represent a flip angle of 90°, while pulses labeled with re correspond to a flip angle of 180°. 
Water saturation/dephasing was 1ninimised through the use of a one-lobe H2O Sine pulse 
(shaped pulse in Figures). The 1H carrier was placed on the water resonance for the duration of 
the experiment. The DIPSI mixing scheme was used for all TOCSY experiments. The 15N 
pulses were applied with a field of kHz, with nitrogen decoupling during acquisition achieved 
through the use of a kHz WALTZ decoupling field. The delays 't, 81 and 82 were set to 
l/(4JNH) = 2.3, 1.5 and 0.5 ms respectively. 
fT:/2. 1t;: 11:::l.2 11:. fT:12 11:. it/ 2 11:. 1Tl'21t;: 
I'" 
"C II "C 11 11 11 "C 11 't 11 't 11 't 
1H I II iu\ I I I I I L.J ~ 
:y -::\. 1J 
ffi•2 f(: 1,:l2 f(: rn'2 IT, -rr:12 f(: 
t1'2 t1'2 11 t<.2 II 82 I 
¢il qQ ~· 
Gr r,__n~___.r~ _ ___.n~--~n~____.n~ __ rL_fl.______,n~-~n~---
efJ gl ,gl g2 g3 g;S g.S g-5 gS g:4 
Figure 1: 2D 15N-HSQC, <1>1 = (x,-x); <1>2 = x. The gradient strengths and durations are: 
g0 = (1 ms, 4 G/cm), gl = (500 µs , 4 G/cm), g2 = (500 µs, 7.5 G/cm), g3 = (1.25 ms, 15 
G/cm), g4 = (125 µs, 14.1 G/cm), g5 = (150 µs , 7.4 G/cm). 
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ffi 2 ffi 2 fl:: ffi •4,:..•2 fTi 2 
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Figure 2: 3D 15N-TOCSY-HSQC, <p 1 = (y ,-y); cp2 = (x,-x); cp3 = 2(x), 2(-x); <p4 = x. The 
gradient strengths and durations are: gl = (1 ms, 2 G/cm), g2 = (1 ms, 2.5 G/cm), g3 = (500 µs, 
2 G/cm), g4 = (750 µs , 2.5 G/cm), g5 = (1.5 ms, -7.85 G/cm), g6 = (1.25 ms, 7.1 G/cm), g7 = 
(500 µs, 4 G/cm), g8 = (125 µs, 7 .1 G/cm) 
,rr-12 ffi2 -rr/2 fl:. fT;/2 fl:: ffi2 rr. ffi2 rr. ffi2 11; 
tl 11 ·tli'C I I -i: 11 •,: 11 11 II -i: 11 -i: 11 -i: 11 -i: I ~j I 51 
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Figure 3: 3D lSN-NOESY-HSQC, cpl = (135°, 315°); cp2 = 2(x), 2(-x); cp3 = x; tM = 
mixing tiine. The gradient strengths and durations are: gl = (lms, 2 G/cm), g2 = (1 ms, 10 
G/cm), g3 = (lms, 4 G/c1n), g4 = (500 µs, 4 G/cm), g5 = (lms, -5 G/cm), g6 = (1.25 ms, 
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14.75 G/cm), g7 = (500 µs, 2 G/c1n), g8 = (125 µs, 14.75 G/c1n) 
ft; i'(: ft; 1't ft; ft; 
-rr/2 fi:'l.2 i'(: -rr/2 «:12 
-rd 2 «/2. «= 'ff/ 2 «12. «12. 
' DIPS! 
,_ 
, - r II "'C 
r , 
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«./2 111'2 
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¢J. -$2 ,}~ y 
Figure 4: 3D 15N-HSQC-TOCSY-NOESY-HSQC, <j>l = (x,-x); <j>2 = 2(x), 2(-x); <j>3 = x, 
t = mixing time. The gradient strengths and durations are: gl = (1 ms, 2 G/cm), g2 = (500 
µs, 1 G/cm), g3 = (1 ms, 7.5 G/cm), g4 = (500 µs , -3.5 G/cm), g5 = (500 µ.s, 2.5 G/cm), 
g6 = (1 ms, 4 G/cm), g7 = (500 µs, 1 G/cm), g8 = (1 ms, -5 G/cm), g9 = (1.25 ms, 14.7 
G/c1n), gl0 = (500 µs, 2 G/cm), gl 1 = (130 µs, 14.45 G/cm) 
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Figure S: HMQC-J, <j>l = 8(x,-x); <j>2 = 4(x,x,-x,-x); <j>3 = 2(x,x,x,x,-x,-x,-x,-x); <j>4 = 8(x), 8(~x). 
-rr/2 ,rr; ffi2 1,:.tl. ,rr; ,rrJ'2 ffi2 rn>2 
,5 t,-'5 n s n t2 n ~ 11 ~-.5 5 II 
ll{ 
.. 
4J ~ ~ ¢4 ¢6 46 
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Figure 6: HNHA, <j>l = x; <j>2 = 4(x), 4(-x); <j>3 = x,-x; <j>4 = 2x, 2(-x); <j>5 = 4x, 4(-x); <j>6 = 
y ,-y; <j>7 = x, <j>8 = 8x, 8y; delay 8 is set to 4.95 ms; delay ~ is set to 12.6 ms. The gradient 
stengths and durations are: g0 = (500 µs, 4 G/cm), gl = (300 µs, 7.396 G/cm), g2 = (400 
µs, 7.396 G/cm), g3 = (750 µs, 7.4 G/cm), g4 = (500 µs, -7.4 G/cm) 
rrJ2 11:: ,rr/2 11:: -rr;/2 ·m'2 -rrJ 2 ffl2 -rrJ2 11:: -rr:: ffl2 -rr/"2 
D t2 D 
ll{ 
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-uu Lr7...J 
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Figure 7: HNHB, <j>l = y,-y; <j>2 = 2(x), 2(-x); <j>3 = 4(x), 4(y), 4(-x), 4(-y); D delay time= 38 
ms. The gradient strengths and durations are: gl = (1 ms, 5 G/cm), g2 = (500 µs, 5.917 G/cm), 
g3 = (500 µs, -5 G/cm), g4 = (lms, 7 .5 G/cm) 
For the following three experiments; 15N T1, 15N T2 and 15N NOEs, 't = 2.25 ms (l/(4JNH)); 
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'tA = 2.75 ms (l/(4JNH)) ; 'tB = 0.5 ms. The delay -t'A is set according to the relation : -t'A = 'tA + 
2pw where pw is the width of the 1H 90° pulse. The delay -t"A is set as -t"A = 'tA + (2/p) pwn 
where pwn is the 90° 15N pulse width. 
'f'i 2 1t;: 'f'i 2 ft;: S:;.t ri ft;: ·r•:l.2 fl:= rn'2 fi:: rn'2 -r,;: 
1H ... f -~- A . . . . 11\ . . JLJCJlJlJLLL-t]rr,-
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1J 
-rd2 'IT; fTi 2 11; rn'2 rn'2 fl:= fTi 2 11; fTi 2 11; 
'IJ'.ll 'IJ'. tl -~A 
1.5N 
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Figure 8: 15 T1, q>l = x,-x; q>2 = y; q>3 = 4(x), 4(y), 4(-x), 4(-y); q>4 = 2(x), 2(-x); q>5 = x. The 
gradient strengths and durations are: gl = (1 ms, 2 G/cm), g2 = (500 µs, 2 G/cm), g3 = (1 ins, 4 
G/cm), g4 = (500 µs, 4 G/cm), g5 = (lms, 2.5 G/cm), g6 = (1.25 ms, 14.7 G/cm), g7 = (500 µs, 
2 G/cm), g8 = (125 µs, 14.6 G/cm) 
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Figure 9: 15N T2, <Pl = x,-x; <P2 = y; <P3 = 4(x), 4(y), 4(x). The gradient strength and durations 
are: gl = (1 ms, 2 G/cm), g2 = (500 µs, 2 G/cm), g3 = (1 ms, 4 G/cm), g4 = (500 µs, 4 G/cm), 
g6 = (1.25 ms, 14.7 G/cm), g7 = (500 µs, 2 G/cm), g8 = (125 µ s, 14.6 G/cm) 
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-
-
-
- -
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Figure 10: 15N NQ,E, q>l = y; q>2 = 2(x), 2(y), 2(-x), 2(-y); q>3 = x,-x; q>4 = x. The gradient 
strengths and durations are: gl = (1.25 ms, 14.65 G/cm), g2 = (500 µ.s, 2 G/cm), g3 = (125 µs, 
14.65 G/cm) 
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APPENDIX2 
IH and 15 N chemical shift resonances of Long-[Arg3]-IGF-I 
194 
Assignments for the lH and 15N resonances of Long-[Arg3]-IGF-1 
in H2O at pH 3.0 and 30 °C 
n.o. = not observed 
Amino Chemical shift of 
acid 15N NH Ha H~ Others 
Met -13 121.9 8.22 4.35 2.07, 2.05 YCH2 2.64, 2.57; £CH3 1.95 
Phe -12 125.8 8.65 4.75 3.20, 2.98 8H 7.26; £H n.o.; sH n.o. 
Pro -11 4.40 2.29 YCH2 2.07 ,2.09; 8CH2 n.o. 
Ala -10 126.3 8.36 4.41 1.41 
Met -9 121.9 8.24 4.34 2.06, 2.02 YCH2 2.61, 2.52; £CH3 1.90 
Pro -8 4.45 2.17 YCH2 1.89, 1.94; 8CH2 3.63, 3.75 
Leu-7 122.1 8.22 4.33 1.80 YCH 1.84; 8CH3 1.41, 1.41 
Ser -6 119.3 8.23 4.50 3.99, 3.91 
Ser -5 119.5 8.31 4.43 3.95, 3.90 
Leu-4 129.2 7.92 4.29 1.61 YCH 1.38; 8CH3 0.92,0.87 
Phe -3 119.7 8.35 5.04 3.06, 2.69 8H 7.22; £H 7.00; sH n.o. 
Val-2 121.6 7.40 4.05 2.19 YCH3 1.04, 1.00 
Asn -1 124.3 8.49 4.15 2.86, 2.74 YNH2 n.o. 
Gly 1 110.9 8.13 4.05, 3.64 
Pro 2 4.39 2.31 YCH2 2.05; 8CH2 3.76, 3.79 
Arg 3 119.3 8.56 4.51 2.07, 1.80 YCH2 1.92, 1.51; 8CH2 3.62, 3.66; 
£NH 7.21 
Thr4 115.3 8.07 4.42 4.30 YCH3 1.25 
Leu 5 123.7 8.31 4.23 1.58 YCH 1.61; 8CH3 0.91 , 0.95 
Cys 6 119.7 8.38 4.58 3.15, 2.88 
Gly 7 110.0 7.74 3.99, 3.70 
Ala8 130.3 8.98 3.92 1.44 
Glu 9 118.1 8.00 4.04 2.26, 2.07 YCH2 2.78, 2.52 
Leu 10 121.7 6.88 3.90 1.89 YCH 2.07; °CH3 1.05, 0.76 
Val 11 119.3 7.29 3.28 2.10 YCH3 0.99, 0.99 
Asp 12 128.1 8.09 4.49 2.82, 2.71 
Ala 13 124.1 7.92 4.07 1.44 
Leu 14 120.5 8.11 3.76 1.14 YCH 1.32; 8CH3 0.64, 0.39 
Gln 15 119.9 8.34 4.14 2.29, 2.10 YCH2 2.62, 2.47, 0NH2 7.29, 6.77 
Phe 16 120.6 7.84 4.08 3.29, 3,24 8H 7.13; £H 7.25; sH n.o. 
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Val 17 119.2 8.70 3.61 2.10 YCH3 0.99, 1. 15 
Cys 18 117.1 8.67 4.81 3.34, 2.91 
Gly 19 110.4 7.72 3.99 
Asp 20 125.3 8.85 4.51 2.87, 2.82 
Arg 21 119.7 8.11 4.17 2.07, 2.02 YCH2 1.89, 1.79; 8CH2 3.33, 3.33; 
£NH 7.14 
Gly 22 105.0 7.38 4.04, 3.76 
Phe 23 115.2 7.53 5.18 3.24, 2.91 8H 6.79; EH 6.81; SH n.o. 
Tyr 24 120.7 8.66 4.82 3.21, 2.93 8H 7.13, EH 6.81 
Phe 25 119.6 8.48 4.79 3.21, 3.02 8H 7 .22; EH 7 .00; SH n.o. 
Asn 26 119.8 8.18 5.00 2.86, 2.71 YNH2 7.54, 6.90 
Lys 27 123.9 8.43 4.44 1.74, 1.70 YCH2 1.37, 1.37; 8CH2 1.65, 1.65; £CH2 
Pro 28 4.42 2.25 
2.83, 2.73 
YCH2 1.92, 1.93; 8CH2 3.59, 3.71 
Thr 29 115.3 8.15 4.21 4.32 YCH3 1.21 
Gly 30 111.8 8.30 3.95, 3.90 
Tyr 31 121.6 8.11 4.54 3.06, 2.93 8H 7.39; EH 6.75 
Gly 32 112.5 8.39 3.99, 3.87 
Ser 33 117.2 8.20 4.46 3.94, 3.85 
Ser 34 118.6 8.19 4.43 3.90, 3.84 
Ser 35 118.8 8.38 4.48 3.97, 3.98 
Arg 36 123.7 8.16 4.33 1.87, 1.85 YCH2 1.75, 1.54; 6CH2 3.17, 3.17; £NH 
n.o. 
Arg 37 122.6 8.15 4.31 1.82, 1.81 _CH2 1.69, 1.58; _CH2 3.14, 3.14; _NH 
n.o. 
Ala 38 127.5 8.12 4.57 1.35 
Pro 39 4.39 2.33 _CH2 2.02, 2.04; _CH2 3.70, 3.74 
Gln 40 121.5 8.48 4.40 2.03, 1.99 _CH2 2.40, 2.26; _NH2 7.48, 6.81 
Thr 41 115.6 8.09 4.44 4.29 CH3 1.25 
-
Gly 42 113.2 8.60 4.30, 4.16 
Ile 43 122.4 7.89 3.81 1.11 _CH2 0.95, 0.90; _CH3 0.72; _CH3 0.63 
Val44 123.59 8.04 3.55 1.93 _CH3 0.91, 0.71 
Asp 45 121.8 7.81 4.44 2.82, 2.78 
Glu 46 119.9 8.24 4.17 2.06, 2.01 
-
CH2 1.88 1.80 
Cys 47 113.6 8.26 5.04 3.27, 3.03 
Cys 48 117.2 7.36 4.44 3.18, 2.91 
Phe49 117.3 7.72 4.69 3.59, 3.43 _H 7.39; _H7.23; _Hn.o. 
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Arg 50 119.9 7.53 4.48 1.93 _CH2 1.71, 1.71; _CH2 3.22, 3.22; _NH 
7.34 
Ser 51 113.3 7.83 4.24 3.72, 3.62 
Cys 52 117.7 8.01 4.70 3.56, 3.25 
Asp 53 118.3 7.95 4.23 2.93, 2.78 
Leu 54 123.6 7.59 3.92 1.36 YCH 1.32; °CH3 0.90, 0.70 
Arg 55 119.9 7.86 4.16 2.05, 1.85 YCH2 1.63, 1.54; 8CH2 3.37, 3.22; £NH 
n.o. 
Arg 56 117.7 7.80 3.93 1.83, 1.67 YCH2 1.61, 1.56; 8CH2 3.16, 2.82; £NH 
7.32 
Leu 57 124.3 8.30 4.42 1.46 YCH 1.64; 8CH3 0.85, 0.80 
Glu 58 114.8 8.09 4.20 1.85, 1.53 YCH2 2.17, 2.07 
Met 59 118.9 7.61 4.21 2.16, 1.99 YCH2 2.84, 2.58; £CH 1.64 
Tyr60 117.0 7.98 4.72 2.82, 2.78 8H 7.37; £H 6.74 
Cys 61 116.9 7.26 5.15 3.21, 2.94 
Ala62 128.6 8.35 4.36 1.22 
Pro 63 4.42 2.27 YCH2 2.07, 2.07; 8CH2 3.70, 3.84 
Leu 64 123.9 8.30 4.42 1.56 YCH 1.87; 8CH3 0.93, 0.83 
Lys 65 125.5 8.34 4.61 1.75, 1.60 YCH2 1.46, 1.56; 8CH2 1.70, 1.70 
Pro 66 4.45 2.16 YCH2 2.02, 2.07; 8CH2 3.62, 3.82 
Ala67 125.7 8.18 4.29 1.39 
Lys 68 123.3 8.02 4.17 1.89, 1.85 YCH2 1.41, 1.37; 8CH2 n.o.; £CH2 n.o. 
Ser 69 113.8 8.01 4.23 4.04, 3.90 
Ala 70 132.1 8.03 4.19 1.36 
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Assignments for the lH and 15N resonances of Long-[Leu60]-IGF-1 
in H20 at pH 3.0 and 30 °C 
n.o. = not observed 
Amino Chemical shift of 
acid 15N NH HCX H~ Others 
Met -13 120.3 8.17 4.25 1.76, 1.82 YCH2 1.40; £CH3 n.o. 
Phe -12 124.2 8.55 4.87 3.10, 2.89 8H 7.10; £H n.o.; sH n.o. 
Pro -11 n.o. 2.00, 1.92 YCH2 1.84, 1.79; 6CH2 3.62 
Ala-10 124.4 8.30 4.23 1.33 
Met -9 120.3 8.04 4.65 1.84 YCH2 2.45; £CH3 1.92 
Pro -8 4.41 2.20 YCH2 1.92, 1.83; 8CH2 3.24 
Leu-7 123.6 8.11 4.22 1.31 YCH 1.16; 6CH3 0.99, 0.76 
Ser -6 117.3 8.15 4.41 3.82 
Ser -5 117.7 8.23 4.35 3.78 
Leu -4 125.0 8.02 4.29 1.59 YCH 1.27; 8CH3 0.79 
Phe -3 120.1 8.08 5.00 3.43, 3.23 8H 7.27; £H n.o.; SH n.o. 
Val-2 120.7 7.37 3.98 2.18 YCH3 0.86 
Asn -1 121.8 8.47 4.37 2.90, 2.81 YNH2 n.o. 
Gly 1 108.9 8.06 n.o. 
Pro 2 4.42 2.10 YCH2 1.85; 8CH2 3.45 
Glu 3 118.3 8.25 4.66 2.12, 1.92 YCH2 2.41, 2.26 
Thr4 116.1 7.85 4.32 3.78 YCH3 1.31 
Leu 5 119.2 7.57 3.95 2.03 YCH 1.66; 8CH3 0.87 
Cys 6 118.3 8.33 4.89 2.89, 2.61 
Gly 7 108.28 7.63 3.91 , 3.58 
Ala8 128.15 8.83 3.86 1.39 
G]u 9 11 5.1 7.94 4.01 2.17, 2.01 YCH2 2.63, 2.51 
Leu 10 120.3 6.87 4.09 1.90, 1.81 YCH 1.2. L 6CH3 1.14, 0.88 
Val 11 117.9 7.38 3.26 1.97 YCH3 0.99 , 0 .. 82 
Asp 12 117.2 8. 11 4 .03 2.85, 2.74 
A]a 13 122.2 7.76 3.99 1. 35 
Leu 14 118.5 8.24 3.73 1.45 YCH 1.91; 8CH3 0.86, 0.73 
Gln 15 118.5 8.12 4.04 2.23, 2.00 YCH2 2.52, 2.37 , 8NH2 7.11, 6.69 , £N 83.2 
Phe 16 117.9 7.38 4 . .35 3. 16 8H 7.23 ; EH n .. o.; sH n .. o. 
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Val 17 117.7 8.60 3.52 1.94 YCH3 1.02, 0.80 
Cys 18 115.1 8.69 4.71 3.25, 2.86 
Gly 19 108.1 7.41 4.02, 3.92 
Asp 20 122.5 8.77 4.48 2.84 
Arg 21 118.3 8.00 4.10 1.94 YCH2 1. 77; 8CH2 3 .22; 
£NH 7.03, £N 90.8 
Gly 22 104.0 7.33 3.93, 3.69 
Phe 23 114.2 7.46 4.94 3.20, 2.80 8H 6.88; £H 7.16; sH n.o. 
Tyr24 119.6 8.41 4.49 3.18, 2.88 8H 6.77, £H 6.94 
Phe 25 120.3 7.86 4.50 2.97, 2.85 8H 7.17; £H 6.87; sH n.o. 
Asn 26 120.1 7.88 4.49 2.56 YNH2 7.50, 6.80, 8N 112.9 
Lys 27 121.8 7.99 4.40 1.72, 1.62 YCH2 1.34; 8CH2 2.59 
Pro 28 4.43 2.18, 2.11 YCH2 1.86; 8CH2 3.41 
Thr 29 113.1 8.07 4.27 4.15 YCH3 1.14 
Gly 30 110.2 8.20 3.90, 3.80 
Tyr 31 120.1 8.04 4.47 2.97, 2.86 8H 7.03; £H 6.88 
Gly 32 110.7 8.30 3.93, 3.79 
Ser 33 115.5 8.13 4.38 3.91, 3.82 
Ser 34 117.0 8.11 4.39 3.82 
Ser 35 117.2 8.32 4.39 3.85 
Arg 36 122.0 8.08 4.25 1.80, 1.65 YCH2 1.55; 8CH2 3.11; £NH 7.08, £N 
85.43 
Arg 37 121.2 8.08 4.27 1.79, 1.67 YCH2 1.54; 8CH2 3.07; £NH 7.17, £N 
85.43. 
Ala38 126.0 8.16 4.51 1.32 
Pro 39 4.36 2.16, 2.06 YCH2 1.95, 1.86; 8CH2 3.40 
Gln 40 118.3 8.46 4.15 1.95, 1.82 YCH2 2.29; 8NH2 7.38, 6.76, £N 111.91 
Thr 41 114.2 7.85 4.26 4.04 YCH3 1.38, 1.18 
Gly 42 109.4 8.26 4.06, 3.95 
Ile 43 121.4 7.74 3.85 2.00 YCH2 1.84, 1.58; YCH3 1.14; 8CH3 0.87 
Val44 120.3 7.79 4.42 2.03 YCH3 0.89 
Asp 45 118.1 8.06 4.30 2.83 
Glu 46 118.1 7.83 4.41 1.76 YCH2 2.15 
Cys 47 115.5 7.22 4.93 3.15, 2.73 
Cys 48 115.7 8.43 4.40 3.42, 3.24 
Phe 49 113.7 7.89 4.73 3.26, 2.85 8H 7 .32; £H n.o.; sH n.o. 
Arg 50 119.4 7.95 4.53 1.89 YCH2 1.57; 8CH2 n.o.; £NH n.o. 
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Ser 51 112.9 7.81 4.16 3.69 
Cys 52 119.0 8.21 4.71 2.99, 2.85 
Asp 53 116.1 7.59 4.24 3.36, 2.95 
Leu 54 122.5 7.57 3.95 1.30 YCH 1.72; 8CH3 0.94 
Arg 55 119.4 7.92 4.10 1.90 YCH2 1.79; 8CH2 3.28; £NH n.o. 
Arg 56 116.8 7.86 3.85 1.74 YCH2 1.59; 8CH2 3.15; £NH 7.37 
Leu 57 117.0 7.73 3.88 1.93 YCH 1.81; 8CH3 1.03, 0.77 
Glu 58 113.7 8.15 4.05 2.07, 1.95 YCH2 2.49, 2.29 
Met 59 117.9 7.53 4.18 2.32, 2.12 YCH2 2.89, 2.59; £CH 1.82 
Leu 60 117.9 7.76 4.03 1.78 YCH 2.15, 8CH3 0.89 
Cys 61 115.3 7.22 4.93 3.16, 2.73 
Ala62 126.4 8.20 4.33 1.77 
Pro 63 4.33 2.15, 2.05 YCH2 1.85, 1.79; 8CH2 3.39 
Leu 64 123.6 8.24 4.53 1.73, 1.65 YCH 1.49; 8CH3 0.85 
Lys 65 122.0 8.18 4.14 1.49 YCH2 1.95, 1.82; 8CH2 2.27 
Pro 66 4.37 2.16, 2.10 YCH2 1.88; 8CH2 3.39 
Ala67 124.6 8.30 4.32 1.33 
Lys 68 122.3 8.19 4.03 1.54, 1.41 YCH2 1.83; 8CH2 n.o.; eCH2 n.o. 
Ser 69 112.9 7.93 4.14 3.88, 3.77 
Ala 70 128.6 8.09 4.17 1.31 
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Distance and dihedral angle restraints used in the three dimensional 
structure calculation of Long-[Arg3]-IGF-I 
Table 1: Dihedral angle restraints 
Residue Dihedral Angle Lower Bound Upper Bound 
1 Met phi -100 -20 
4Ala phi -100 -20 
5 Met phi -100 -20 
7Leu phi -160 -80 
7Leu psi 60 180 
8 Ser phi -160 -80 
8 Ser psi 60 180 
9 Ser phi -160 -80 
9 Ser psi 60 180 
12 Val phi -100 -20 
13 Asn phi -100 -20 
16 Arg phi -100 -20 
17 Thr phi -100 -20 
18 Leu phi -100 -20 
19 Cys phi -100 -20 
21 Ala phi -90 -30 
21 Ala psi -80 -20 
22 Glu phi -90 -30 
22 Glu psi -80 -20 
23 Leu phi -90 -30 
23 Leu psi -80 -20 
24 Val phi -90 -30 
24 Val psi -80 -20 
26Ala phi -90 -30 
26 Ala psi -80 -20 
28 Gln phi -90 -30 
28 Gln psi -80 -20 
29 Phe phi -90 -30 
29 Phe psi -80 -20 
30Val phi -90 -30 
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30Val psi -80 -20 
31 Cys phi -90 -30 
31 Cys psi -80 -20 
33 Asp phi -90 -30 
36 Phe phi -100 -20 
37 Tyr phi -100 -20 
39 Asn phi -100 -40 
40 Lys phi -100 -40 
42 Thr phi -160 -40 
43 Gly phi -100 180 
44 Tyr phi -160 -40 
44 Tyr psi 60 -80 
45 Gly phi -160 -80 
46 Ser phi -160 -80 
46 Ser psi 60 180 
47 Ser phi -160 -80 
47 Ser psi 60 180 
48 Ser phi -160 -80 
48 Ser psi 60 180 
49 Arg phi -160 -40 
50Arg phi -160 -40 
51 Ala phi -160 -40 
53 Gln phi -100 -20 
54 Thr phi -90 -30 
55 Gly phi -100 -20 
56 Ile phi -90 -30 
56 Ile psi -100 -20 
57 Val phi -100 -20 
58 Asp phi -90 -30 
58 Asp psi -80 -20 
59 Glu phi -90 -30 
59 Glu psi -80 -20 
61 Cys phi -90 -30 
61 Cys psi -80 -20 
62 Phe phi -90 -30 
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62 Phe psi -80 -20 
63 Arg phi -100 -20 
64 Ser phi -100 -20 
65 Cys phi -160 -80 
65 Cys psi 60 180 
66 Asp phi -160 -40 
67Leu phi -90 -30 
67Leu psi -80 -20 
68 Arg phi -90 -30 
68 Arg psi -80 -20 
69 Arg phi -90 -30 
69 Arg psi -80 -20 
71 Glu phi -90 -30 
71 Glu psi -80 -20 
72Met phi -100 -20 
72Met psi -80 -20 
73 Tyr phi -100 -20 
73 Tyr psi -80 -20 
74 Cys phi -100 -20 
75 Ala phi -100 -20 
77 Leu phi -160 -40 
78 Lys phi -160 -40 
80Ala phi -160 -80 
82 Ser phi -100 -20 
83 Ala phi -100 -20 
Table 2: Lower Bounds Distance Restraints 
Residue 1 Atom Residue 2 Atom Lower Bound 
19 Cys CB 61 Cys SG 3.00 
SG 61 Cys CB 3.00 
SG 61 Cys SG 2.00 
21 Ala 0 25 Asp HN 1.50 
0 25 Asp N 2.30 
22 Glu 0 26 Ala HN 1.50 
0 26Ala N 2.30 
23 Leu 0 27 Leu HN 1.50 
0 27 Leu N 2.30 
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24 Val 0 28 Gln HN 1.50 
0 28 Gln N 2.30 
25 Asp 0 29 Phe HN 1.50 
0 29 Phe N 2.30 
26 Ala 0 30Val HN 1.50 
0 30Val N 2.30 
27 Leu 0 31 Cys HN 1.50 
0 31 Cys N 2.30 
31 Cys CB 74 Cys SG 3.00 
SG 74 Cys CB 3.00 
SG 74 Cys SG 2.00 
32 Gly 0 35 Gly HN 1.50 
0 35 Gly N 2.30 
57 Val 0 61 Cys HN 1.50 
0 61 Cys N 2.30 
58 Asp 0 62 Phe HN 1.50 
0 62 Phe N 2.30 
59 Glu 0 63 Arg HN 1.50 
0 63 Arg N 2.30 
60 Cys CB 65 Cys SG 3.00 
SG 65 Cys CB 3.00 
SG 65 Cys SG 2.00 
67 Leu 0 71 Glu HN 1.50 
0 71 Glu N 2.30 
68 Arg 0 72Met HN 1.50 
0 72 Met N 2.30 
Table 3: Upper Bound Distance Restraints 
Residue 1 Atom Residue 2 Atom Upper Weighting 
Bound 
1 Met HB2 8 Ser HN 6.50 1.00 
HB3 8 Ser HN 6.50 1.00 
2 Phe HN 2 Phe HA 2.40 5.00 
QB 5 Met HN 3.99 4.00 
3 Pro HA 4Ala HN 4.50 3.00 
4Ala HN 4Ala HA 2.40 5.00 
5 Met HN 5 Met QG 6.38 5.00 -
7Leu QDl 8 Ser HN 6.00 2.00 
QD2 8 Ser HN 6.00 2.00 
8 Ser HN 9 Ser HN 2.52 5.00 
QB 12 Val HN 5.45 2.00 
9 Ser HN 9 Ser HA 2.90 5.00 
HN 11 Phe QB 6.00 2.00 
10 Leu HN 12 Val HN 3.30 5.00 
11 Phe HN 11 Phe HB2 3.30 5.00 
HN 11 Phe HB3 3.30 5.00 
HN 12 Val HN 3.02 6.00 
HN 12 Val HA 3.83 6.00 
HN 12 Val HB 3.48 6.00 
HN 12 Val QQG 5.89 5.00 
HA 19 Cys HN 6.50 4.00 
HA 20 Gly HN 6.50 4.00 
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12 Val HN 12 Val HB 3.02 5.00 
HN 13 Asn HN 4.17 6.00 
HN 19 Cys HN 6.50 4.00 
HA 14 Gly HN 4.00 5.00 
HA 19 Cys HN 6.50 4.00 
HB 19 Cys HN 6.50 4.00 
QQG 20 Gly HN 6.50 4.00 
QQG 19 Cys HN 6.50 4.00 
13 Asn HN 13 Asn HB2 3.76 5.00 
HN 13 Asn HB3 3.76 5.00 
HN 14 Gly HN 4.63 6.00 
16 Arg HN 16 Arg HB2 3.48 5.00 
HN 16 Arg HB3 3.48 5.00 
HN 16 Arg QB 3.13 5.00 
HN 16 Arg HG2 4.48 5.00 
HN 16 Arg HG3 4.48 5.00 
HN 16 Arg QG 4.50 5.00 
HN 16 Arg QD 5.82 4.00 
HN 16 Arg NHI 4.69 4.00 
HN 16 Arg NH2 4.54 4.00 
HN 17 Thr HN 3.55 6.00 
HN 21 Ala HN 6.50 
HA 17 Thr HN 5.00 3.00 
HG2 17 Thr HN 6.00 3.00 
17 Thr HN 18 Leu HN 2.71 6.00 
18 Leu HN 18 Leu HG 5.38 3.00 
HN 18 Leu QQD 7.63 3.00 
19 Cys HN 19 Cys HA 2.68 5.00 
HN 19 Cys QB 3.76 5.00 
HN 20 Gly HN 2.99 6.00 
HA 20 Gly HN 2.93 7.00 
CB 61 Cys SG 3.10 8.00 
HB2 20 Gly HN 4.14 6.00 
HB3 20 Gly HN 4.14 6.00 
QB 20 Gly HN 4.50 6.00 
SG 61 Cys CB 3.10 8.00 
SG 61 Cys SG 2.10 8.00 
20 Gly HAI 21 Ala HN 3.48 5.00 
HA2 21 Ala HN 3.48 5.00 
QA 22 Glu HN 5.07 6.00 
21 Ala HN 22 Glu HN 3.33 6.00 
HA 22 Glu HN 3.27 6.00 
HA 24 Val HN 3.80 8.00 
HA 25 Asp HN 4.50 7.00 
QB 22 Glu HN 4.23 6.00 
QB 23 Leu HN 6.53 3.00 
QB 24 Val HN 6.00 4.00 
0 25 Asp HN 2.30 8.00 
0 25 Asp N 3.30 8.00 
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22 Glu HN 22 Glu HB2 3.08 5.00 
HN 22 Glu HB3 3.08 5.00 
HN 22 Glu QB 3.08 5.00 
HN 22 Glu HG2 4.97 5.00 
HN 22 Glu HG3 4.97 5.00 
HN 22 Glu QG 5.00 5.00 
HN 23 Leu HN 3.17 6.00 
HN 24 Val HN 4.50 6.00 
HA 24 Val HN 3.61 6.00 
HA 25 Asp HN 3.80 8.00 
HA 26 Ala HN 4.50 7.00 
0 26Ala HN 2.30 8.00 
0 26Ala N 2.30 8.00 
23 Leu HN 23 Leu HG 4.88 4.00 
HN 23 Leu QDl 6.00 3.00 
HN 23 Leu QD2 6.00 3.00 
HN 23 Leu QQD 6.00 3.00 
HN 24 Val HN 3.64 6.00 
HA 26Ala HN 3.80 8.00 
HA 27 Leu HN 4.50 7.00 
QB 24 Val HN 4.92 5.00 
HA 36 Phe HN 7.00 
QD2 27 Leu HN 6.50 5.00 
0 27 Leu HN 2.30 8.00 
0 27 Leu N 3.30 8.00 
24 Val HN 24 Val HB 3.08 5.00 
HA 27 Leu HN 3.50 8.00 
HA 28 Gln HN 4.40 7.00 
HN 25 Asp HN 3.00 6.00 
HN 26 Ala HN 4.40 6.00 
0 28 Gln HN 2.30 8.00 
0 28 Gln N 3.30 8.00 
HB 56 Ile QG2 6.00 4.00 
HB 57 Val QG2 6.00 4.00 
HB 57 Val QGl 6.00 4.00 
QGl 38 Phe QD 6.00 4.00 
QG2 38 Phe QD 6.00 4.00 
QGl 38 Phe QE 6.00 4.00 
QG2 38 Phe QE 6.00 4.00 
25 Asp HB2 26 Ala HN 3.80 6.00 
HB3 26 Ala HN 3.80 6.00 
QB 26 Ala HN 3.80 6.00 
HN 26 Ala HN 3.30 6.00 
HA 28 Gln HN 3.80 8.00 
HA 29 Phe HN 4.50 7.00 
0 29 Phe HN 2.30 8.00 
0 29 Phe N 3.30 8.00 
26Ala HN 27Leu HN 2.99 6.00 
HN 28 Gln HN 3.72 6.00 
HN 67 Leu QB 7.00 
HA 29 Phe HN 3.80 8.00 
HA 30Val HN 4.50 6.00 
QB 28 Gln HN 6.53 5.00 
0 30Val HN 2.30 8.00 
0 30Val N 3.30 8.00 
QB 56 Ile QGl 6.00 4.00 
QB 56 Ile QG2 6.00 4.00 
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27Leu HN 27 Leu HB2 3.50 4.00 
HN 27Leu HB3 3.50 4.00 
HN 27Leu QB 3.40 4.00 
HN 27 Leu HG 5.47 4.00 
HN 27 Leu QDl 6.00 3.00 
HN 27 Leu QD2 6.00 3.00 
HN 27 Leu QQD 6.00 3.00 
HN 28 Gln HN 2.83 6.00 
HA 30Val HN 3.80 8.00 
HA 31 Cys HN 4.50 7.00 
QB 28 Gln HN 4.30 6.00 
QB 29 Phe HN 5.14 5.00 
QB 73 Tyr HN 7.49 3.00 
HG 28 Gln HN 4.32 5.00 
HG 73 Tyr HN 5.38 3.00 
QQD 28 Gln HN 6.92 4.00 
QQD 73 Tyr HN 8.10 3.00 
0 31 Cys HN 2.30 8.00 
0 31 Cys N 3.30 8.00 
QB 36 Phe QD 6.00 4.00 
QDl 36 Phe QD 6.00 4.00 
QD2 36 Phe QD 6.00 4.00 
QB 36 Phe QE 6.00 4.00 
QDl 36 Phe QE 6.00 4.00 
QD2 36 Phe QE 6.00 4.00 
QD2 56 Ile HB 6.50 3.00 
QDl 56 Ile HA 6.50 2.00 
QD2 56 Ile QGl 6.50 2.00 
QD2 56 Ile QG2 6.50 3.00 
QDl 56 Ile QDl 6.50 3.00 
QD2 70Leu GB 6.50 2.00 
QD2 70Leu QDl 6.50 3.00 
QD2 70Leu QD2 6.50 3.00 
QDl 57 Val QGl 6.50 3.00 
QDl 57 Val QG2 6.50 3.00 
28 Gln HN 28 Gln HB2 3.02 5.00 
HN 28 Gln HB3 3.02 5.00 
HN 28 Gln HG2 5.07 5.00 
HN 28 Gln HG3 5.07 5.00 
HN 28 Gln QG 5.00 5.00 
HN 28 Gln QE2 6.37 4.00 
HN 29 Phe HN 3.17 6.00 
HA 29 Phe HN 3.05 8.00 
HA 31 Cys HN 4.11 8.00 
HB2 29 Phe HN 3.83 6.00 
HB3 29 Phe HN 3.83 6.00 
QB 29 Phe HN 4.00 6.00 
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29 Phe HN 30Val HN 3.12 6.00 
HA 32 Gly HN 4.23 6.00 
QD 30Val HN 7.62 3.00 
HA 30Val HN 3.50 8.00 
QD 67 Leu QDl 6.50 3.00 
QD 67 Leu HG 6.50 3.00 
QD 67 Leu QD2 6.50 3.00 
QE 67 Leu QDl 6.50 3.00 
QE 67 Leu HG 6.50 3.00 
QE 67 Leu QD2 6.50 3.00 
QD 70Leu QDl 6.50 3.00 
QE 70Leu QD2 6.50 3.00 
30 Val HN 30Val HB 3.05 5.00 
HN 30Val QGl 4.79 5.00 
HN 30Val QG2 4.79 5.00 
HN 31 Cys HN 3.20 6.00 
HA 31 Cys HN 3.50 8.00 
HB 31 Cys HN 5.00 6.00 
HB 32 Gly HN 5.00 5.00 
QGl 31 Cys HN 5.13 4.00 
QG2 31 Cys HN 5.13 3.00 
QQG 31 Cys HN 4.76 3.00 
31 Cys HN 31 Cys HB2 3.05 5.00 
HN 31 Cys HB3 3.05 5.00 
HN 32 Gly HN 2.90 6.00 
HN 32 Gly QA 5.23 6.00 
HA 32 Gly HN 3.42 6.00 
CB 74 Cys SG 3.10 8.00 
HB2 32 Gly HN 3.52 6.00 
HB3 32 Gly HN 3.52 6.00 
QB 32 Gly HN 3.26 6.00 
QB 35 Gly HN 6.50 
SG 74 Cys CB 3.10 8.00 
SG 74 Cys SG 2.10 8.00 
32 Gly HN 33 Asp HN 3.36 6.00 
QA 34 Arg HN 4.83 6.00 
0 35 Gly HN 2.30 8.00 
0 35 Gly N 3.30 8.00 
33 Asp HN 34 Arg HN 3.08 6.00 
HN 35 Gly HN 4.91 6.00 
HA 34 Arg HN 4.50 6.00 
HA 35 Gly HN 3.36 6.00 
QB 34 Arg HN 4.42 6.00 
34 Arg HN 34Arg HG2 3.33 5.00 
HN 34Arg HG3 3.33 5.00 
HN 34 Arg QD 5.35 4.00 
HN 34 Arg NHl 6.00 4.00 
HN 35 Gly HN 2.99 6.00 
HN 35 Gly QA 5.57 6.00 
HG2 35 Gly HN 5.50 6.00 
HG3 35 Gly HN 5.50 6.00 
QG 35 Gly HN 5.18 3.00 
QD 35 Gly HN 6.38 2.00 
35 Gly HN 36 Phe HN 5.07 6.00 
HAI 36 Phe HN 3.11 6.00 
HA2 36 Phe HN 3.11 6.00 
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36 Phe HN 36 Phe HB2 3.95 5.00 
HN 36 Phe HB3 3.95 5.00 
HN 36 Phe QB 3.77 5.00 
HN 37 Tyr HN 5.50 6.00 
HA 37 Tyr HN 3.02 6.00 
QD 75 Ala HA 6.50 3.00 
QD 75 Ala QB 6.50 3.00 
QE 75 Ala HA 6.50 3.00 
QE 75 Ala QB 6.50 3.00 
37 Tyr HN 37 Tyr HB2 3.21 5.00 
HN 37 Tyr HB3 3.21 5.00 
HN 37 Tyr QE 7.63 3.00 
38 Phe HN 38 Phe HB2 3.64 5.00 
HN 38 Phe HB3 3.64 5.00 
HN 38 Phe QB 3.36 5.00 
HN 39 Asn HN 3.50 6.00 
HA 39 Asn HN 3.21 6.00 
HB2 39 Asn HN 3.52 6.00 
HB3 39 Asn HN 3.52 6.00 
QB 39 Asn HN 3.34 6.00 
QE 56 Ile QGI 6.00 3.00 
QD 56 Ile QGI 6.00 3.00 
QE 56 Ile QG2 6.50 3.00 
QD . 56 Ile QG2 6.50 3.00 
39 Asn HN 39 Asn HB2 3.30 5.00 
HN 39 Asn HB3 3.30 5.00 
HA 40Lys HN 3.50 6.00 
QB 40Lys HN 4.52 6.00 
HA 73 Tyr QD 6.00 3.00 
HA 73 Tyr QE 6.00 3.00 
40 Lys HN 40Lys QG 6.38 3.00 
HN 40Lys QE 6.38 3.00 
HN 42 Thr HN 5.00 4.00 
41 Pro HA 42 Thr HN 4.50 3.00 
42 Thr HN 42 Thr HA 2.46 5.00 · 
HN 42 Thr HB 2.96 5.00 
HN 42 Thr QG2 4.54 5.00 
HB 43 Gly HN 3.36 6.00 
HA 43 Gly HN 4.50 6.00 
43 Gly HN 43 Gly HAI 2.43 5.00 
HN 43 Gly HA2 2.43 5.00 
QA 44Tyr HN 3.50 6.00 
44 Tyr HN 44Tyr HB2 2.90 5.00 
HN 44Tyr HB3 2.90 5.00 
HN 45 Gly HN 4.00 6.00 
HA 45 Gly HN 3.00 6.00 
HB2 45 Gly HN 4.50 6.00 
HB3 45 Gly HN 4.50 6.00 
QB 45 Gly HN 4.00 6.00 
HB2 46 Ser HN 5.50 3.00 
HB3 46 Ser HN 5.50 3.00 
HB2 47 Ser HN 6.50 1.00 
45 Gly HN 45 Gly HAI 2.59 5.00 
HN 45 Gly HA2 2.59 5.00 
HN 46 Ser HN 4.00 6.00 
HAI 46 ser HN 3.50 6.00 
HA2 46 Ser HN 3.50 6.00 
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46 Ser HN 46 Ser HB2 2.56 5.00 
HN 46 Ser HB3 2.56 5.00 
HN 47 Ser HN 3.76 6.00 
HA 47 Ser HN 2.50 6.00 
HB2 47 Ser HN 5.00 3.00 
HB3 47 Ser HN 5.00 3.00 
47 Ser HN 47 Ser HA 2.56 5.00 
HN 48 Ser HN 3.86 6.00 
HA 48 Ser HN 2.50 6.00 
48 Ser HA 49 Arg HN 2.50 6.00 
HN 49 Arg HN 4.40 6.00 
49 Arg HN 49Arg HA 2.56 5.00 
HN 49 Arg HB2 4.00 5.00 
HN 49 Arg HB3 4.00 5.00 
HN 49Arg QB 4.50 5.00 
HN 49 Arg QG 4.73 4.00 
HN 49 Arg NHl 5.50 3.00 
HA 50Arg HN 2.50 6.00 
HN 50Arg HN 4.40 6.00 
50Arg HN 50Arg HA 2.40 5.00 
HN 50Arg HG2 3.73 5.00 
HN 50Arg HG3 3.73 5.00 
HN 50Arg QG 3.44 5.00 
HA 53 Gin HN 6.50 2.00 
HA 51 Ala HN 2.50 6.00 
HN 51 Ala HN 4.40 6.00 
HB2 51 Ala HN 5.00 6.00 
HB3 51 Ala HN 5.00 6.00 
HG2 51 Ala HN 6.00 2.00 
53 Gin HN 53 Gin HA 2.40 5.00 
HN 53 Gin HB2 3.30 5.00 
HN 53 Gin HB3 3.30 5.00 
HN 53 Gin QB 3.50 5.00 
HN 53 Gin HG2 4.50 4.00 
HN 53 Gin HG3 4.50 4.00 
HN 53 Gin QG 5.00 4.00 
HN 54Thr HN 2.99 6.00 
HG2 54 Thr HN 3.95 6.00 
HG3 54 Thr HN 3.95 6.00 
QG 54 Thr HN 3.64 6.00 
HA 54 Thr HN 4.50 6.00 
54 Thr HN 54 Thr HA 2.40 5.00 
HN 54 Thr HB 3.05 5.00 
HN 54 Thr QG2 4.17 4.00 
HN 55 Gly HN 3.08 6.00 
HA 55 Gly HN 2.96 6.00 
QG2 55 Gly HN 6.12 3.00 
HN 56 Ile HN 5.00 3.00 
55 Gly HN 56 Ile HN 3.89 6.00 
HAl 56 Ile HN 2.99 6.00 
HA2 56 Ile HN 2.99 6.00 
QA 56 Ile HN 2.79 6.00 
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56 Ile HN 56 Ile HB 3.24 5.00 
HN 56 Ile QG2 4.83 5.00 
N 56 Ile QGl 4.08 5.00 
HN 57 Val HN 3.05 6.00 
HN 73 Tyr QD 7.24 5.00 
HA 59 Glu HN 3.80 8.00 
HA 60 Cys HN 4.50 7.00 
HB 57 Val HN 4.51 6.00 
QGl 73 Tyr QD 6.00 3.00 
HB 73 Tyr QD 6.00 3.00 
57 Val HN 57 Val HB 3.11 5.00 
HN 57 Val QGl 4.33 5.00 
HN 57 Val QG2 4.33 5.00 
HN 57 Val QQG 4.50 4.00 
HN 58 Asp HN 3.21 6.00 
HN 60 Cys HN 3.21 7.00 
HA 58 Asp HN 3.48 6.00 
HA 60 Cys HN 4.00 8.00 
HA 61 Cys HN 4.50 7.00 
HB 58 Asp HN 3.33 6.00 
QGl 58 Asp HN 6.06 4.00 
QG2 58 Asp HN 6.06 4.00 
QQG 58 Asp HN 5.31 4.00 
QQG 60 Cys HN 7.50 4.00 
0 61 Cys HN 2.30 8.00 
0 61 Cys N 3.30 8.00 
58 Asp HA 59 Glu HN 3.50 7.00 
HN 59 Glu HN 3.20 6.00 
HA 60 Cys HN 3.80 8.00 
HA 62 Phe HN 4.50 7.00 
0 62 Phe HN 2.30 8.00 
0 62 Phe N 3.30 8.00 
59 Glu HN 59 Glu HA 2.80 5.00 
HN 59 Glu QG 4.27 5.00 
HN 60 Cys HN 3.27 4.00 
HA 62 Phe HN 3.80 8.00 
HA 63 Arg HN 4.50 7.00 
0 63 Arg HN 2.30 8.00 
0 63 Arg N 3.30 8.00 
60 Cys HN 60 Cys HB2 3.48 5.00 
HN 60 Cys HB3 3.48 5.00 
HN 60 Cys QB 3.50 5.00 
HN 62 Phe HN 3.42 5.00 
HA 61 Cys HN 3.58 6.00 
HN 61 Cys HN 3.20 6.00 
HA 63 Arg HN 3.80 8.00 
CB 65 Cys SG 3.10 8.00 
SG 65 Cys CB 3.10 8.00 
SG 65 Cys SG 2.10 8.00 
61 Cys HN 61 Cys HB2 3.70 5.00 
HN 61 Cys HB3 3.70 5.00 
HN 61 Cys QB 3.80 5.00 
HN 62 Phe HN 3.01 6.00 
HN 63 Arg HN 4.04 6.00 
HB2 62 Phe HN 3.39 6.00 
HB3 62 Phe HN 3.39 6.00 
QB 62 Phe HN 3.20 6.00 
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62 Phe HN 62 Phe HB2 3.64 5.00 
HN 62 Phe HB3 3.64 5.00 
HN 62 Phe QB 3.42 5.00 
HN 63 Arg HN 2.96 6.00 
HN 64 Ser HN 6.17 4.00 
HN 65 Cys HN 6.50 2.00 
HA 64 Ser HN 6.01 2.00 
HB2 63 Arg HN 4.32 6.00 
HB3 63 Arg HN 4.32 6.00 
QB 63 Arg HN 4.08 6.00 
63 Arg HN 63 Arg QG 5.73 5.00 
HN 63 Arg QD 6.19 5.00 
HN 64 Ser HN 4.00 6.00 
HN 65 Cys HN 5.61 2.00 
HA 64 Ser HN 2.71 6.00 
QB 64 Ser HN 4.90 4.00 
QG 64 Ser HN 5.79 3.00 
64 Ser HA 66 Asp HN 4.90 2.00 
QB 66 Asp HN 5.64 2.00 
65 Cys HN 65 Cys HB2 3.76 5.00 
HN 65 Cys HB3 3.76 5.00 
HN 65 Cys QB 3.34 5.00 
66 Asp HN 66 Asp HB2 3.73 5.00 
HN 66 Asp HB3 3.73 5.00 
HN 66 Asp QB 3.28 5.00 
HN 67 Leu HN 4.00 6.00 
67 Leu HN 67 Leu QDl 5.69 4.00 
HN 67 Leu QD2 5.69 4.00 
HN 67 Leu QQD 4.98 4.00 
HN 68 Arg HN 3.00 6.00 
HA 69 Arg HN 3.58 6.00 
HA 70Leu HN 3.80 8.00 
HA 71 Glu HN 4.58 7.00 
QQD 68 Arg HN 6.67 3.00 
QQD 69 Arg HN 7.85 3.00 
0 71 Glu HN 2.30 8.00 
0 71 Glu N 3.30 8.00 
68 Arg HN 68 Arg HB2 3.59 5.00 
HN 68 Arg HB3 3.59 5.00 
HN 68 Arg HG2 5.00 4.00 
HN 68 Arg HG3 5.00 4.00 
HN 68 Arg QG 5.00 4.00 
HN 68 Arg QD 6.38 3.00 
HA 69 Arg HN 3.52 6.00 
HA 71 Glu HN 3.80 8.00 
HA 72Met HN 4.50 7.00 
QB 69 Arg HN 4.05 6.00 
HN 69 Arg HN 3.20 6.00 
0 72Met HN 2.30 8.00 
0 72Met N 3.30 8.00 
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69 Arg HN 69 Arg HB2 3.24 5.00 
HN 69 Arg HB3 3.24 5.00 
HN 69 Arg QB 2.81 5.00 
HN 69 Arg HG2 4.48 4.00 
HN 69 Arg HG3 4.48 4.00 
HN 69 Arg QG 4.50 4.00 
HN 69 Arg QD 5.79 3.00 
HN 70Leu HN 3.10 7.00 
HA 71 Glu HN 3.89 6.00 
HA 73 Tyr HN 4.50 7.00 
HA 72Met HN 3.80 8.00 
70Leu HN 70Leu HA 2.40 5.00 
HN 70Leu HB2 3.50 5.00 
HN 70Leu HB3 3.50 5.00 
HN 70Leu QB 3.50 5.00 
HN 70Leu QQD 7.32 3.00 
HA 73 Tyr HN 3.80 8.00 
QB 71 Glu HN 5.17 6.00 
QQD 71 Glu HN 7.60 3.00 
HN 71 Glu HN 3.20 3.00 
QQD 72Met HN 7.63 2.00 
71 Glu HN 71 Glu HB2 3.67 5.00 
HN 71 Glu HB3 3.67 5.00 
HN 71 Glu QB 3.35 5.00 
HN 71 Glu HG2 4.00 5.00 
HN 71 Glu HG3 4.00 5.00 
HN 72Met HN 3.01 7.00 
72 Met HN 72Met HA 2.56 5.00 
HN 72Met HB2 3.30 5.00 
HN 72Met HB3 3.30 5.00 
HN 72Met HG2 5.50 5.00 
HN 72Met HG3 5.50 5.00 
HN 72Met QG 5.50 5.00 
HN 72Met QE 6.53 3.00 
HN 74 Cys HN 3.55 6.00 
HA 73 Tyr HN 3.50 7.00 
HN 73 Tyr HN 3.10 7.00 
HA 74 Cys HN 4.64 6.00 
HB2 73 Tyr HN 5.50 3.00 
HB3 73 Tyr HN 5.50 3.00 
QB 75 Ala HN 6.92 2.00 
73 Tyr HN 73 Tyr HA 2.74 5.00 
HN 73 Tyr HB2 3.76 5.00 
HN 73 Tyr HB3 3.76 5.00 
HN 73 Tyr QB 3.46 5.00 
HN 74 Cys HN 3.36 6.00 
HA 74 Cys HN 3.48 6.00 
HB2 74 Cys HN 3.73 6.00 
HB2 75 Ala HN 4.42 5.00 
HB3 74 Cys HN 3.73 6.00 
HB3 75 Ala HN 3.42 5.00 
QB 74 Cys HN 4.28 5.00 
QB 75 Ala HN 5.00 5.00 
QD 75 Ala HN 7.64 3.00 
74 Cys HN 75 Ala HN 4.07 6.00 
HA 75 Ala HN 2.49 6.00 
QB 75 Ala HN 4.08 6.00 
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77 Leu HN 77Leu HA 2.40 5.00 
HN 77Leu QB 3.46 5.00 
HN 77 Leu HG 4.69 5.00 
HN 77 Leu QDl 6.53 4.00 
HN 77 Leu QD2 6.53 4.00 
HN 77 Leu QQD 6.39 4.00 
QQD 78 Lys HN 6.45 4.00 
78 Lys HN 78 Lys HB2 3.02 5.00 
HN 78 Lys HB3 3.02 5.00 
HN 78 Lys QB 3.00 5.00 
HN 78 Lys HG2 5.00 5.00 
HN 78 Lys HG3 5.00 5.00 
HN 78 Lys QG 5.00 5.00 
80 Ala HN 80Ala HA 2.71 5.00 
81 Lys HN 81 Lys QG 6.31 3.00 
HN 82 ser HA 3.39 6.00 
QB 82 Ser HN 6.00 3.00 
QG 82 ser HN 6.38 3.00 
82 Ser HN 82 Ser HB2 3.11 5.00 
HN 82 Ser HB3 3.11 5.00 
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